09897755

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:SSSPTA1613SXW

PASSWORD:
TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * * * * * * Welcome to STN International * * * * * * * * * *

NEWS 1		Web Page URLs for STN Seminar Schedule - N. America
NEWS 2	Apr 08	"Ask CAS" for self-help around the clock
NEWS 3	Jun 03	New e-mail delivery for search results now available
NEWS 4	Aug 08	PHARMAMarketLetter(PHARMAML) - new on STN
NEWS 5	Aug 19	Aquatic Toxicity Information Retrieval (AQUIRE) now available on STN
NEWS 6	Aug 26	Sequence searching in REGISTRY enhanced
NEWS 7	Sep 03	JAPIO has been reloaded and enhanced
NEWS 8	Sep 16	Experimental properties added to the REGISTRY file
NEWS 9	Sep 16	CA Section Thesaurus available in CAPLUS and CA
NEWS 10	Oct 01	CASREACT Enriched with Reactions from 1907 to 1985
NEWS 11	Oct 24	BEILSTEIN adds new search fields
NEWS 12	Oct 24	Nutraceuticals International (NUTRACEUT) now available on STN
NEWS 13	Nov 18	DKILIT has been renamed APOLLIT
NEWS 14	Nov 25	More calculated properties added to REGISTRY
NEWS 15	Dec 04	CSA files on STN
NEWS 16	Dec 17	PCTFULL now covers WP/PCT Applications from 1978 to date
NEWS 17	Dec 17	TOXCENTER enhanced with additional content
NEWS 18	Dec 17	Adis Clinical Trials Insight now available on STN
NEWS 19	Jan 29	Simultaneous left and right truncation added to COMPENDEX, ENERGY, INSPEC
NEWS 20	Feb 13	CANCERLIT is no longer being updated
NEWS 21	Feb 24	METADEX enhancements
NEWS 22	Feb 24	PCTGEN now available on STN
NEWS 23	Feb 24	TEMA now available on STN
NEWS 24	Feb 26	NTIS now allows simultaneous left and right truncation
NEWS 25	Feb 26	PCTFULL now contains images
NEWS 26	Mar 04	SDI PACKAGE for monthly delivery of multifile SDI results
NEWS 27	Mar 19	APOLLIT offering free connect time in April 2003
NEWS 28	Mar 20	EVENTLINE will be removed from STN
NEWS 29	Mar 24	PATDPAFULL now available on STN
NEWS 30	Mar 24	Additional information for trade-named substances without structures available in REGISTRY
NEWS 31	Apr 11	Display formats in DGENE enhanced
NEWS 32	Apr 14	MEDLINE Reload
NEWS 33	Apr 17	Polymer searching in REGISTRY enhanced
NEWS 34	Apr 21	Indexing from 1947 to 1956 being added to records in CA/CAPLUS
NEWS 35	Apr 21	New current-awareness alert (SDI) frequency in WPIDS/WPINDEX/WPIX
NEWS 36	Apr 28	RDISCLOSURE now available on STN
NEWS 37	May 05	Pharmacokinetic information and systematic chemical names added to PHAR

```
 NEWS EXPRESS  April 4 CURRENT WINDOWS VERSION IS V6.01a, CURRENT
               MACINTOSH VERSION IS V6.0b(ENG) AND V6.0Jb(JP),
               AND CURRENT DISCOVER FILE IS DATED 01 APRIL 2003
 NEWS HOURS    STN Operating Hours Plus Help Desk Availability
 NEWS INTER    General Internet Information
 NEWS LOGIN    Welcome Banner and News Items
 NEWS PHONE    Direct Dial and Telecommunication Network Access to STN
 NEWS WWW      CAS World Wide Web Site (general information)

Enter NEWS followed by the item number or name to see news on that
specific topic.

  All use of STN is subject to the provisions of the STN Customer
  agreement.  Please note that this agreement limits use to scientific
  research.  Use for software development or design or implementation
  of commercial gateways or other similar uses is prohibited and may
  result in loss of user privileges and other penalties.

  * * * * * * * * * * * * * * STN  Columbus  * * * * * * * * * * * * * * *



FILE 'HOME' ENTERED AT 14:41:35 ON 08 MAY 2003

=> fil reg
COST IN U.S. DOLLARS                            SINCE FILE      TOTAL
                                                   ENTRY    SESSION
FULL ESTIMATED COST                                 0.21       0.21

FILE 'REGISTRY' ENTERED AT 14:41:43 ON 08 MAY 2003
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2003 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES:     6 MAY 2003  HIGHEST RN 511508-58-0
DICTIONARY FILE UPDATES:    6 MAY 2003  HIGHEST RN 511508-58-0

TSCA INFORMATION NOW CURRENT THROUGH JANUARY 6, 2003

  Please note that search-term pricing does apply when
  conducting SmartSELECT searches.

Crossover limits have been increased.  See HELP CROSSOVER for details.

Experimental and calculated property data are now available.  See HELP
PROPERTIES for more information.  See STNote 27, Searching Properties
in the CAS Registry File, for complete details:
http://www.cas.org/ONLINE/STN/STNOTES/stnotes27.pdf

=>
Uploading 09897755c.str

L1      STRUCTURE UPLOADED

=> d
```

09897755

L1 HAS NO ANSWERS
L1 STR



Structure attributes must be viewed using STN Express query preparation.

=> s l1 sss sam
SAMPLE SEARCH INITIATED 14:42:08 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED - 59 TO ITERATE

100.0% PROCESSED 59 ITERATIONS 0 ANSWERS
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **COMPLETE**
BATCH **COMPLETE**
PROJECTED ITERATIONS: 720 TO 1640
PROJECTED ANSWERS: 0 TO 0

L2 0 SEA SSS SAM L1

=> s l1 full
FULL SEARCH INITIATED 14:42:14 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED - 1297 TO ITERATE

100.0% PROCESSED 1297 ITERATIONS 14 ANSWERS
SEARCH TIME: 00.00.01

L3 14 SEA SSS FUL L1

=> fil caplus
COST IN U.S. DOLLARS SINCE FILE ENTRY TOTAL SESSION
FULL ESTIMATED COST 148.15 148.36

FILE 'CAPLUS' ENTERED AT 14:42:19 ON 08 MAY 2003

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2003 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 8 May 2003 VOL 138 ISS 19
FILE LAST UPDATED: 7 May 2003 (20030507/ED)

This file contains CAS Registry Numbers for easy and accurate substance identification.

=> s l3 full
L4 10 L3

=> d l4 1-10 ibib abs hitstr

L4 ANSWER 1 OF 10 CAPLUS COPYRIGHT 2003 ACS
ACCESSION NUMBER: 2000:500184 CAPLUS
DOCUMENT NUMBER: 133:234344
TITLE: DoMCoSAR: A Novel Approach for Establishing the Docking Mode That Is Consistent with the Structure-Activity Relationship. Application to HIV-1 Protease Inhibitors and VEGF Receptor Tyrosine Kinase Inhibitors
AUTHOR(S): Vieth, Michal; Cummins, David J.
CORPORATE SOURCE: Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, IN, 46285, USA
SOURCE: Journal of Medicinal Chemistry (2000), 43(16), 3020-3032
CODEN: JMCMAR; ISSN: 0022-2623
PUBLISHER: American Chemical Society
DOCUMENT TYPE: Journal
LANGUAGE: English
AB DoMCoSAR is a novel approach for statistically detg. the docking mode that is consistent with a structure-activity relationship. The approach establishes the binding mode for the compds. in a chem. series with the assumption that all mols. exhibit the same binding mode. It involves three stages. In the first stage all mols. that belong to a given chem. series are docked to the active site of the protein target. The only bias used in the docking at this stage involves the location of the protein binding site. Coordinates of the common substructure (CS) that results from the unbiased docking are then clustered to establish the major substructure docking modes. In the second stage all mols. are docked to the major docking modes (MDMs) with constraints based on the common substructure. The third stage generates, for the major docking modes, interaction-based descriptors that include electrostatic, VDW, strain, and solvation contributions. The problem of docking mode evaluation is now reduced to the question of which descriptor set is more predictive. To

establish a quant. comparison of the descriptor sets assocd. with the major docking modes, we use 50 instances of random 4-fold cross-validation. For each 4-fold cross-validation the predictive squared correlation coeff. (R2) is computed. T-Tests are applied to establish significance of the differences in mean R for one docking mode vs. another. We test the methodol. on two test cases: HIV-1 protease inhibitors (Holloway et al. J. Med. Chem. 1995, 38, 305-317) and vascular endothelial growth factor (VEGF) receptor tyrosine kinase oxoindoles (Sun et al. J. Med. Chem. 1998, 41, 2588-2603). For both test cases there is statistically significant preference for the binding mode consistent with the x-ray structure. The appeal of this methodol. is that researchers gain the objectivity of statistical justification for the selected docking mode. The methodol. is relatively insensitive to subtle variations of the protein structure that include, but are not limited to, side chain and small backbone rearrangement during binding. In addn., predictive models that result from the approach can be used to further optimize chem. series.

IT **186611-29-0 186611-48-3**
RL: BPR (Biological process); BSU (Biological study, unclassified); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); PROC (Process); USES (Uses)
(VEGF kinase-inhibitor; DoMCoSAR - novel approach for establishing docking mode that is consistent with structure-activity relationship with application to HIV-1 protease inhibitors and VEGF receptor tyrosine kinase inhibitors)

RN 186611-29-0 CAPLUS
CN 2H-Indol-2-one, 3-[(3-ethyl-4,5-dimethyl-1H-pyrrol-2-yl)methylene]-1,3-dihydro- (9CI) (CA INDEX NAME)



RN 186611-48-3 CAPLUS
CN 2H-Indol-2-one, 3-[(4-ethyl-3,5-dimethyl-1H-pyrrol-2-yl)methylene]-1,3-dihydro- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 45 THERE ARE 45 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 2 OF 10 CAPLUS COPYRIGHT 2003 ACS
ACCESSION NUMBER: 1999:205317 CAPLUS
DOCUMENT NUMBER: 130:252240

09897755

TITLE: Preparation of 3-benzylidene-2-indolinones as tyrosine kinase activity modulators
INVENTOR(S): Tang, Peng Cho; Sun, Li; McMahon, Gerald
PATENT ASSIGNEE(S): Sugen, Inc., USA
SOURCE: U.S., 40 pp., Cont.-in-part of U.S. Ser. No. 485,323.
CODEN: USXXAM
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 9
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 5886020	A	19990323	US 1996-655226	19960605
US 5880141	A	19990309	US 1995-485323	19950607
CA 2192797	AA	19961219	CA 1996-2192797	19960605
EP 934931	A2	19990811	EP 1999-103667	19960605
EP 934931	A3	19991020		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI				
JP 2000026412	A2	20000125	JP 1999-159567	19960605
ES 2159741	T3	20011016	ES 1996-918093	19960605
JP 3231044	B2	20011119	JP 1997-501363	19960605
US 2002022626	A1	20020221	US 2000-617529	20000713
US 2002102608	A1	20020801	US 2001-897755	20010703
US 2003069421	A1	20030410	US 2002-201593	20020724

PRIORITY APPLN. INFO.:

US 1995-485323	A2	19950607
EP 1996-918093	A3	19960605
JP 1997-501363	A3	19960605
US 1996-655223	A2	19960605
US 1996-655224	A2	19960605
US 1996-655226	A2	19960605
US 1996-655255	B2	19960605
US 1996-659191	A2	19960605
US 1996-702232	B1	19960823
US 1997-915366	A3	19970820
US 1998-75271	B1	19980508

OTHER SOURCE(S): MARPAT 130:252240
GI



I

AB Title compds. [I; R1 = H or alkyl; R3 = ZR2; R2 = OR, NRaRb, 5-membered heteroaryl, etc.; R = H, alkyl, aryl; Ra,Rb = H, alkyl, COR; NRaRb = heterocyclyl; R4-R7 = H, halo, alkyl, alkoxy, etc.; X = O or S; Z = (un)substituted 1,4-phenylene] were prepd. Thus, 2-oxindole was condensed with PhCHO to give 3-benzylidene-2-indolinone. Data for biol. activity of

I were given.

IT **186610-95-7P 186611-29-0P 186611-48-3P**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of 3-benzylidene-2-indolinones as tyrosine kinase activity modulators)

RN 186610-95-7 CAPLUS
CN 2H-Indol-2-one, 3-[(4,5-dimethyl-1H-pyrrol-2-yl)methylene]-1,3-dihydro- (9CI) (CA INDEX NAME)



RN 186611-29-0 CAPLUS
CN 2H-Indol-2-one, 3-[(3-ethyl-4,5-dimethyl-1H-pyrrol-2-yl)methylene]-1,3-dihydro- (9CI) (CA INDEX NAME)



RN 186611-48-3 CAPLUS
CN 2H-Indol-2-one, 3-[(4-ethyl-3,5-dimethyl-1H-pyrrol-2-yl)methylene]-1,3-dihydro- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 80 THERE ARE 80 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 3 OF 10 CAPLUS COPYRIGHT 2003 ACS
ACCESSION NUMBER: 1999:193848 CAPLUS
DOCUMENT NUMBER: 130:237471
TITLE: 3-(2-Alkoxybenzylidene)-2-indolinones and their analogs for the treatment of disease
INVENTOR(S): Tang, Peng Cho; Sun, Li; McMahon, Gerald
PATENT ASSIGNEE(S): Sugen, Inc., USA

09897755

SOURCE: U.S., 36 pp., Cont.-in-part of U.S. Ser. No. 485,323.
CODEN: USXXAM
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 9
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 5883116	A	19990316	US 1996-655224	19960605
US 5880141	A	19990309	US 1995-485323	19950607
CA 2192797	AA	19961219	CA 1996-2192797	19960605
EP 934931	A2	19990811	EP 1999-103667	19960605
EP 934931	A3	19991020		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI				
JP 2000026412	A2	20000125	JP 1999-159567	19960605
ES 2159741	T3	20011016	ES 1996-918093	19960605
JP 3231044	B2	20011119	JP 1997-501363	19960605
US 2002022626	A1	20020221	US 2000-617529	20000713
US 2002102608	A1	20020801	US 2001-897755	20010703

PRIORITY APPLN. INFO.:

US 1995-485323	A2	19950607
EP 1996-918093	A3	19960605
JP 1997-501363	A3	19960605
US 1996-655223	A2	19960605
US 1996-655224	A2	19960605
US 1996-655226	A2	19960605
US 1996-655255	B2	19960605
US 1996-659191	A2	19960605
US 1996-702232	B1	19960823
US 1997-915366	A3	19970820

OTHER SOURCE(S): MARPAT 130:237471
GI



I

AB Indolinones such as I were prepd. for modulating tyrosine kinase signal transduction in order to regulate, modulate, and/or inhibit abnormal cell proliferation. Thus, a mixt. of 134.0 mg oxindole, 151.4 mg 3-methyl-2-thiophenecarboxaldehyde, and 3 drops of piperidine in 2 mL EtOH was stirred at 90.degree. for 3 h to give a 65% yield of I. In an ELISA assay to measure the inhibition of protein tyrosine kinase activity on the FLK-1 receptor, I showed an IC50 of 4.5 .mu.M.

IT **186611-29-0P**, SU 5453 **186611-48-3P**, SU 5477
RL: BAC (Biological activity or effector, except adverse); BSU (Biological

study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
(3-(2-alkoxybenzylidene)-2-indolinones and their analogs for modulating tyrosine kinase signal transduction)

RN 186611-29-0 CAPLUS
CN 2H-Indol-2-one, 3-[(3-ethyl-4,5-dimethyl-1H-pyrrol-2-yl)methylene]-1,3-dihydro- (9CI) (CA INDEX NAME)



RN 186611-48-3 CAPLUS
CN 2H-Indol-2-one, 3-[(4-ethyl-3,5-dimethyl-1H-pyrrol-2-yl)methylene]-1,3-dihydro- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 72 THERE ARE 72 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 4 OF 10 CAPLUS COPYRIGHT 2003 ACS
ACCESSION NUMBER: 1999:193846 CAPLUS
DOCUMENT NUMBER: 130:237470
TITLE: Preparation of 3-benzylidene-2-indolinones as tyrosine kinase activity modulators
INVENTOR(S): Tang, Peng Cho; Sun, Li; McMahon, Gerald
PATENT ASSIGNEE(S): Sugen, Inc., USA
SOURCE: U.S., 38 pp., Cont.-in-part of U.S. Ser. No. 485,233.
CODEN: USXXAM
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 9
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 5883113	A	19990316	US 1996-659191	19960605
US 5880141	A	19990309	US 1995-485323	19950607
CA 2192797	AA	19961219	CA 1996-2192797	19960605
EP 934931	A2	19990811	EP 1999-103667	19960605
EP 934931	A3	19991020		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI				
JP 2000026412	A2	20000125	JP 1999-159567	19960605

ES 2159741	T3	20011016	ES 1996-918093	19960605
JP 3231044	B2	20011119	JP 1997-501363	19960605
US 6225335	B1	20010501	US 1998-212494	19981215
US 6316635	B1	20011113	US 1999-293518	19990415
US 2002022626	A1	20020221	US 2000-617529	20000713
US 2002102608	A1	20020801	US 2001-897755	20010703

PRIORITY APPLN. INFO.:

US 1995-485323 A2 19950607
EP 1996-918093 A3 19960605
JP 1997-501363 A3 19960605
US 1996-655223 A2 19960605
US 1996-655224 A2 19960605
US 1996-655226 A2 19960605
US 1996-655255 B2 19960605
US 1996-659191 A1 19960605
US 1996-702232 B1 19960823
US 1997-915366 A3 19970820
US 1998-82056P P 19980416
US 1998-212494 A2 19981215

OTHER SOURCE(S): MARPAT 130:237470

GI



I

AB Title compds. [I; R1 = H or alkyl; R3 = ZR2, 5-membered heteroaryl, etc.; R2 = OR, NRaRb, etc.; R = H, alkyl, aryl, etc.; Ra,Rb = H, alkyl, COR, etc.; NRaRb = heterocyclyl; R4-R7 = H, halo, alkyl, alkoxy, etc.; X = O or S; Z = (un)substituted 1,4-phenylene] were prepd. Thus, PhCHO was condensed with 2-oxindole to give I (R1 = R4-R7 = H, R3 = Ph, X = O). Data for biol. activity of I were given.

IT **186611-29-0P**, SU 5453 **186611-48-3P**, SU 5477
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of 3-benzylidene-2-indolinones as tyrosine kinase activity modulators)

RN 186611-29-0 CAPLUS

CN 2H-Indol-2-one, 3-[(3-ethyl-4,5-dimethyl-1H-pyrrol-2-yl)methylene]-1,3-dihydro- (9CI) (CA INDEX NAME)





RN 186611-48-3 CAPLUS
CN 2H-Indol-2-one, 3-[(4-ethyl-3,5-dimethyl-1H-pyrrol-2-yl)methylene]-1,3-dihydro- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 56 THERE ARE 56 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 5 OF 10 CAPLUS COPYRIGHT 2003 ACS
ACCESSION NUMBER: 1998:747592 CAPLUS
DOCUMENT NUMBER: 130:3771
TITLE: Preparation of 3-(hetero)arylmethylidene-2-indolinone derivatives as modulators of protein kinase activity for use in treating cancer.
INVENTOR(S): Tang, Peng Cho; Sun, Li; McMahon, Gerald; Shawver, Laura Kay; Hirth, Klaus Peter
PATENT ASSIGNEE(S): Sugen, Inc., USA
SOURCE: PCT Int. Appl., 269 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 3
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9850356	A1	19981112	WO 1998-US9017	19980507
W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, GW, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
AU 9876842	A1	19981127	AU 1998-76842	19980507
EP 984930	A1	20000315	EP 1998-924746	19980507
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI				
JP 2002511852	T2	20020416	JP 1998-548319	19980507
US 6051593	A	20000418	US 1998-99721	19980619

US 6313158	B1	20011106	US 1998-100854		19980619
US 6133305	A	20001017	US 1998-161046		19980925
US 2001056094	A1	20011227	US 2000-482198		20000112
US 2001007033	A1	20010705	US 2000-516948		20000301
US 2002026053	A1	20020228	US 2001-916331		20010730
US 6506763	B2	20030114			
US 2002058661	A1	20020516	US 2001-948106		20010907
US 2002183370	A1	20021205	US 2001-29946		20011231

PRIORITY APPLN. INFO.:

US 1997-45838P	P	19970507
US 1997-46868P	P	19970508
US 1997-49324P	P	19970611
US 1997-50412P	P	19970620
US 1997-50413P	P	19970620
US 1997-50977P	P	19970620
US 1997-59336P	P	19970919
US 1997-59381P	P	19970919
US 1997-59384P	P	19970919
US 1997-59544P	P	19970919
US 1997-59677P	P	19970919
US 1997-59971P	P	19970925
US 1997-60194P	P	19970926
WO 1998-US9017	W	19980507
US 1998-100854	A3	19980619
US 1998-99721	A1	19980619
US 1998-161046	A3	19980925
US 2000-482198	A3	20000112
US 2000-516948	B1	20000301

OTHER SOURCE(S): MARPAT 130:3771

GI



I

AB Title compds. [I; A1-A4 = C, N; when any of A1-A4 = N, then the corresponding R3-R6 = null; R1 = H, alkyl, cycloalkyl, alkenyl, alkynyl, aryl, heteroaryl, heteroalicyclyl, trihalomethylcarbonyl, OH, CO2H, trihalomethylsulfonyl, etc.; R2 = H, alkyl, cycloalkyl, aryl, heteroaryl, heteroalicyclyl, halo; R3-R6 = H, alkyl, trihalomethyl, cycloalkyl, alkenyl, alkynyl, aryl, heteroaryl, heteroalicyclyl, OH, SH, alkoxy, aryloxy, amino, phosphonyl, guanidinyl, NO2, halo, (iso)cyanato, etc.; R3R4 or R4R5 or R5R6 = cycloalkyl, aryl, heteroaryl, heteroalicyclyl, OCH2O, OCH2CH2O; Q = specified (substituted) (hetero)aryl; Z = O, S], were prepd. Thus, 3-(4-imidazolylmethylidenyl)-4,6-dimethyl-2-indolinone inhibited CDK2 with IC50 = <0.78 .mu.M.

IT **215537-01-2**

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(prepn. of 3-(hetero)arylmethylidene-2-indolinone derivs. as modulators of protein kinase activity for use in treating cancer)

RN 215537-01-2 CAPLUS

CN 2H-Indol-2-one, 5,7-dibromo-3-[(4-ethyl-3,5-dimethyl-1H-pyrrol-2-yl)methylene]-1,3-dihydro-4-methyl- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 6 OF 10 CAPLUS COPYRIGHT 2003 ACS

ACCESSION NUMBER: 1998:735056 CAPLUS

DOCUMENT NUMBER: 129:330650

TITLE: Preparation of 3-benzylidene-2-indolinones and analogs as tyrosine kinase signal transduction modulators

INVENTOR(S): Tang, Peng Cho; Sun, Li; McMahon, Gerald

PATENT ASSIGNEE(S): Sugen Inc., USA

SOURCE: U.S., 34 pp., Cont.-in-part of U.S. Ser. No. 485,323.
CODEN: USXXAM

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 9

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 5834504	A	19981110	US 1996-655225	19960605
US 5880141	A	19990309	US 1995-485323	19950607
CA 2192797	AA	19961219	CA 1996-2192797	19960605
EP 934931	A2	19990811	EP 1999-103667	19960605
EP 934931	A3	19991020		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI				
JP 2000026412	A2	20000125	JP 1999-159567	19960605
ES 2159741	T3	20011016	ES 1996-918093	19960605
JP 3231044	B2	20011119	JP 1997-501363	19960605
US 2002022626	A1	20020221	US 2000-617529	20000713

PRIORITY APPLN. INFO.:
US 1995-485323 A2 19950607
EP 1996-918093 A3 19960605
JP 1997-501363 A3 19960605
US 1997-915366 A3 19970820

OTHER SOURCE(S): MARPAT 129:330650

GI



I

AB Title compds. [I; R1 = H or alkyl; R2 = 2-halo-4-hydroxy- or -alkoxyphenyl, 4-hydroxy- or -alkoxyphenyl, 4-(di)(alkyl)aminophenyl, heteroaryl, etc.; R4-R7 = H, halo, alkyl, alkoxy, etc.; X = O or S] were prepd. Thus, oxindole was condensed with 2-chloro-4-methoxybenzaldehyde to give I (R1 = R4-R7 = H, R2 = 2-chloro-4-methoxyphenyl, X = O). Data for biol. activity of I were given.

IT **186611-29-0P 186611-48-3P**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of 3-benzylidene-2-indolinones and analogs as tyrosine kinase signal transduction modulators)

RN 186611-29-0 CAPLUS
CN 2H-Indol-2-one, 3-[(3-ethyl-4,5-dimethyl-1H-pyrrol-2-yl)methylene]-1,3-dihydro- (9CI) (CA INDEX NAME)



RN 186611-48-3 CAPLUS
CN 2H-Indol-2-one, 3-[(4-ethyl-3,5-dimethyl-1H-pyrrol-2-yl)methylene]-1,3-dihydro- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 181 THERE ARE 181 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 7 OF 10 CAPLUS COPYRIGHT 2003 ACS
ACCESSION NUMBER: 1998:542764 CAPLUS
DOCUMENT NUMBER: 129:175549
TITLE: Preparation of 3-(hetero)arylmethylene-2-indolinones

as tyrosine kinase signal transduction modulators
INVENTOR(S): Tang, Peng Cho; Sun, Li; McMahon, Gerald
PATENT ASSIGNEE(S): Sugen, Inc., USA
SOURCE: U.S., 37 pp., Cont.-in-part of U. S. Ser. No. 485,323.
CODEN: USXXAM
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 9
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 5792783	A	19980811	US 1996-655223	19960605
US 5880141	A	19990309	US 1995-485323	19950607
CA 2192797	AA	19961219	CA 1996-2192797	19960605
EP 934931	A2	19990811	EP 1999-103667	19960605
EP 934931	A3	19991020		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI				
JP 2000026412	A2	20000125	JP 1999-159567	19960605
ES 2159741	T3	20011016	ES 1996-918093	19960605
JP 3231044	B2	20011119	JP 1997-501363	19960605
US 6316635	B1	20011113	US 1999-293518	19990415
US 2002022626	A1	20020221	US 2000-617529	20000713
US 2002102608	A1	20020801	US 2001-897755	20010703

PRIORITY APPLN. INFO.:

US 1995-485323	A2	19950607
EP 1996-918093	A3	19960605
JP 1997-501363	A3	19960605
US 1996-655223	A2	19960605
US 1996-655224	A2	19960605
US 1996-655226	A2	19960605
US 1996-655255	B2	19960605
US 1996-659191	A1	19960605
US 1996-702232	B1	19960823
US 1997-915366	A3	19970820
US 1998-82056P	P	19980416
US 1998-212494	A2	19981215

OTHER SOURCE(S): MARPAT 129:175549
GI



I

AB Title compds. [I; R1 = H or alkyl; R2 = (un)substituted (hetero)aryl; R4-R7 = H, halo, alkyl, alkoxy, etc.; X = O or S] were prepd. Thus, oxindole was condensed with 4-pyridinecarboxaldehyde to give I (R1,R4-R7 = H, R2 = 4-pyridinyl, X = O). Data for biol. activity of I were given.

IT **186611-29-0P 186611-48-3P**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use);

BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of 3-(hetero)arylmethylene-2-indolinones as tyrosine kinase signal transduction modulators)

RN 186611-29-0 CAPLUS
CN 2H-Indol-2-one, 3-[(3-ethyl-4,5-dimethyl-1H-pyrrol-2-yl)methylene]-1,3-dihydro- (9CI) (CA INDEX NAME)



RN 186611-48-3 CAPLUS
CN 2H-Indol-2-one, 3-[(4-ethyl-3,5-dimethyl-1H-pyrrol-2-yl)methylene]-1,3-dihydro- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 179 THERE ARE 179 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 8 OF 10 CAPLUS COPYRIGHT 2003 ACS
ACCESSION NUMBER: 1998:429042 CAPLUS
DOCUMENT NUMBER: 129:117426
TITLE: Synthesis and Biological Evaluations of 3-Substituted Indolin-2-ones: A Novel Class of Tyrosine Kinase Inhibitors That Exhibit Selectivity toward Particular Receptor Tyrosine Kinases
AUTHOR(S): Sun, Li; Tran, Ngoc; Tang, Flora; App, Harald; Hirth, Peter; McMahon, Gerald; Tang, Cho
CORPORATE SOURCE: SUGEN Inc, Redwood City, CA, 94063, USA
SOURCE: Journal of Medicinal Chemistry (1998), 41(14), 2588-2603
CODEN: JMCMAR; ISSN: 0022-2623
PUBLISHER: American Chemical Society
DOCUMENT TYPE: Journal
LANGUAGE: English

AB 3-Substituted indolin-2-ones have been designed and synthesized as a novel class of tyrosine kinase inhibitors which exhibit selectivity toward different receptor tyrosine kinases (RTKs). These compds. have been evaluated for their relative inhibitory properties against a panel of RTKs in intact cells. By modifying the 3-substituted indolin-2-ones, we have identified compds. which showed selective inhibition of the ligand-dependent autophosphorylation of various RTKs at submicromolar levels in cells. Structure-activity anal. for these compds. and their

relative potency and selectivity to inhibit particular RTKs has detd. that (1) 3-[(five-membered heteroaryl ring)methylidenyl]indolin-2-ones are highly specific against the VEGF (Flk-1) RTK activity, (2) 3-(substituted benzylidenyl)indolin-2-ones contg. bulky group(s) in the Ph ring at the C-3 position of indolin-2-ones showed high selectivity toward the EGF and Her-2 RTKs, and (3) the compd. contg. an extended side chain at the C-3 position of the indolin-2-one exhibited high potency and selectivity when tested against the PDGF and VEGF (Flk-1) RTKs. Recent published crystallog. data for two of these 3-substituted indolin-2-ones provides a rationale to suggest that these compds. may bind in the ATP binding pocket of RTKs. The structure-activity anal. supports the use of subsets of these compds. as specific chem. leads for the development of RTK-specific drugs with broad application for the treatment of human diseases.

IT **210303-53-0P 210303-55-2P**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); PRP (Properties); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
(prepn. and evaluation of 3-substituted indolin-2-ones as inhibitors of selective growth factor receptors)

RN 210303-53-0 CAPLUS
CN 2H-Indol-2-one, 3-[(4-ethyl-3,5-dimethyl-1H-pyrrol-2-yl)methylene]-1,3-dihydro-, (3Z)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 210303-55-2 CAPLUS
CN 2H-Indol-2-one, 3-[(3-ethyl-4,5-dimethyl-1H-pyrrol-2-yl)methylene]-1,3-dihydro-, (3Z)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



REFERENCE COUNT: 20 THERE ARE 20 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 9 OF 10 CAPLUS COPYRIGHT 2003 ACS
ACCESSION NUMBER: 1998:147306 CAPLUS
DOCUMENT NUMBER: 128:204803
TITLE: Indolinone combinatorial libraries and related products and methods for the treatment of disease
INVENTOR(S): Tang, Peng Cho; Sun, Li; McMahon, Gerald; Hirth, Klaus Peter; Shawver, Laura Kay; et al.

PATENT ASSIGNEE(S): Sugen, Inc., USA; Tang, Peng Cho; Sun, Li; McMahon, Gerald
SOURCE: PCT Int. Appl., 293 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 9
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9807695	A1	19980226	WO 1997-US14736	19970820
W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
CN 1155838	A	19970730	CN 1996-190616	19960605
EP 929520	A1	19990721	EP 1997-939480	19970820
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI				
US 6147106	A	20001114	US 1997-915366	19970820
JP 2001503736	T2	20010321	JP 1998-510973	19970820
EP 1247803	A2	20021009	EP 2002-77564	19970820
EP 1247803	A3	20021016		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI				
AU 9741556	A1	19980306	AU 1997-41556	19970821
US 2002022626	A1	20020221	US 2000-617529	20000713

PRIORITY APPLN. INFO.:			
US 1996-702232	A	19960823
US 1996-31585P	P	19961205
US 1996-31586P	P	19961205
US 1996-31588P	P	19961205
US 1996-32546P	P	19961205
US 1996-32547P	P	19961205
US 1997-45565P	P	19970505
US 1997-45566P	P	19970505
US 1997-45714P	P	19970505
US 1997-45715P	P	19970505
US 1997-46843P	P	19970505
US 1996-45715P	P	19961205
US 1997-31565P	P	19970505
EP 1997-939480	A3	19970820
US 1997-915366	A3	19970820
WO 1997-US14736	W	19970820

OTHER SOURCE(S): MARPAT 128:204803
GI



I

AB The invention relates to indolinone derivs. capable of modulating, regulating, and/or inhibiting protein kinase signal transduction. The compds. are useful for the treatment of diseases related to unregulated protein kinase signal transduction, including cell proliferative diseases such as cancer, atherosclerosis, arthritis, and restenosis, and metabolic diseases such as diabetes. Inhibitors specific to the FLK protein kinase can be obtained by adding chem. substituents to the 3-[(indole-3-yl)methylene]-2-indolinone system, in particular at the 1' position of the indole ring. Indolinone compds. that specifically inhibit the FLK and platelet derived growth factor protein kinases can harbor a tetrahydroindole or cyclopentano[b]pyrrole moiety. Indolinone compds. that are modified with substituents, particularly at the 5 position of the oxindole ring, can effectively activate protein kinases. This invention also features novel hydrosol. indolinone compds. that are tyrosine kinase inhibitors, and related products and methods. Approx. 1200 title compds., such as I, were prepd. by combinatorial condensation of certain (un)substituted indolinones with aldehydes at the 3-position. I gave complete inhibition of MET kinase at chimeric MET receptors in vitro.

IT **203989-88-2P**, 3-[(2,4-Dimethyl-3-ethylpyrrol-5-yl)methylidenyl]-5,7-dibromo-2-indolinone **203989-98-4P**, 3-[(2,4-Dimethyl-3-ethylpyrrol-5-yl)methylidenyl]-5-iodo-2-indolinone **203990-08-3P**, 3-[(2,4-Dimethyl-3-ethylpyrrol-5-yl)methylidenyl]-5-bromo-4-methyl-2-indolinone **203990-18-5P**, 3-[(2,4-Dimethyl-3-ethylpyrrol-5-yl)methylidenyl]-5-[(methylamino)sulfonyl]-2-indolinone **203990-28-7P**, 3-[(2,4-Dimethyl-3-ethylpyrrol-5-yl)methylidenyl]-5-[[[4-(trifluoromethyl)phenyl]amino]sulfonyl]-2-indolinone **203990-38-9P**, 3-[(2,4-Dimethyl-3-ethylpyrrol-5-yl)methylidenyl]-5-(morpholinosulfonyl)-2-indolinone **203990-48-1P**, 3-[(2,4-Dimethyl-3-ethylpyrrol-5-yl)methylidenyl]-5-(2-chloroethyl)-2-indolinone **204005-38-9P**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. and testing of indolinone combinatorial library as protein kinase inhibitors)

RN 203989-88-2 CAPLUS

CN 2H-Indol-2-one, 5,7-dibromo-3-[(4-ethyl-3,5-dimethyl-1H-pyrrol-2-yl)methylene]-1,3-dihydro- (9CI) (CA INDEX NAME)



RN 203989-98-4 CAPLUS
CN 2H-Indol-2-one, 3-[(4-ethyl-3,5-dimethyl-1H-pyrrol-2-yl)methylene]-1,3-dihydro-5-iodo- (9CI) (CA INDEX NAME)



RN 203990-08-3 CAPLUS
CN 2H-Indol-2-one, 5-bromo-3-[(4-ethyl-3,5-dimethyl-1H-pyrrol-2-yl)methylene]-1,3-dihydro-4-methyl- (9CI) (CA INDEX NAME)



RN 203990-18-5 CAPLUS
CN 1H-Indole-5-sulfonamide, 3-[(4-ethyl-3,5-dimethyl-1H-pyrrol-2-yl)methylene]-2,3-dihydro-N-methyl-2-oxo- (9CI) (CA INDEX NAME)



RN 203990-28-7 CAPLUS
CN 1H-Indole-5-sulfonamide, 3-[(4-ethyl-3,5-dimethyl-1H-pyrrol-2-yl)methylene]-2,3-dihydro-2-oxo-N-[4-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



RN 203990-38-9 CAPLUS
CN Morpholine, 4-[[3-[(4-ethyl-3,5-dimethyl-1H-pyrrol-2-yl)methylene]-2,3-dihydro-2-oxo-1H-indol-5-yl]sulfonyl]- (9CI) (CA INDEX NAME)



RN 203990-48-1 CAPLUS
CN 2H-Indol-2-one, 5-(2-chloroethyl)-3-[(4-ethyl-3,5-dimethyl-1H-pyrrol-2-yl)methylene]-1,3-dihydro- (9CI) (CA INDEX NAME)



RN 204005-38-9 CAPLUS
CN 2H-Indol-2-one, 5-amino-3-[(4-ethyl-3,5-dimethyl-1H-pyrrol-2-yl)methylene]-1,3-dihydro- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 15 THERE ARE 15 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 10 OF 10 CAPLUS COPYRIGHT 2003 ACS
ACCESSION NUMBER: 1997:140244 CAPLUS
DOCUMENT NUMBER: 126:139901
TITLE: Indolinone compounds capable of modulating tyrosine kinase signal transduction

INVENTOR(S): Tang, Peng Cho; Sun, Li; Mcmahon, Gerald
PATENT ASSIGNEE(S): Sugen, Inc., USA
SOURCE: PCT Int. Appl., 133 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 9
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9640116	A1	19961219	WO 1996-US8903	19960605
W: AL, AM, AU, AZ, BB, BG, BR, BY, CA, CN, CZ, EE, FI, GE, HU, IL, IS, JP, KG, KP, KR, KZ, LK, LR, LS, LT, LV, MD, MG, MK, MN, MX, NO, NZ, PL, RO, RU, SG, SI, SK, TJ, TM, TR, TT, UA, UZ, VN, AM, AZ, BY				
RW: KE, LS, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
US 5880141	A	19990309	US 1995-485323	19950607
CA 2192797	AA	19961219	CA 1996-2192797	19960605
AU 9660441	A1	19961230	AU 1996-60441	19960605
AU 706597	B2	19990617		
EP 769947	A1	19970502	EP 1996-918093	19960605
EP 769947	B1	20010502		
R: AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE				
BR 9606410	A	19971230	BR 1996-6410	19960605
JP 10504323	T2	19980428	JP 1996-501363	19960605
EP 934931	A2	19990811	EP 1999-103667	19960605
EP 934931	A3	19991020		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI				
JP 2000026412	A2	20000125	JP 1999-159567	19960605
AT 200863	E	20010515	AT 1996-918093	19960605
ES 2159741	T3	20011016	ES 1996-918093	19960605
JP 3231044	B2	20011119	JP 1997-501363	19960605
NO 9605377	A	19970212	NO 1996-5377	19961213
HK 1011933	A1	20020118	HK 1998-113193	19981211
US 2002022626	A1	20020221	US 2000-617529	20000713

PRIORITY APPLN. INFO.:

US 1995-485323	A	19950607
EP 1996-918093	A3	19960605
JP 1997-501363	A3	19960605
WO 1996-US8903	W	19960605
US 1997-915366	A3	19970820

OTHER SOURCE(S): MARPAT 126:139901

AB The present invention relates to org. mols. capable of modulating tyrosine kinase signal transduction in order to regulate, modulate and/or inhibit abnormal cell proliferation. Representatives of the 5 different classes of compds. described are SU 4932 [3-(2-chloro-4-hydroxybenzylidenyl)-2-indolinone], SU 4312 [3-(4-dimethylaminobenzylidenyl)-2-indolinone], SU 5416 {3-[(2,4-dimethylpyrrol-5-yl)methylene]-2-indolinone}, SU 5204 [3-(2-ethoxybenzylidenyl)-2-indolinone], and SU 4942 [3-(4-bromobenzylidenyl)-2-indolinone]. Diseases which these compds. and their pharmaceutically acceptable prepns. may be effective against include arthritis, hepatic cirrhosis, diabetic nephropathy and psoriasis.

IT **186611-29-0P**, SU 5453 **186611-48-3P**, SU 5477
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use);

BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of indolinones capable of modulating tyrosine kinase signal transduction)

RN 186611-29-0 CAPLUS
CN 2H-Indol-2-one, 3-[(3-ethyl-4,5-dimethyl-1H-pyrrol-2-yl)methylene]-1,3-dihydro- (9CI) (CA INDEX NAME)



RN 186611-48-3 CAPLUS
CN 2H-Indol-2-one, 3-[(4-ethyl-3,5-dimethyl-1H-pyrrol-2-yl)methylene]-1,3-dihydro- (9CI) (CA INDEX NAME)



09897755

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:SSSPTA1613SXW

PASSWORD:
TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * * * * * * Welcome to STN International * * * * * * * * * *

NEWS	1		Web Page URLs for STN Seminar Schedule - N. America
NEWS	2	Apr 08	"Ask CAS" for self-help around the clock
NEWS	3	Jun 03	New e-mail delivery for search results now available
NEWS	4	Aug 08	PHARMAMarketLetter(PHARMAML) - new on STN
NEWS	5	Aug 19	Aquatic Toxicity Information Retrieval (AQUIRE) now available on STN
NEWS	6	Aug 26	Sequence searching in REGISTRY enhanced
NEWS	7	Sep 03	JAPIO has been reloaded and enhanced
NEWS	8	Sep 16	Experimental properties added to the REGISTRY file
NEWS	9	Sep 16	CA Section Thesaurus available in CAPLUS and CA
NEWS	10	Oct 01	CASREACT Enriched with Reactions from 1907 to 1985
NEWS	11	Oct 24	BEILSTEIN adds new search fields
NEWS	12	Oct 24	Nutraceuticals International (NUTRACEUT) now available on STN
NEWS	13	Nov 18	DKILIT has been renamed APOLLIT
NEWS	14	Nov 25	More calculated properties added to REGISTRY
NEWS	15	Dec 04	CSA files on STN
NEWS	16	Dec 17	PCTFULL now covers WP/PCT Applications from 1978 to date
NEWS	17	Dec 17	TOXCENTER enhanced with additional content
NEWS	18	Dec 17	Adis Clinical Trials Insight now available on STN
NEWS	19	Jan 29	Simultaneous left and right truncation added to COMPENDEX, ENERGY, INSPEC
NEWS	20	Feb 13	CANCERLIT is no longer being updated
NEWS	21	Feb 24	METADEX enhancements
NEWS	22	Feb 24	PCTGEN now available on STN
NEWS	23	Feb 24	TEMA now available on STN
NEWS	24	Feb 26	NTIS now allows simultaneous left and right truncation
NEWS	25	Feb 26	PCTFULL now contains images
NEWS	26	Mar 04	SDI PACKAGE for monthly delivery of multifile SDI results
NEWS	27	Mar 19	APOLLIT offering free connect time in April 2003
NEWS	28	Mar 20	EVENTLINE will be removed from STN
NEWS	29	Mar 24	PATDPAFULL now available on STN
NEWS	30	Mar 24	Additional information for trade-named substances without structures available in REGISTRY
NEWS	31	Apr 11	Display formats in DGENE enhanced
NEWS	32	Apr 14	MEDLINE Reload
NEWS	33	Apr 17	Polymer searching in REGISTRY enhanced
NEWS	34	Apr 21	Indexing from 1947 to 1956 being added to records in CA/CAPLUS
NEWS	35	Apr 21	New current-awareness alert (SDI) frequency in WPIDS/WPINDEX/WPIX
NEWS	36	Apr 28	RDISCLOSURE now available on STN
NEWS	37	May 05	Pharmacokinetic information and systematic chemical names added to PHAR

09897755

```
 NEWS EXPRESS  April 4 CURRENT WINDOWS VERSION IS V6.01a, CURRENT
               MACINTOSH VERSION IS V6.0b(ENG) AND V6.0Jb(JP),
               AND CURRENT DISCOVER FILE IS DATED 01 APRIL 2003
 NEWS HOURS    STN Operating Hours Plus Help Desk Availability
 NEWS INTER    General Internet Information
 NEWS LOGIN    Welcome Banner and News Items
 NEWS PHONE    Direct Dial and Telecommunication Network Access to STN
 NEWS WWW      CAS World Wide Web Site (general information)

Enter NEWS followed by the item number or name to see news on that
specific topic.

  All use of STN is subject to the provisions of the STN Customer
  agreement.  Please note that this agreement limits use to scientific
  research.  Use for software development or design or implementation
  of commercial gateways or other similar uses is prohibited and may
  result in loss of user privileges and other penalties.

  * * * * * * * * * * * * * * STN  Columbus  * * * * * * * * * * * * * * *



FILE 'HOME' ENTERED AT 16:01:55 ON 08 MAY 2003

=> fil reg
COST IN U.S. DOLLARS                            SINCE FILE      TOTAL
                                                   ENTRY    SESSION
FULL ESTIMATED COST                                 0.21       0.21

FILE 'REGISTRY' ENTERED AT 16:02:04 ON 08 MAY 2003
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2003 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES:     6 MAY 2003  HIGHEST RN 511508-58-0
DICTIONARY FILE UPDATES:    6 MAY 2003  HIGHEST RN 511508-58-0

TSCA INFORMATION NOW CURRENT THROUGH JANUARY 6, 2003

  Please note that search-term pricing does apply when
  conducting SmartSELECT searches.

Crossover limits have been increased.  See HELP CROSSOVER for details.

Experimental and calculated property data are now available.  See HELP
PROPERTIES for more information.  See STNote 27, Searching Properties
in the CAS Registry File, for complete details:
http://www.cas.org/ONLINE/STN/STNOTES/stnotes27.pdf

=>
Uploading 09897755.str

L1      STRUCTURE UPLOADED

=> d
```

09897755

L1 HAS NO ANSWERS
L1 STR



Structure attributes must be viewed using STN Express query preparation.

=> s l1 sss sam
SAMPLE SEARCH INITIATED 16:02:20 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED - 3611 TO ITERATE

27.7% PROCESSED 1000 ITERATIONS 17 ANSWERS
INCOMPLETE SEARCH (SYSTEM LIMIT EXCEEDED)
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **COMPLETE**
BATCH **COMPLETE**
PROJECTED ITERATIONS: 68618 TO 75822
PROJECTED ANSWERS: 757 TO 1697

L2 17 SEA SSS SAM L1

=> s l1 full
FULL SEARCH INITIATED 16:02:23 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED - 73085 TO ITERATE

100.0% PROCESSED 73085 ITERATIONS 1549 ANSWERS
SEARCH TIME: 00.00.02

L3 1549 SEA SSS FUL L1

=> fil caplus
COST IN U.S. DOLLARS SINCE FILE ENTRY TOTAL SESSION
FULL ESTIMATED COST 148.15 148.36

FILE 'CAPLUS' ENTERED AT 16:02:30 ON 08 MAY 2003
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2003 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is

held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 8 May 2003 VOL 138 ISS 19
FILE LAST UPDATED: 7 May 2003 (20030507/ED)

This file contains CAS Registry Numbers for easy and accurate substance identification.

=> s l3 full
L4 121 L3

=> d l4 111-121 ibib abs hitstr

L4 ANSWER 111 OF 121 CAPLUS COPYRIGHT 2003 ACS
ACCESSION NUMBER: 1998:735056 CAPLUS
DOCUMENT NUMBER: 129:330650
TITLE: Preparation of 3-benzylidene-2-indolinones and analogs as tyrosine kinase signal transduction modulators
INVENTOR(S): Tang, Peng Cho; Sun, Li; McMahon, Gerald
PATENT ASSIGNEE(S): Sugen Inc., USA
SOURCE: U.S., 34 pp., Cont.-in-part of U.S. Ser. No. 485,323.
CODEN: USXXAM
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 9
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 5834504	A	19981110	US 1996-655225	19960605
US 5880141	A	19990309	US 1995-485323	19950607
CA 2192797	AA	19961219	CA 1996-2192797	19960605
EP 934931	A2	19990811	EP 1999-103667	19960605
EP 934931	A3	19991020		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI				
JP 2000026412	A2	20000125	JP 1999-159567	19960605
ES 2159741	T3	20011016	ES 1996-918093	19960605
JP 3231044	B2	20011119	JP 1997-501363	19960605
US 2002022626	A1	20020221	US 2000-617529	20000713

PRIORITY APPLN. INFO.: US 1995-485323 A2 19950607
EP 1996-918093 A3 19960605
JP 1997-501363 A3 19960605
US 1997-915366 A3 19970820
OTHER SOURCE(S): MARPAT 129:330650
GI



I

AB Title compds. [I; R1 = H or alkyl; R2 = 2-halo-4-hydroxy- or -alkoxyphenyl, 4-hydroxy- or -alkoxyphenyl, 4-(di)(alkyl)aminophenyl, heteroaryl, etc.; R4-R7 = H, halo, alkyl, alkoxy, etc.; X = O or S] were prepd. Thus, oxindole was condensed with 2-chloro-4-methoxybenzaldehyde to give I (R1 = R4-R7 = H, R2 = 2-chloro-4-methoxyphenyl, X = O). Data for biol. activity of I were given.

IT **15966-93-5P 186610-94-6P 186611-14-3P**
186611-16-5P 186611-29-0P 186611-30-3P
186611-31-4P 186611-37-0P 186611-39-2P
186611-48-3P 204005-03-8P 204005-46-9P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of 3-benzylidene-2-indolinones and analogs as tyrosine kinase signal transduction modulators)

RN 15966-93-5 CAPLUS

CN 1H-Pyrrole-3-carboxylic acid, 5-[(1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl-, ethyl ester (9CI) (CA INDEX NAME)



RN 186610-94-6 CAPLUS

CN 2H-Indol-2-one, 3-[(3,4-dimethyl-1H-pyrrol-2-yl)methylene]-1,3-dihydro- (9CI) (CA INDEX NAME)



RN 186611-14-3 CAPLUS

CN 1H-Pyrrole-3-propanoic acid, 5-[(1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-4-methyl- (9CI) (CA INDEX NAME)



RN 186611-16-5 CAPLUS
CN 1H-Pyrrole-2-carboxaldehyde, 5-[(1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-3,4-dimethyl- (9CI) (CA INDEX NAME)



RN 186611-29-0 CAPLUS
CN 2H-Indol-2-one, 3-[(3-ethyl-4,5-dimethyl-1H-pyrrol-2-yl)methylene]-1,3-dihydro- (9CI) (CA INDEX NAME)



RN 186611-30-3 CAPLUS
CN 1H-Pyrrole-3-propanoic acid, 5-[(1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2-(ethoxycarbonyl)-4-(2-ethoxy-2-oxoethyl)-, ethyl ester (9CI) (CA INDEX NAME)



RN 186611-31-4 CAPLUS
CN 1H-Pyrrole-2-carboxylic acid, 5-[(1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-4-ethyl-3-methyl- (9CI) (CA INDEX NAME)



RN 186611-37-0 CAPLUS
CN 1H-Pyrrole-3-carboxylic acid, 5-[(1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-4-methyl-, ethyl ester (9CI) (CA INDEX NAME)



RN 186611-39-2 CAPLUS
CN 1H-Pyrrole-3-propanoic acid, 2-[(1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-5-(ethoxycarbonyl)-4-(2-ethoxy-2-oxoethyl)-, ethyl ester (9CI) (CA INDEX NAME)



RN 186611-48-3 CAPLUS
CN 2H-Indol-2-one, 3-[(4-ethyl-3,5-dimethyl-1H-pyrrol-2-yl)methylene]-1,3-dihydro- (9CI) (CA INDEX NAME)



RN 204005-03-8 CAPLUS
CN 1H-Pyrrole-3-propanoic acid, 5-[(1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-4-methyl-, methyl ester (9CI) (CA INDEX NAME)



RN 204005-46-9 CAPLUS
CN 2H-Indol-2-one, 3-[(3,5-dimethyl-1H-pyrrol-2-yl)methylene]-1,3-dihydro-(9CI) (CA INDEX NAME)



REFERENCE COUNT: 181 THERE ARE 181 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 112 OF 121 CAPLUS COPYRIGHT 2003 ACS
ACCESSION NUMBER: 1998:685118 CAPLUS
DOCUMENT NUMBER: 129:310905
TITLE: Study and treatment of diseases related to specific cellular functions of receptor protein tyrosine kinases
INVENTOR(S): Clary, Douglas
PATENT ASSIGNEE(S): Sugen, Inc., USA
SOURCE: PCT Int. Appl., 81 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9845708	A1	19981015	WO 1998-US6842	19980407
W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, GW, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
AU 9868876	A1	19981030	AU 1998-68876	19980407
US 2002068361	A1	20020606	US 1998-57150	19980407
US 6235769	B1	20010522	US 1998-109883	19980702

PRIORITY APPLN. INFO.: US 1997-43207P P 19970408
US 1997-51715P P 19970703

WO 1998-US6842 W 19980407

AB The invention relates to methods of evaluating the specific function of a receptor protein tyrosine kinase in cells by activating the receptor in a ligand-independent fashion. In addn., the invention includes methods of identifying compds. that modulate receptor protein tyrosine kinase function. The invention also relates to a method of preventing or treating an abnormal condition caused by an aberration in the function of the C-RET receptor, and specifically to the treatment and prevention of neurodegenerative disorders by administering a compd. that modulates the function of the C-RET receptor.

IT **204003-90-7 204003-91-8 204003-96-3**
204003-97-4
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(study and treatment of diseases related to specific cellular functions of receptor protein tyrosine kinases, and screening method)

RN 204003-90-7 CAPLUS

CN 1H-Indole-5-carboxylic acid, 3-[(3,5-dimethyl-1H-pyrrol-2-yl)methylene]-2,3-dihydro-2-oxo- (9CI) (CA INDEX NAME)



RN 204003-91-8 CAPLUS

CN 1H-Indole-5-carboxylic acid, 3-[(3,5-diethyl-1H-pyrrol-2-yl)methylene]-2,3-dihydro-2-oxo- (9CI) (CA INDEX NAME)



RN 204003-96-3 CAPLUS

CN 1H-Indole-5-carboxylic acid, 3-[[3,5-bis(1-methylethyl)-1H-pyrrol-2-yl]methylene]-2,3-dihydro-2-oxo- (9CI) (CA INDEX NAME)



RN 204003-97-4 CAPLUS
CN 1H-Indole-5-propanoic acid, 3-[(3,5-dimethyl-1H-pyrrol-2-yl)methylene]-2,3-dihydro-2-oxo- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 8 THERE ARE 8 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 113 OF 121 CAPLUS COPYRIGHT 2003 ACS
ACCESSION NUMBER: 1998:542764 CAPLUS
DOCUMENT NUMBER: 129:175549
TITLE: Preparation of 3-(hetero)arylmethylene-2-indolinones as tyrosine kinase signal transduction modulators
INVENTOR(S): Tang, Peng Cho; Sun, Li; McMahon, Gerald
PATENT ASSIGNEE(S): Sugen, Inc., USA
SOURCE: U.S., 37 pp., Cont.-in-part of U. S. Ser. No. 485,323.
CODEN: USXXAM
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 9
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 5792783	A	19980811	US 1996-655223	19960605
US 5880141	A	19990309	US 1995-485323	19950607
CA 2192797	AA	19961219	CA 1996-2192797	19960605
EP 934931	A2	19990811	EP 1999-103667	19960605
EP 934931	A3	19991020		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI				
JP 2000026412	A2	20000125	JP 1999-159567	19960605
ES 2159741	T3	20011016	ES 1996-918093	19960605
JP 3231044	B2	20011119	JP 1997-501363	19960605
US 6316635	B1	20011113	US 1999-293518	19990415
US 2002022626	A1	20020221	US 2000-617529	20000713
US 2002102608	A1	20020801	US 2001-897755	20010703

PRIORITY APPLN. INFO.:
US 1995-485323 A2 19950607
EP 1996-918093 A3 19960605
JP 1997-501363 A3 19960605
US 1996-655223 A2 19960605
US 1996-655224 A2 19960605
US 1996-655226 A2 19960605
US 1996-655255 B2 19960605
US 1996-659191 A1 19960605
US 1996-702232 B1 19960823
US 1997-915366 A3 19970820
US 1998-82056P P 19980416
US 1998-212494 A2 19981215

OTHER SOURCE(S): MARPAT 129:175549

GI



I

AB Title compds. [I; R1 = H or alkyl; R2 = (un)substituted (hetero)aryl; R4-R7 = H, halo, alkyl, alkoxy, etc.; X = O or S] were prepd. Thus, oxindole was condensed with 4-pyridinecarboxaldehyde to give I (R1,R4-R7 = H, R2 = 4-pyridinyl, X = O). Data for biol. activity of I were given.

IT **15966-93-5P 186610-94-6P 186611-14-3P**
186611-16-5P 186611-17-6P 186611-29-0P
186611-30-3P 186611-31-4P 186611-37-0P
186611-39-2P 186611-48-3P 186611-56-3P
186611-67-6P 204005-46-9P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of 3-(hetero)arylmethylene-2-indolinones as tyrosine kinase signal transduction modulators)

RN 15966-93-5 CAPLUS

CN 1H-Pyrrole-3-carboxylic acid, 5-[(1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl-, ethyl ester (9CI) (CA INDEX NAME)



RN 186610-94-6 CAPLUS

CN 2H-Indol-2-one, 3-[(3,4-dimethyl-1H-pyrrol-2-yl)methylene]-1,3-dihydro- (9CI) (CA INDEX NAME)



RN 186611-14-3 CAPLUS
CN 1H-Pyrrole-3-propanoic acid, 5-[(1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-4-methyl- (9CI) (CA INDEX NAME)



RN 186611-16-5 CAPLUS
CN 1H-Pyrrole-2-carboxaldehyde, 5-[(1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-3,4-dimethyl- (9CI) (CA INDEX NAME)



RN 186611-17-6 CAPLUS
CN 1H-Pyrrole-3-propanoic acid, 2-[(1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-4-methyl-, methyl ester (9CI) (CA INDEX NAME)



RN 186611-29-0 CAPLUS
CN 2H-Indol-2-one, 3-[(3-ethyl-4,5-dimethyl-1H-pyrrol-2-yl)methylene]-1,3-dihydro- (9CI) (CA INDEX NAME)



RN 186611-30-3 CAPLUS
CN 1H-Pyrrole-3-propanoic acid, 5-[(1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2-(ethoxycarbonyl)-4-(2-ethoxy-2-oxoethyl)-, ethyl ester

(9CI) (CA INDEX NAME)



RN 186611-31-4 CAPLUS
CN 1H-Pyrrole-2-carboxylic acid, 5-[(1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-4-ethyl-3-methyl- (9CI) (CA INDEX NAME)



RN 186611-37-0 CAPLUS
CN 1H-Pyrrole-3-carboxylic acid, 5-[(1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-4-methyl-, ethyl ester (9CI) (CA INDEX NAME)



RN 186611-39-2 CAPLUS
CN 1H-Pyrrole-3-propanoic acid, 2-[(1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-5-(ethoxycarbonyl)-4-(2-ethoxy-2-oxoethyl)-, ethyl ester (9CI) (CA INDEX NAME)



RN 186611-48-3 CAPLUS

CN 2H-Indol-2-one, 3-[(4-ethyl-3,5-dimethyl-1H-pyrrol-2-yl)methylene]-1,3-dihydro- (9CI) (CA INDEX NAME)



RN 186611-56-3 CAPLUS
CN 2H-Indol-2-one, 5-chloro-3-[(3,5-dimethyl-1H-pyrrol-2-yl)methylene]-1,3-dihydro- (9CI) (CA INDEX NAME)



RN 186611-67-6 CAPLUS
CN 2H-Indol-2-one, 3-[(3,5-dimethyl-1H-pyrrol-2-yl)methylene]-1,3-dihydro-5-nitro- (9CI) (CA INDEX NAME)



RN 204005-46-9 CAPLUS
CN 2H-Indol-2-one, 3-[(3,5-dimethyl-1H-pyrrol-2-yl)methylene]-1,3-dihydro- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 179 THERE ARE 179 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 114 OF 121 CAPLUS COPYRIGHT 2003 ACS
ACCESSION NUMBER: 1998:429042 CAPLUS
DOCUMENT NUMBER: 129:117426
TITLE: Synthesis and Biological Evaluations of 3-Substituted Indolin-2-ones: A Novel Class of Tyrosine Kinase Inhibitors That Exhibit Selectivity toward Particular Receptor Tyrosine Kinases
AUTHOR(S): Sun, Li; Tran, Ngoc; Tang, Flora; App, Harald; Hirth, Peter; McMahon, Gerald; Tang, Cho
CORPORATE SOURCE: SUGEN Inc, Redwood City, CA, 94063, USA
SOURCE: Journal of Medicinal Chemistry (1998), 41(14), 2588-2603
CODEN: JMCMAR; ISSN: 0022-2623
PUBLISHER: American Chemical Society
DOCUMENT TYPE: Journal
LANGUAGE: English

AB 3-Substituted indolin-2-ones have been designed and synthesized as a novel class of tyrosine kinase inhibitors which exhibit selectivity toward different receptor tyrosine kinases (RTKs). These compds. have been evaluated for their relative inhibitory properties against a panel of RTKs in intact cells. By modifying the 3-substituted indolin-2-ones, we have identified compds. which showed selective inhibition of the ligand-dependent autophosphorylation of various RTKs at submicromolar levels in cells. Structure-activity anal. for these compds. and their relative potency and selectivity to inhibit particular RTKs has detd. that (1) 3-[(five-membered heteroaryl ring)methylidenyl]indolin-2-ones are highly specific against the VEGF (Flk-1) RTK activity, (2) 3-(substituted benzylidenyl)indolin-2-ones contg. bulky group(s) in the Ph ring at the C-3 position of indolin-2-ones showed high selectivity toward the EGF and Her-2 RTKs, and (3) the compd. contg. an extended side chain at the C-3 position of the indolin-2-one exhibited high potency and selectivity when tested against the PDGF and VEGF (Flk-1) RTKs. Recent published crystallog. data for two of these 3-substituted indolin-2-ones provides a rationale to suggest that these compds. may bind in the ATP binding pocket of RTKs. The structure-activity anal. supports the use of subsets of these compds. as specific chem. leads for the development of RTK-specific drugs with broad application for the treatment of human diseases.

IT **194413-58-6P 210303-48-3P 210303-49-4P**
210303-50-7P 210303-51-8P 210303-52-9P
210303-53-0P 210303-54-1P 210303-55-2P
210303-58-5P 210303-59-6P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); PRP (Properties); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
(prepn. and evaluation of 3-substituted indolin-2-ones as inhibitors of selective growth factor receptors)

RN 194413-58-6 CAPLUS
CN 2H-Indol-2-one, 3-[(3,5-dimethyl-1H-pyrrol-2-yl)methylene]-1,3-dihydro-, (3Z)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.





RN 210303-48-3 CAPLUS
CN 2H-Indol-2-one, 3-[(3,4-dimethyl-1H-pyrrol-2-yl)methylene]-1,3-dihydro-, (3Z)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 210303-49-4 CAPLUS
CN 1H-Pyrrole-3-propanoic acid, 2-[(Z)-(1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-4-methyl- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 210303-50-7 CAPLUS
CN 1H-Pyrrole-3-propanoic acid, 5-[(Z)-(1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-4-methyl- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 210303-51-8 CAPLUS
CN 1H-Pyrrole-3-carboxylic acid, 5-[(Z)-(1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-4-methyl-, ethyl ester (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 210303-52-9 CAPLUS
CN 2H-Indol-2-one, 3-[(3,5-dimethyl-1H-pyrrol-2-yl)methylene]-6-fluoro-1,3-dihydro-, (3Z)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 210303-53-0 CAPLUS
CN 2H-Indol-2-one, 3-[(4-ethyl-3,5-dimethyl-1H-pyrrol-2-yl)methylene]-1,3-dihydro-, (3Z)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 210303-54-1 CAPLUS
CN 1H-Pyrrole-3-carboxylic acid, 5-[(Z)-(1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl-, ethyl ester (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 210303-55-2 CAPLUS
CN 2H-Indol-2-one, 3-[(3-ethyl-4,5-dimethyl-1H-pyrrol-2-yl)methylene]-1,3-dihydro-, (3Z)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 210303-58-5 CAPLUS
CN 2H-Indol-2-one, 3-[(3,5-dimethyl-1H-pyrrol-2-yl)methylene]-1,3-dihydro-4-methyl-, (3Z)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 210303-59-6 CAPLUS
CN 2H-Indol-2-one, 3-[(3,5-dimethyl-1H-pyrrol-2-yl)methylene]-1,3-dihydro-5-methyl-, (3Z)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



REFERENCE COUNT: 20 THERE ARE 20 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 115 OF 121 CAPLUS COPYRIGHT 2003 ACS
ACCESSION NUMBER: 1998:151222 CAPLUS
DOCUMENT NUMBER: 128:164361
TITLE: Crystal structures of a protein tyrosine kinase
INVENTOR(S): Mohammadi, Moosa; Li, Sun; Liang, Congxin; Schlessinger, Joseph; Hubbard, Stevan R.; McMahon, Gerald; Tang, Peng C.
PATENT ASSIGNEE(S): Sugen, Inc., USA; Mohammadi, Moosa; Li, Sun; Liang, Congxin; Schlessinger, Joseph; Hubbard, Stevan R.; McMahon, Gerald; Tang, Peng C.

09897755

SOURCE: PCT Int. Appl., 493 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9807835	A2	19980226	WO 1997-US14885	19970821
WO 9807835	A3	19981001		
W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
US 5942428	A	19990824	US 1996-701191	19960821
AU 9741603	A1	19980306	AU 1997-41603	19970821
EP 931152	A2	19990728	EP 1997-939534	19970821
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI				
JP 2001514484	T2	20010911	JP 1998-511036	19970821

PRIORITY APPLN. INFO.: US 1996-701191 A 19960821
US 1996-34168P P 19961219
WO 1997-US14885 W 19970821

OTHER SOURCE(S): MARPAT 128:164361

AB The present invention relates to the 3-dimensional structures of a protein tyrosine kinase optionally complexed with one or more compds. Thus, a 310-amino acid fragment fibroblast growth factor receptor 1 (residues 456-765, FGFR1) was recombinantly prepd. contg. the amino acid substitutions Cys488.fwdarw.Ala, Cys584.fwdarw.Ser, and Leu457.fwdarw.Val, and an addnl. 5 residues (Ser-Ala-Ala-Gly-Thr) at the N-terminus. X-ray crystallog. yielded the at. structural coordinates of cryst. FGFR1 and its complexes with adenylyl diphosphonate, 3-[(3-(2-carboxyethyl)-4-methylpyrrol-5-yl)methylene]-2-indolinone, or 3-[4-(4-formylpiperazine-1-yl)benzylidenyl]-2-indolinone. Two forms of cryst. FGFR1 were obtained: one form (designated C2-A form) with unit cell dimensions of a = 208.3, b = 57.2, c = 65.5.ANG. and .beta. = 107.2.degree., and another C2-B form with dimensions a = 211.6, b = 51.3, c = 66.1.ANG. and .beta. = 107.7.degree.. The overall structure of FGFR1 is bi-lobate. The N-terminal lobe of FGFR1 spans amino acid residues 456-567 and comprises a curled .beta.-sheet of five antiparallel strands and one .alpha.-helix. The C-terminal lobe spans amino acid residues 568-765 and comprises two .beta.-strands and seven .alpha.-helixes. The at. coordinates that define the structures of the protein tyrosine kinase and any of the compds. bound to it are pertinent to methods for detg. the 3-dimensional structures of protein tyrosine kinases with unknown structure and to methods that identify modulators of protein tyrosine kinase functions.

IT **186611-14-3D**, complex with fibroblast growth factor receptor 1
RL: BUU (Biological use, unclassified); PRP (Properties); BIOL (Biological study); USES (Uses)
(crystal structures of a protein tyrosine kinase)

RN 186611-14-3 CAPLUS

CN 1H-Pyrrole-3-propanoic acid, 5-[(1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-4-methyl- (9CI) (CA INDEX NAME)



L4 ANSWER 116 OF 121 CAPLUS COPYRIGHT 2003 ACS
ACCESSION NUMBER: 1998:147306 CAPLUS
DOCUMENT NUMBER: 128:204803
TITLE: Indolinone combinatorial libraries and related products and methods for the treatment of disease
INVENTOR(S): Tang, Peng Cho; Sun, Li; McMahon, Gerald; Hirth, Klaus Peter; Shawver, Laura Kay; et al.
PATENT ASSIGNEE(S): Sugen, Inc., USA; Tang, Peng Cho; Sun, Li; McMahon, Gerald
SOURCE: PCT Int. Appl., 293 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 9
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9807695	A1	19980226	WO 1997-US14736	19970820
W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
CN 1155838	A	19970730	CN 1996-190616	19960605
EP 929520	A1	19990721	EP 1997-939480	19970820
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI				
US 6147106	A	20001114	US 1997-915366	19970820
JP 2001503736	T2	20010321	JP 1998-510973	19970820
EP 1247803	A2	20021009	EP 2002-77564	19970820
EP 1247803	A3	20021016		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI				
AU 9741556	A1	19980306	AU 1997-41556	19970821
US 2002022626	A1	20020221	US 2000-617529	20000713

PRIORITY APPLN. INFO.:

US 1996-702232	A	19960823
US 1996-31585P	P	19961205
US 1996-31586P	P	19961205
US 1996-31588P	P	19961205
US 1996-32546P	P	19961205
US 1996-32547P	P	19961205
US 1997-45565P	P	19970505
US 1997-45566P	P	19970505
US 1997-45714P	P	19970505

US 1997-45715P P 19970505
US 1997-46843P P 19970505
US 1996-45715P P 19961205
US 1997-31565P P 19970505
EP 1997-939480 A3 19970820
US 1997-915366 A3 19970820
WO 1997-US14736 W 19970820

OTHER SOURCE(S): MARPAT 128:204803

GI



I

AB The invention relates to indolinone derivs. capable of modulating, regulating, and/or inhibiting protein kinase signal transduction. The compds. are useful for the treatment of diseases related to unregulated protein kinase signal transduction, including cell proliferative diseases such as cancer, atherosclerosis, arthritis, and restenosis, and metabolic diseases such as diabetes. Inhibitors specific to the FLK protein kinase can be obtained by adding chem. substituents to the 3-[(indole-3-yl)methylene]-2-indolinone system, in particular at the 1' position of the indole ring. Indolinone compds. that specifically inhibit the FLK and platelet derived growth factor protein kinases can harbor a tetrahydroindole or cyclopentano[b]pyrrole moiety. Indolinone compds. that are modified with substituents, particularly at the 5 position of the oxindole ring, can effectively activate protein kinases. This invention also features novel hydrosol. indolinone compds. that are tyrosine kinase inhibitors, and related products and methods. Approx. 1200 title compds., such as I, were prepd. by combinatorial condensation of certain (un)substituted indolinones with aldehydes at the 3-position. I gave complete inhibition of MET kinase at chimeric MET receptors in vitro.

IT **203989-05-3P**, 3-[[2,4-Dimethyl-3-(ethoxycarbonyl)pyrrol-5-yl]methylidenyl]-5,7-dibromo-2-indolinone **203989-08-6P**, 3-[[2-(Ethoxycarbonyl)-3-[2-(ethoxycarbonyl)ethyl]-4-[(ethoxycarbonyl)methyl]pyrrol-5-yl]methylidenyl]-5,7-dibromo-2-indolinone **203989-10-0P**, 3-[[2,3-Bis(methoxycarbonyl)-5-methylpyrrol-4-yl]methylidenyl]-5,7-dibromo-2-indolinone **203989-14-4P**, 3-[[2,4-Dimethyl-3-(ethoxycarbonyl)pyrrol-5-yl]methylidenyl]-5-iodo-2-indolinone **203989-17-7P**, 3-[[2-(Ethoxycarbonyl)-3-[2-(ethoxycarbonyl)ethyl]-4-[(ethoxycarbonyl)methyl]pyrrol-5-yl]methylidenyl]-5-iodo-2-indolinone **203989-19-9P**, 3-[[2,3-Bis(methoxycarbonyl)-5-methylpyrrol-4-yl]methylidenyl]-5-iodo-2-indolinone **203989-24-6P**, 3-[[2,4-Dimethyl-3-(ethoxycarbonyl)pyrrol-5-yl]methylidenyl]-5-bromo-4-methyl-2-indolinone **203989-27-9P**, 3-[[2-(Ethoxycarbonyl)-3-[2-(ethoxycarbonyl)ethyl]-4-[(ethoxycarbonyl)methyl]pyrrol-5-yl]methylidenyl]-5-bromo-4-methyl-2-indolinone **203989-29-1P**, 3-[[2,3-

Bis(methoxycarbonyl)-5-methylpyrrol-4-yl]methylidenyl]-5-bromo-4-methyl-2-indolinone **203989-35-9P**, 3-[[2,4-Dimethyl-3-(ethoxycarbonyl)pyrrol-5-yl]methylidenyl]-5-[(methylamino)sulfonyl]-2-indolinone **203989-40-6P**, 3-[[2-(Ethoxycarbonyl)-3-[2-(ethoxycarbonyl)ethyl]-4-[(ethoxycarbonyl)methyl]pyrrol-5-yl]methylidenyl]-5-[(methylamino)sulfonyl]-2-indolinone **203989-43-9P**, 3-[[2,3-Bis(methoxycarbonyl)-5-methylpyrrol-4-yl]methylidenyl]-5-[(methylamino)sulfonyl]-2-indolinone **203989-52-0P**, 3-[[2,4-Dimethyl-3-(ethoxycarbonyl)pyrrol-5-yl]methylidenyl]-5-[[[4-(trifluoromethyl)phenyl]amino]sulfonyl]-2-indolinone **203989-56-4P**, 3-[[2-(Ethoxycarbonyl)-3-[2-(ethoxycarbonyl)ethyl]-4-[(ethoxycarbonyl)methyl]pyrrol-5-yl]methylidenyl]-5-[[[4-(trifluoromethyl)phenyl]amino]sulfonyl]-2-indolinone **203989-58-6P**, 3-[[2,3-Bis(methoxycarbonyl)-5-methylpyrrol-4-yl]methylidenyl]-5-[[[4-(trifluoromethyl)phenyl]amino]sulfonyl]-2-indolinone **203989-65-5P**, 3-[[2,4-Dimethyl-3-(ethoxycarbonyl)pyrrol-5-yl]methylidenyl]-5-(morpholinosulfonyl)-2-indolinone **203989-68-8P**, 3-[[2-(Ethoxycarbonyl)-3-[2-(ethoxycarbonyl)ethyl]-4-[(ethoxycarbonyl)methyl]pyrrol-5-yl]methylidenyl]-5-(morpholinosulfonyl)-2-indolinone **203989-70-2P**, 3-[[2,3-Bis(methoxycarbonyl)-5-methylpyrrol-4-yl]methylidenyl]-5-(morpholinosulfonyl)-2-indolinone **203989-75-7P**, 3-[[2,4-Dimethyl-3-(ethoxycarbonyl)pyrrol-5-yl]methylidenyl]-5-(2-chloroethyl)-2-indolinone **203989-78-0P**, 3-[[2-(Ethoxycarbonyl)-3-[2-(ethoxycarbonyl)ethyl]-4-[(ethoxycarbonyl)methyl]pyrrol-5-yl]methylidenyl]-5-(2-chloroethyl)-2-indolinone **203989-80-4P**, 3-[[2,3-Bis(methoxycarbonyl)-5-methylpyrrol-4-yl]methylidenyl]-5-(2-chloroethyl)-2-indolinone **203989-88-2P**, 3-[(2,4-Dimethyl-3-ethylpyrrol-5-yl)methylidenyl]-5,7-dibromo-2-indolinone **203989-98-4P**, 3-[(2,4-Dimethyl-3-ethylpyrrol-5-yl)methylidenyl]-5-iodo-2-indolinone **203990-08-3P**, 3-[(2,4-Dimethyl-3-ethylpyrrol-5-yl)methylidenyl]-5-bromo-4-methyl-2-indolinone **203990-18-5P**, 3-[(2,4-Dimethyl-3-ethylpyrrol-5-yl)methylidenyl]-5-[(methylamino)sulfonyl]-2-indolinone **203990-28-7P**, 3-[(2,4-Dimethyl-3-ethylpyrrol-5-yl)methylidenyl]-5-[[[4-(trifluoromethyl)phenyl]amino]sulfonyl]-2-indolinone **203990-38-9P**, 3-[(2,4-Dimethyl-3-ethylpyrrol-5-yl)methylidenyl]-5-(morpholinosulfonyl)-2-indolinone **203990-48-1P**, 3-[(2,4-Dimethyl-3-ethylpyrrol-5-yl)methylidenyl]-5-(2-chloroethyl)-2-indolinone **203991-62-2P**, 3-[(2,4-Dimethylpyrrol-5-yl)methylidenyl]-5,7-dibromo-2-indolinone **203991-72-4P**, 3-[(2,4-Dimethylpyrrol-5-yl)methylidenyl]-5-iodo-2-indolinone **203991-82-6P**, 3-[(2,4-Dimethylpyrrol-5-yl)methylidenyl]-5-bromo-4-methyl-2-indolinone **203991-92-8P**, 3-[(2,4-Dimethylpyrrol-5-yl)methylidenyl]-5-[(methylamino)sulfonyl]-2-indolinone **203992-02-3P**, 3-[(2,4-Dimethylpyrrol-5-yl)methylidenyl]-5-[[[4-(trifluoromethyl)phenyl]amino]sulfonyl]-2-indolinone **203992-12-5P**, 3-[(2,4-Dimethylpyrrol-5-yl)methylidenyl]-5-(morpholinosulfonyl)-2-indolinone **203992-22-7P**, 3-[(2,4-Dimethylpyrrol-5-yl)methylidenyl]-5-(2-chloroethyl)-2-indolinone **203994-35-8P**, 3-[[2-Chloro-4-(methoxycarbonyl)-3-[(methoxycarbonyl)methyl]pyrrol-5-yl]methylidenyl]-5,7-dibromo-2-indolinone **203994-53-0P**, 3-[[2-Chloro-4-(methoxycarbonyl)-3-[(methoxycarbonyl)methyl]pyrrol-5-yl]methylidenyl]-5-iodo-2-indolinone **203994-72-3P**, 3-[[2-Chloro-4-(methoxycarbonyl)-3-[(methoxycarbonyl)methyl]pyrrol-5-yl]methylidenyl]-5-bromo-4-methyl-2-indolinone **203994-91-6P**, 3-[[2-Chloro-4-(methoxycarbonyl)-3-[(methoxycarbonyl)methyl]pyrrol-5-yl]methylidenyl]-5-[(methylamino)sulfonyl]-2-indolinone **203995-11-3P**, 3-[[2-Chloro-4-(methoxycarbonyl)-3-[(methoxycarbonyl)methyl]pyrrol-5-yl]methylidenyl]-5-[[[4-

(trifluoromethyl)phenyl]amino]sulfonyl]-2-indolinone **203995-26-0P**
, 3-[[2-Chloro-4-(methoxycarbonyl)-3-[(methoxycarbonyl)methyl]pyrrol-5-
yl]methylidenyl]-5-(morpholinosulfonyl)-2-indolinone **203995-36-2P**
, 3-[[2-Chloro-4-(methoxycarbonyl)-3-[(methoxycarbonyl)methyl]pyrrol-5-
yl]methylidenyl]-5-(2-chloroethyl)-2-indolinone **203995-39-5P**,
3-[[2-(Ethoxycarbonyl)-4-(methoxycarbonyl)-3-methylpyrrol-5-
yl]methylidenyl]-5,7-dibromo-2-indolinone **203995-42-0P**,
3-[(1,3-Dimethylpyrrol-4-yl)methylidenyl]-5,7-dibromo-2-indolinone
203995-48-6P, 3-[[2-(Ethoxycarbonyl)-4-(methoxycarbonyl)-3-
methylpyrrol-5-yl]methylidenyl]-5-iodo-2-indolinone **203995-51-1P**
, 3-[(1,3-Dimethylpyrrol-4-yl)methylidenyl]-5-iodo-2-indolinone
203995-57-7P, 3-[[2-(Ethoxycarbonyl)-4-(methoxycarbonyl)-3-
methylpyrrol-5-yl]methylidenyl]-5-bromo-4-methyl-2-indolinone
203995-60-2P, 3-[(1,3-Dimethylpyrrol-4-yl)methylidenyl]-5-bromo-4-
methyl-2-indolinone **203995-66-8P**, 3-[[2-(Ethoxycarbonyl)-4-
(methoxycarbonyl)-3-methylpyrrol-5-yl]methylidenyl]-5-
[(methylamino)sulfonyl]-2-indolinone **203995-69-1P**,
3-[(1,3-Dimethylpyrrol-4-yl)methylidenyl]-5-[(methylamino)sulfonyl]-2-
indolinone **203995-75-9P**, 3-[[2-(Ethoxycarbonyl)-4-
(methoxycarbonyl)-3-methylpyrrol-5-yl]methylidenyl]-5-[[[4-
(trifluoromethyl)phenyl]amino]sulfonyl]-2-indolinone **203995-78-2P**
, 3-[(1,3-Dimethylpyrrol-4-yl)methylidenyl]-5-[[[4-
(trifluoromethyl)phenyl]amino]sulfonyl]-2-indolinone **203995-84-0P**
, 3-[[2-(Ethoxycarbonyl)-4-(methoxycarbonyl)-3-methylpyrrol-5-
yl]methylidenyl]-5-(morpholinosulfonyl)-2-indolinone **203995-87-3P**
, 3-[(1,3-Dimethylpyrrol-4-yl)methylidenyl]-5-(morpholinosulfonyl)-2-
indolinone **203995-93-1P**, 3-[[2-(Ethoxycarbonyl)-4-
(methoxycarbonyl)-3-methylpyrrol-5-yl]methylidenyl]-5-(2-chloroethyl)-2-
indolinone **203995-96-4P**, 3-[(1,3-Dimethylpyrrol-4-
yl)methylidenyl]-5-(2-chloroethyl)-2-indolinone **203996-03-6P**,
3-[(2,4-Diethylpyrrol-5-yl)methylidenyl]-5,7-dibromo-2-indolinone
203996-13-8P, 3-[(2,4-Diethylpyrrol-5-yl)methylidenyl]-5-iodo-2-
indolinone **203996-23-0P**, 3-[(2,4-Diethylpyrrol-5-
yl)methylidenyl]-5-bromo-4-methyl-2-indolinone **203996-33-2P**,
3-[(2,4-Diethylpyrrol-5-yl)methylidenyl]-5-[(methylamino)sulfonyl]-2-
indolinone **203996-43-4P**, 3-[(2,4-Diethylpyrrol-5-
yl)methylidenyl]-5-[[[4-(trifluoromethyl)phenyl]amino]sulfonyl]-2-
indolinone **203996-53-6P**, 3-[(2,4-Diethylpyrrol-5-
yl)methylidenyl]-5-(morpholinosulfonyl)-2-indolinone **203996-63-8P**
, 3-[(2,4-Diethylpyrrol-5-yl)methylidenyl]-5-(2-chloroethyl)-2-indolinone
204003-90-7P 204003-91-8P 204003-96-3P
204003-97-4P 204004-86-4P 204004-92-2P
204004-94-4P 204005-03-8P 204005-21-0P
204005-38-9P 204005-39-0P 204005-46-9P
204005-54-9P 204005-56-1P 204005-58-3P
204005-59-4P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological
study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use);
BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. and testing of indolinone combinatorial library as protein
kinase inhibitors)

RN 203989-05-3 CAPLUS

CN 1H-Pyrrole-3-carboxylic acid, 5-[(5,7-dibromo-1,2-dihydro-2-oxo-3H-indol-3-
ylidene)methyl]-2,4-dimethyl-, ethyl ester (9CI) (CA INDEX NAME)



RN 203989-08-6 CAPLUS
CN 1H-Pyrrole-3-propanoic acid, 5-[(5,7-dibromo-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2-(ethoxycarbonyl)-4-(2-ethoxy-2-oxoethyl)-, ethyl ester (9CI) (CA INDEX NAME)



RN 203989-10-0 CAPLUS
CN 1H-Pyrrole-2,3-dicarboxylic acid, 4-[(5,7-dibromo-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-5-methyl-, dimethyl ester (9CI) (CA INDEX NAME)



RN 203989-14-4 CAPLUS
CN 1H-Pyrrole-3-carboxylic acid, 5-[(1,2-dihydro-5-iodo-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl-, ethyl ester (9CI) (CA INDEX NAME)





RN 203989-17-7 CAPLUS
CN 1H-Pyrrole-3-propanoic acid, 5-[(1,2-dihydro-5-iodo-2-oxo-3H-indol-3-ylidene)methyl]-2-(ethoxycarbonyl)-4-(2-ethoxy-2-oxoethyl)-, ethyl ester (9CI) (CA INDEX NAME)



RN 203989-19-9 CAPLUS
CN 1H-Pyrrole-2,3-dicarboxylic acid, 4-[(1,2-dihydro-5-iodo-2-oxo-3H-indol-3-ylidene)methyl]-5-methyl-, dimethyl ester (9CI) (CA INDEX NAME)



RN 203989-24-6 CAPLUS
CN 1H-Pyrrole-3-carboxylic acid, 5-[(5-bromo-1,2-dihydro-4-methyl-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl-, ethyl ester (9CI) (CA INDEX NAME)



RN 203989-27-9 CAPLUS
CN 1H-Pyrrole-3-propanoic acid, 5-[(5-bromo-1,2-dihydro-4-methyl-2-oxo-3H-indol-3-ylidene)methyl]-2-(ethoxycarbonyl)-4-(2-ethoxy-2-oxoethyl)-, ethyl ester (9CI) (CA INDEX NAME)



RN 203989-29-1 CAPLUS
CN 1H-Pyrrole-2,3-dicarboxylic acid, 4-[(5-bromo-1,2-dihydro-4-methyl-2-oxo-3H-indol-3-ylidene)methyl]-5-methyl-, dimethyl ester (9CI) (CA INDEX NAME)



RN 203989-35-9 CAPLUS
CN 1H-Pyrrole-3-carboxylic acid, 5-[[1,2-dihydro-5-[(methylamino)sulfonyl]-2-oxo-3H-indol-3-ylidene]methyl]-2,4-dimethyl-, ethyl ester (9CI) (CA INDEX NAME)



RN 203989-40-6 CAPLUS
CN 1H-Pyrrole-3-propanoic acid, 5-[[1,2-dihydro-5-[(methylamino)sulfonyl]-2-oxo-3H-indol-3-ylidene]methyl]-2-(ethoxycarbonyl)-4-(2-ethoxy-2-oxoethyl)-, ethyl ester (9CI) (CA INDEX NAME)



RN 203989-43-9 CAPLUS
CN 1H-Pyrrole-2,3-dicarboxylic acid, 4-[[1,2-dihydro-5-[(methylamino)sulfonyl]-2-oxo-3H-indol-3-ylidene]methyl]-5-methyl-, dimethyl ester (9CI) (CA INDEX NAME)



RN 203989-52-0 CAPLUS
CN 1H-Pyrrole-3-carboxylic acid, 5-[[1,2-dihydro-2-oxo-5-[[[4-(trifluoromethyl)phenyl]amino]sulfonyl]-3H-indol-3-ylidene]methyl]-2,4-dimethyl-, ethyl ester (9CI) (CA INDEX NAME)



RN 203989-56-4 CAPLUS
CN 1H-Pyrrole-3-propanoic acid, 5-[[1,2-dihydro-2-oxo-5-[[[4-(trifluoromethyl)phenyl]amino]sulfonyl]-3H-indol-3-ylidene]methyl]-2-(ethoxycarbonyl)-4-(2-ethoxy-2-oxoethyl)-, ethyl ester (9CI) (CA INDEX NAME)





RN 203989-58-6 CAPLUS
CN 1H-Pyrrole-2,3-dicarboxylic acid, 4-[[1,2-dihydro-2-oxo-5-[[[4-(trifluoromethyl)phenyl]amino]sulfonyl]-3H-indol-3-ylidene]methyl]-5-methyl-, dimethyl ester (9CI) (CA INDEX NAME)



RN 203989-65-5 CAPLUS
CN 1H-Pyrrole-3-carboxylic acid, 5-[[1,2-dihydro-5-(4-morpholinylsulfonyl)-2-oxo-3H-indol-3-ylidene]methyl]-2,4-dimethyl-, ethyl ester (9CI) (CA INDEX NAME)



RN 203989-68-8 CAPLUS
CN 1H-Pyrrole-3-propanoic acid, 5-[[1,2-dihydro-5-(4-morpholinylsulfonyl)-2-oxo-3H-indol-3-ylidene]methyl]-2-(ethoxycarbonyl)-4-(2-ethoxy-2-oxoethyl)-, ethyl ester (9CI) (CA INDEX NAME)



RN 203989-70-2 CAPLUS
CN 1H-Pyrrole-2,3-dicarboxylic acid, 4-[[1,2-dihydro-5-(4-morpholinylsulfonyl)-2-oxo-3H-indol-3-ylidene]methyl]-5-methyl-, dimethyl ester (9CI) (CA INDEX NAME)



RN 203989-75-7 CAPLUS
CN 1H-Pyrrole-3-carboxylic acid, 5-[[5-(2-chloroethyl)-1,2-dihydro-2-oxo-3H-indol-3-ylidene]methyl]-2,4-dimethyl-, ethyl ester (9CI) (CA INDEX NAME)



RN 203989-78-0 CAPLUS
CN 1H-Pyrrole-3-propanoic acid, 5-[[5-(2-chloroethyl)-1,2-dihydro-2-oxo-3H-indol-3-ylidene]methyl]-2-(ethoxycarbonyl)-4-(2-ethoxy-2-oxoethyl)-, ethyl ester (9CI) (CA INDEX NAME)



RN 203989-80-4 CAPLUS
CN 1H-Pyrrole-2,3-dicarboxylic acid, 4-[[5-(2-chloroethyl)-1,2-dihydro-2-oxo-3H-indol-3-ylidene]methyl]-5-methyl-, dimethyl ester (9CI) (CA INDEX NAME)



RN 203989-88-2 CAPLUS
CN 2H-Indol-2-one, 5,7-dibromo-3-[(4-ethyl-3,5-dimethyl-1H-pyrrol-2-yl)methylene]-1,3-dihydro- (9CI) (CA INDEX NAME)



RN 203989-98-4 CAPLUS
CN 2H-Indol-2-one, 3-[(4-ethyl-3,5-dimethyl-1H-pyrrol-2-yl)methylene]-1,3-dihydro-5-iodo- (9CI) (CA INDEX NAME)



RN 203990-08-3 CAPLUS
CN 2H-Indol-2-one, 5-bromo-3-[(4-ethyl-3,5-dimethyl-1H-pyrrol-2-yl)methylene]-1,3-dihydro-4-methyl- (9CI) (CA INDEX NAME)



RN 203990-18-5 CAPLUS
CN 1H-Indole-5-sulfonamide, 3-[(4-ethyl-3,5-dimethyl-1H-pyrrol-2-yl)methylene]-2,3-dihydro-N-methyl-2-oxo- (9CI) (CA INDEX NAME)



RN 203990-28-7 CAPLUS
CN 1H-Indole-5-sulfonamide, 3-[(4-ethyl-3,5-dimethyl-1H-pyrrol-2-yl)methylene]-2,3-dihydro-2-oxo-N-[4-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



RN 203990-38-9 CAPLUS
CN Morpholine, 4-[[3-[(4-ethyl-3,5-dimethyl-1H-pyrrol-2-yl)methylene]-2,3-dihydro-2-oxo-1H-indol-5-yl]sulfonyl]- (9CI) (CA INDEX NAME)



RN 203990-48-1 CAPLUS
CN 2H-Indol-2-one, 5-(2-chloroethyl)-3-[(4-ethyl-3,5-dimethyl-1H-pyrrol-2-yl)methylene]-1,3-dihydro- (9CI) (CA INDEX NAME)



RN 203991-62-2 CAPLUS
CN 2H-Indol-2-one, 5,7-dibromo-3-[(3,5-dimethyl-1H-pyrrol-2-yl)methylene]-1,3-dihydro- (9CI) (CA INDEX NAME)



RN 203991-72-4 CAPLUS
CN 2H-Indol-2-one, 3-[(3,5-dimethyl-1H-pyrrol-2-yl)methylene]-1,3-dihydro-5-iodo- (9CI) (CA INDEX NAME)



RN 203991-82-6 CAPLUS
CN 2H-Indol-2-one, 5-bromo-3-[(3,5-dimethyl-1H-pyrrol-2-yl)methylene]-1,3-dihydro-4-methyl- (9CI) (CA INDEX NAME)



RN 203991-92-8 CAPLUS
CN 1H-Indole-5-sulfonamide, 3-[(3,5-dimethyl-1H-pyrrol-2-yl)methylene]-2,3-dihydro-N-methyl-2-oxo- (9CI) (CA INDEX NAME)



RN 203992-02-3 CAPLUS
CN 1H-Indole-5-sulfonamide, 3-[(3,5-dimethyl-1H-pyrrol-2-yl)methylene]-2,3-dihydro-2-oxo-N-[4-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



RN 203992-12-5 CAPLUS
CN Morpholine, 4-[[3-[(3,5-dimethyl-1H-pyrrol-2-yl)methylene]-2,3-dihydro-2-oxo-1H-indol-5-yl]sulfonyl]- (9CI) (CA INDEX NAME)



RN 203992-22-7 CAPLUS
CN 2H-Indol-2-one, 5-(2-chloroethyl)-3-[(3,5-dimethyl-1H-pyrrol-2-yl)methylene]-1,3-dihydro- (9CI) (CA INDEX NAME)



RN 203994-35-8 CAPLUS
CN 1H-Pyrrole-3-acetic acid, 2-chloro-5-[(5,7-dibromo-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-4-(methoxycarbonyl)-, methyl ester (9CI) (CA INDEX NAME)



RN 203994-53-0 CAPLUS
CN 1H-Pyrrole-3-acetic acid, 2-chloro-5-[(1,2-dihydro-5-iodo-2-oxo-3H-indol-3-ylidene)methyl]-4-(methoxycarbonyl)-, methyl ester (9CI) (CA INDEX NAME)



RN 203994-72-3 CAPLUS
CN 1H-Pyrrole-3-acetic acid, 5-[(5-bromo-1,2-dihydro-4-methyl-2-oxo-3H-indol-3-ylidene)methyl]-2-chloro-4-(methoxycarbonyl)-, methyl ester (9CI) (CA INDEX NAME)



RN 203994-91-6 CAPLUS
CN 1H-Pyrrole-3-acetic acid, 2-chloro-5-[[1,2-dihydro-5-[(methylamino)sulfonyl]-2-oxo-3H-indol-3-ylidene]methyl]-4-(methoxycarbonyl)-, methyl ester (9CI) (CA INDEX NAME)



RN 203995-11-3 CAPLUS
CN 1H-Pyrrole-3-acetic acid, 2-chloro-5-[[1,2-dihydro-2-oxo-5-[[[4-(trifluoromethyl)phenyl]amino]sulfonyl]-3H-indol-3-ylidene]methyl]-4-(methoxycarbonyl)-, methyl ester (9CI) (CA INDEX NAME)



RN 203995-26-0 CAPLUS
CN 1H-Pyrrole-3-acetic acid, 2-chloro-5-[[1,2-dihydro-5-(4-morpholinylsulfonyl)-2-oxo-3H-indol-3-ylidene]methyl]-4-(methoxycarbonyl)-, methyl ester (9CI) (CA INDEX NAME)



RN 203995-36-2 CAPLUS
CN 1H-Pyrrole-3-acetic acid, 2-chloro-5-[[5-(2-chloroethyl)-1,2-dihydro-2-oxo-3H-indol-3-ylidene]methyl]-4-(methoxycarbonyl)-, methyl ester (9CI) (CA INDEX NAME)



RN 203995-39-5 CAPLUS
CN 1H-Pyrrole-2,4-dicarboxylic acid, 5-[(5,7-dibromo-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-3-methyl-, 2-ethyl 4-methyl ester (9CI) (CA INDEX NAME)



RN 203995-42-0 CAPLUS
CN 2H-Indol-2-one, 5,7-dibromo-3-[(1,4-dimethyl-1H-pyrrol-3-yl)methylene]-1,3-dihydro- (9CI) (CA INDEX NAME)



RN 203995-48-6 CAPLUS
CN 1H-Pyrrole-2,4-dicarboxylic acid, 5-[(1,2-dihydro-5-iodo-2-oxo-3H-indol-3-ylidene)methyl]-3-methyl-, 2-ethyl 4-methyl ester (9CI) (CA INDEX NAME)



RN 203995-51-1 CAPLUS
CN 2H-Indol-2-one, 3-[(1,4-dimethyl-1H-pyrrol-3-yl)methylene]-1,3-dihydro-5-iodo- (9CI) (CA INDEX NAME)



RN 203995-57-7 CAPLUS
CN 1H-Pyrrole-2,4-dicarboxylic acid, 5-[(5-bromo-1,2-dihydro-4-methyl-2-oxo-

3H-indol-3-ylidene)methyl]-3-methyl-, 2-ethyl 4-methyl ester (9CI) (CA INDEX NAME)



RN 203995-60-2 CAPLUS
CN 2H-Indol-2-one, 5-bromo-3-[(1,4-dimethyl-1H-pyrrol-3-yl)methylene]-1,3-dihydro-4-methyl- (9CI) (CA INDEX NAME)



RN 203995-66-8 CAPLUS
CN 1H-Pyrrole-2,4-dicarboxylic acid, 5-[[1,2-dihydro-5-[(methylamino)sulfonyl]-2-oxo-3H-indol-3-ylidene]methyl]-3-methyl-, 2-ethyl 4-methyl ester (9CI) (CA INDEX NAME)



RN 203995-69-1 CAPLUS
CN 1H-Indole-5-sulfonamide, 3-[(1,4-dimethyl-1H-pyrrol-3-yl)methylene]-2,3-dihydro-N-methyl-2-oxo- (9CI) (CA INDEX NAME)



RN 203995-75-9 CAPLUS
CN 1H-Pyrrole-2,4-dicarboxylic acid, 5-[[1,2-dihydro-2-oxo-5-[[[4-(trifluoromethyl)phenyl]amino]sulfonyl]-3H-indol-3-ylidene]methyl]-3-methyl-, 2-ethyl 4-methyl ester (9CI) (CA INDEX NAME)



RN 203995-78-2 CAPLUS
CN 1H-Indole-5-sulfonamide, 3-[(1,4-dimethyl-1H-pyrrol-3-yl)methylene]-2,3-dihydro-2-oxo-N-[4-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



RN 203995-84-0 CAPLUS
CN 1H-Pyrrole-2,4-dicarboxylic acid, 5-[[1,2-dihydro-5-(4-morpholinylsulfonyl)-2-oxo-3H-indol-3-ylidene]methyl]-3-methyl-, 2-ethyl 4-methyl ester (9CI) (CA INDEX NAME)



RN 203995-87-3 CAPLUS
CN Morpholine, 4-[[3-[(1,4-dimethyl-1H-pyrrol-3-yl)methylene]-2,3-dihydro-2-oxo-1H-indol-5-yl]sulfonyl]- (9CI) (CA INDEX NAME)



RN 203995-93-1 CAPLUS
CN 1H-Pyrrole-2,4-dicarboxylic acid, 5-[[5-(2-chloroethyl)-1,2-dihydro-2-oxo-3H-indol-3-ylidene]methyl]-3-methyl-, 2-ethyl 4-methyl ester (9CI) (CA INDEX NAME)



RN 203995-96-4 CAPLUS
CN 2H-Indol-2-one, 5-(2-chloroethyl)-3-[(1,4-dimethyl-1H-pyrrol-3-yl)methylene]-1,3-dihydro- (9CI) (CA INDEX NAME)



RN 203996-03-6 CAPLUS
CN 2H-Indol-2-one, 5,7-dibromo-3-[(3,5-diethyl-1H-pyrrol-2-yl)methylene]-1,3-dihydro- (9CI) (CA INDEX NAME)



RN 203996-13-8 CAPLUS
CN 2H-Indol-2-one, 3-[(3,5-diethyl-1H-pyrrol-2-yl)methylene]-1,3-dihydro-5-iodo- (9CI) (CA INDEX NAME)



RN 203996-23-0 CAPLUS
CN 2H-Indol-2-one, 5-bromo-3-[(3,5-diethyl-1H-pyrrol-2-yl)methylene]-1,3-dihydro-4-methyl- (9CI) (CA INDEX NAME)



RN 203996-33-2 CAPLUS
CN 1H-Indole-5-sulfonamide, 3-[(3,5-diethyl-1H-pyrrol-2-yl)methylene]-2,3-dihydro-N-methyl-2-oxo- (9CI) (CA INDEX NAME)



RN 203996-43-4 CAPLUS
CN 1H-Indole-5-sulfonamide, 3-[(3,5-diethyl-1H-pyrrol-2-yl)methylene]-2,3-dihydro-2-oxo-N-[4-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



RN 203996-53-6 CAPLUS
CN Morpholine, 4-[[3-[(3,5-diethyl-1H-pyrrol-2-yl)methylene]-2,3-dihydro-2-oxo-1H-indol-5-yl]sulfonyl]- (9CI) (CA INDEX NAME)



RN 203996-63-8 CAPLUS
CN 2H-Indol-2-one, 5-(2-chloroethyl)-3-[(3,5-diethyl-1H-pyrrol-2-yl)methylene]-1,3-dihydro- (9CI) (CA INDEX NAME)



RN 204003-90-7 CAPLUS
CN 1H-Indole-5-carboxylic acid, 3-[(3,5-dimethyl-1H-pyrrol-2-yl)methylene]-2,3-dihydro-2-oxo- (9CI) (CA INDEX NAME)



RN 204003-91-8 CAPLUS
CN 1H-Indole-5-carboxylic acid, 3-[(3,5-diethyl-1H-pyrrol-2-yl)methylene]-2,3-dihydro-2-oxo- (9CI) (CA INDEX NAME)



RN 204003-96-3 CAPLUS
CN 1H-Indole-5-carboxylic acid, 3-[[3,5-bis(1-methylethyl)-1H-pyrrol-2-yl]methylene]-2,3-dihydro-2-oxo- (9CI) (CA INDEX NAME)



RN 204003-97-4 CAPLUS
CN 1H-Indole-5-propanoic acid, 3-[(3,5-dimethyl-1H-pyrrol-2-yl)methylene]-2,3-dihydro-2-oxo- (9CI) (CA INDEX NAME)



RN 204004-86-4 CAPLUS
CN 1H-Pyrrole-3-propanoic acid, 5-[(5-amino-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-4-methyl-, methyl ester (9CI) (CA INDEX NAME)



RN 204004-92-2 CAPLUS
CN 1H-Pyrrole-3-propanoic acid, 5-[(5-chloro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-4-methyl-, methyl ester (9CI) (CA INDEX NAME)



RN 204004-94-4 CAPLUS
CN 1H-Pyrrole-3-propanoic acid, 5-[(1,2-dihydro-4-methyl-2-oxo-3H-indol-3-ylidene)methyl]-4-methyl-, methyl ester (9CI) (CA INDEX NAME)



RN 204005-03-8 CAPLUS
CN 1H-Pyrrole-3-propanoic acid, 5-[(1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-4-methyl-, methyl ester (9CI) (CA INDEX NAME)



RN 204005-21-0 CAPLUS
CN 1H-Pyrrole-3-carboxylic acid, 5-[(1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-1,2,4-trimethyl-, ethyl ester (9CI) (CA INDEX NAME)



RN 204005-38-9 CAPLUS
CN 2H-Indol-2-one, 5-amino-3-[(4-ethyl-3,5-dimethyl-1H-pyrrol-2-yl)methylene]-1,3-dihydro- (9CI) (CA INDEX NAME)



RN 204005-39-0 CAPLUS
CN 2H-Indol-2-one, 5-amino-3-[(3,5-dimethyl-1H-pyrrol-2-yl)methylene]-1,3-dihydro- (9CI) (CA INDEX NAME)



RN 204005-46-9 CAPLUS
CN 2H-Indol-2-one, 3-[(3,5-dimethyl-1H-pyrrol-2-yl)methylene]-1,3-dihydro- (9CI) (CA INDEX NAME)



RN 204005-54-9 CAPLUS
CN 2H-Indol-2-one, 3-[(3,5-dimethyl-1H-pyrrol-2-yl)methylene]-1,3-dihydro-4-methyl- (9CI) (CA INDEX NAME)



RN 204005-56-1 CAPLUS
CN 2H-Indol-2-one, 5-amino-3-[(3,5-diethyl-1H-pyrrol-2-yl)methylene]-1,3-dihydro- (9CI) (CA INDEX NAME)



RN 204005-58-3 CAPLUS
CN 2H-Indol-2-one, 3-[(3,5-diethyl-1H-pyrrol-2-yl)methylene]-1,3-dihydro- (9CI) (CA INDEX NAME)



RN 204005-59-4 CAPLUS
CN 2H-Indol-2-one, 3-[(3,5-diethyl-1H-pyrrol-2-yl)methylene]-1,3-dihydro-4-methyl- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 15 THERE ARE 15 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 117 OF 121 CAPLUS COPYRIGHT 2003 ACS
ACCESSION NUMBER: 1997:640690 CAPLUS
DOCUMENT NUMBER: 127:314804
TITLE: Assays for KDR/FLK-1 receptor tyrosine kinase inhibitors, and use of the inhibitors for treatment of vasculogenesis- and angiogenesis-related diseases
INVENTOR(S): Hirth, Klaus P.; McMahon, Gerald; Shawver, Laura K.
PATENT ASSIGNEE(S): Sugen, Inc., USA
SOURCE: PCT Int. Appl., 65 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9734920	A1	19970925	WO 1997-US3378	19970304
W: AL, AM, AU, AZ, BA, BB, BG, BR, BY, CA, CN, CU, CZ, EE, GE, GH, HU, IL, IS, JP, KG, KP, KR, KZ, LC, LK, LR, LT, LV, MD, MG, MK, MN, MX, NO, NZ, PL, RO, RU, SG, SI, SK, TJ, TM, TR, TT, UA, UZ, VN, YU, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, KE, LS, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
AU 9720667	A1	19971010	AU 1997-20667	19970304
PRIORITY APPLN. INFO.:			US 1996-621734	19960321
			WO 1997-US3378	19970304

AB Processes are disclosed for the identification of compds. and pharmaceutical compns. capable of selectively and potently inhibiting KDR/FLK-1 tyrosine kinase signal transduction in order to inhibit vasculogenesis and/or angiogenesis. The invention also relates to compds. and compns. identified using the methods of the invention and the use

thereof for the treatment of disease relating to inappropriate vasculogenesis and/or angiogenesis. The invention provides an assay cascade comprised of several "filter steps" of increasing selectivity which identify a limited subset of candidate compds. affecting the VEGF receptor on the mol. level.

IT **204005-46-9**, SU 5416
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(KDR/FLK-1 receptor tyrosine kinase inhibitor identification assay, and use of compds. for treatment of vasculogenesis- and angiogenesis-related diseases)

RN 204005-46-9 CAPLUS
CN 2H-Indol-2-one, 3-[(3,5-dimethyl-1H-pyrrol-2-yl)methylene]-1,3-dihydro- (9CI) (CA INDEX NAME)



L4 ANSWER 118 OF 121 CAPLUS COPYRIGHT 2003 ACS
ACCESSION NUMBER: 1997:322412 CAPLUS
DOCUMENT NUMBER: 127:44439
TITLE: Structure of the tyrosine kinase domain of fibroblast growth factor receptor in complex with inhibitors
AUTHOR(S): Mohammadi, Moosa; McMahon, Gerald; Sun, Li; Tang, Cho; Hirth, Peter; Yeh, Brian K.; Hubbard, Stevan R.; Schlessinger, Joseph
CORPORATE SOURCE: Dep. Pharmacology, New York Univ. Med. Center, New York, NY, 10016, USA
SOURCE: Science (Washington, D. C.) (1997), 276(5314), 955-960
CODEN: SCIEAS; ISSN: 0036-8075
PUBLISHER: American Association for the Advancement of Science
DOCUMENT TYPE: Journal
LANGUAGE: English

AB A new class of protein tyrosine kinase inhibitors was identified that is based on an oxindole core (indolinones). Two compds. from this class inhibited the kinase activity of fibroblast growth factor receptor 1 (FGFR1) and showed differential specificity toward others receptor tyrosine kinases. Crystal structures of the tyrosine kinase domain of FGFR1 in complex with the two compds. were detd. The oxindole occupies the sites in which the adenine of ATP binds, whereas the moieties that extend from the oxindole contact residues in the hinge region between the two kinase lobes. The more specific inhibitor of FGFR1 induces a conformational change in the nucleotide-binding loop. This structural information will facilitate the design of new inhibitors for use in the treatment of cancer and other diseases in which cell signaling by tyrosine kinases plays a crucial role in disease pathogenesis.

IT **186611-14-3**, SU 5402
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(inhibitor; structure of tyrosine kinase domain of fibroblast growth

factor receptor in complex with inhibitors)
RN 186611-14-3 CAPLUS
CN 1H-Pyrrole-3-propanoic acid, 5-[(1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-4-methyl- (9CI) (CA INDEX NAME)



L4 ANSWER 119 OF 121 CAPLUS COPYRIGHT 2003 ACS
ACCESSION NUMBER: 1997:140244 CAPLUS
DOCUMENT NUMBER: 126:139901
TITLE: Indolinone compounds capable of modulating tyrosine kinase signal transduction
INVENTOR(S): Tang, Peng Cho; Sun, Li; Mcmahon, Gerald
PATENT ASSIGNEE(S): Sugen, Inc., USA
SOURCE: PCT Int. Appl., 133 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 9
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9640116	A1	19961219	WO 1996-US8903	19960605
W: AL, AM, AU, AZ, BB, BG, BR, BY, CA, CN, CZ, EE, FI, GE, HU, IL, IS, JP, KG, KP, KR, KZ, LK, LR, LS, LT, LV, MD, MG, MK, MN, MX, NO, NZ, PL, RO, RU, SG, SI, SK, TJ, TM, TR, TT, UA, UZ, VN, AM, AZ, BY				
RW: KE, LS, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
US 5880141	A	19990309	US 1995-485323	19950607
CA 2192797	AA	19961219	CA 1996-2192797	19960605
AU 9660441	A1	19961230	AU 1996-60441	19960605
AU 706597	B2	19990617		
EP 769947	A1	19970502	EP 1996-918093	19960605
EP 769947	B1	20010502		
R: AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE				
BR 9606410	A	19971230	BR 1996-6410	19960605
JP 10504323	T2	19980428	JP 1996-501363	19960605
EP 934931	A2	19990811	EP 1999-103667	19960605
EP 934931	A3	19991020		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI				
JP 2000026412	A2	20000125	JP 1999-159567	19960605
AT 200863	E	20010515	AT 1996-918093	19960605
ES 2159741	T3	20011016	ES 1996-918093	19960605
JP 3231044	B2	20011119	JP 1997-501363	19960605
NO 9605377	A	19970212	NO 1996-5377	19961213

HK 1011933	A1	20020118	HK 1998-113193		19981211
US 2002022626	A1	20020221	US 2000-617529		20000713
PRIORITY APPLN. INFO.:			US 1995-485323	A	19950607
			EP 1996-918093	A3	19960605
			JP 1997-501363	A3	19960605
			WO 1996-US8903	W	19960605
			US 1997-915366	A3	19970820

OTHER SOURCE(S): MARPAT 126:139901

AB The present invention relates to org. mols. capable of modulating tyrosine kinase signal transduction in order to regulate, modulate and/or inhibit abnormal cell proliferation. Representatives of the 5 different classes of compds. described are SU 4932 [3-(2-chloro-4-hydroxybenzylidenyl)-2-indolinone], SU 4312 [3-(4-dimethylaminobenzylidenyl)-2-indolinone], SU 5416 {3-[(2,4-dimethylpyrrol-5-yl)methylene]-2-indolinone}, SU 5204 [3-(2-ethoxybenzylidenyl)-2-indolinone], and SU 4942 [3-(4-bromobenzylidenyl)-2-indolinone]. Diseases which these compds. and their pharmaceutically acceptable prepns. may be effective against include arthritis, hepatic cirrhosis, diabetic nephropathy and psoriasis.

IT **15966-93-5P**, SU 5408 **186610-94-6P**, SU 5406
186611-14-3P, SU 5402 **186611-16-5P**, SU 5405
186611-17-6P, SU 5407 **186611-29-0P**, SU 5453
186611-30-3P, SU 5454 **186611-31-4P**, SU 5455 **186611-33-6P**, SU 5459 **186611-34-7P**, SU 5460 **186611-37-0P**, SU 5463 **186611-39-2P**, SU 5465 **186611-48-3P**, SU 5477
186611-50-7P, SU 5479 **186611-56-3P**, SU 5614
186611-67-6P, SU 5626 **204005-46-9P**, SU 5416
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of indolinones capable of modulating tyrosine kinase signal transduction)

RN 15966-93-5 CAPLUS

CN 1H-Pyrrole-3-carboxylic acid, 5-[(1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl-, ethyl ester (9CI) (CA INDEX NAME)



RN 186610-94-6 CAPLUS

CN 2H-Indol-2-one, 3-[(3,4-dimethyl-1H-pyrrol-2-yl)methylene]-1,3-dihydro- (9CI) (CA INDEX NAME)





RN 186611-14-3 CAPLUS
CN 1H-Pyrrole-3-propanoic acid, 5-[(1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-4-methyl- (9CI) (CA INDEX NAME)



RN 186611-16-5 CAPLUS
CN 1H-Pyrrole-2-carboxaldehyde, 5-[(1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-3,4-dimethyl- (9CI) (CA INDEX NAME)



RN 186611-17-6 CAPLUS
CN 1H-Pyrrole-3-propanoic acid, 2-[(1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-4-methyl-, methyl ester (9CI) (CA INDEX NAME)



RN 186611-29-0 CAPLUS
CN 2H-Indol-2-one, 3-[(3-ethyl-4,5-dimethyl-1H-pyrrol-2-yl)methylene]-1,3-dihydro- (9CI) (CA INDEX NAME)



RN 186611-30-3 CAPLUS
CN 1H-Pyrrole-3-propanoic acid, 5-[(1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2-(ethoxycarbonyl)-4-(2-ethoxy-2-oxoethyl)-, ethyl ester (9CI) (CA INDEX NAME)



RN 186611-31-4 CAPLUS
CN 1H-Pyrrole-2-carboxylic acid, 5-[(1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-4-ethyl-3-methyl- (9CI) (CA INDEX NAME)



RN 186611-33-6 CAPLUS
CN 1H-Pyrrole-3-acetic acid, 2-chloro-5-[(1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-4-(methoxycarbonyl)-, methyl ester (9CI) (CA INDEX NAME)



RN 186611-34-7 CAPLUS
CN 1H-Pyrrole-2-carboxylic acid, 4-acetyl-5-[(1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-3-methyl-, ethyl ester (9CI) (CA INDEX NAME)



RN 186611-37-0 CAPLUS
CN 1H-Pyrrole-3-carboxylic acid, 5-[(1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-4-methyl-, ethyl ester (9CI) (CA INDEX NAME)



RN 186611-39-2 CAPLUS
CN 1H-Pyrrole-3-propanoic acid, 2-[(1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-5-(ethoxycarbonyl)-4-(2-ethoxy-2-oxoethyl)-, ethyl ester (9CI) (CA INDEX NAME)



RN 186611-48-3 CAPLUS
CN 2H-Indol-2-one, 3-[(4-ethyl-3,5-dimethyl-1H-pyrrol-2-yl)methylene]-1,3-dihydro- (9CI) (CA INDEX NAME)



RN 186611-50-7 CAPLUS
CN 2H-Indol-2-one, 3-[[3,5-dimethyl-4-(1-methylethenyl)-1H-pyrrol-2-yl]methylene]-1,3-dihydro- (9CI) (CA INDEX NAME)



RN 186611-56-3 CAPLUS
CN 2H-Indol-2-one, 5-chloro-3-[(3,5-dimethyl-1H-pyrrol-2-yl)methylene]-1,3-dihydro- (9CI) (CA INDEX NAME)



RN 186611-67-6 CAPLUS
CN 2H-Indol-2-one, 3-[(3,5-dimethyl-1H-pyrrol-2-yl)methylene]-1,3-dihydro-5-nitro- (9CI) (CA INDEX NAME)



RN 204005-46-9 CAPLUS
CN 2H-Indol-2-one, 3-[(3,5-dimethyl-1H-pyrrol-2-yl)methylene]-1,3-dihydro- (9CI) (CA INDEX NAME)



L4 ANSWER 120 OF 121 CAPLUS COPYRIGHT 2003 ACS
ACCESSION NUMBER: 1968:496372 CAPLUS
DOCUMENT NUMBER: 69:96372
TITLE: Stokvis reaction. XVII. Vilsmeier reaction with

pyrrole and pyrrolone derivatives
AUTHOR(S): Schnierle, Franz; Reinhard, Horst; Dieter, Norbert; Lippacher, Eberhard; Von Dobeneck, Henning
CORPORATE SOURCE: Tech. Hochsch. Muenchen, Munich, Fed. Rep. Ger.
SOURCE: Justus Liebigs Annalen der Chemie (1968), 715, 90-7
CODEN: JLACBF; ISSN: 0075-4617
DOCUMENT TYPE: Journal
LANGUAGE: German

AB Vilsmeier formylation of 4-methyl-3-acetyl-2-methoxycarbonylpyrrole gave 4-methyl-2-methoxycarbonyl-3-(1-chloro-3-dimethylimmonio-1-propenyl)pyrrole perchlorate. Formylation of I (R = Me or Et) in the presence of POX3 (X = Br or Cl) gave II. 3-methyl-4-(R-substituted) 3-pyrrolin-2-one, treated as above, gave 3-methyl-4-(R-substituted)-5-(X-substituted)-2-formylpyrrole. The Vilsmeier reaction of 4-methyl-3-(R-substituted)-3-pyrrolin-2-one with ClCOCOCl gave III. 16 references.

IT **19713-94-1P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(prepn. of)

RN 19713-94-1 CAPLUS

CN 2-Indolinone, 3-[(5-chloro-3,4-dimethylpyrrol-2-yl)methylene]- (8CI) (CA INDEX NAME)



L4 ANSWER 121 OF 121 CAPLUS COPYRIGHT 2003 ACS
ACCESSION NUMBER: 1967:433817 CAPLUS
DOCUMENT NUMBER: 67:33817
TITLE: Isoindigo dyes of the pyrrole series
AUTHOR(S): Treibs, Alfred; Jacob, Karl; Dietl, Anton
CORPORATE SOURCE: Tech. Hochsch. Munich, Munich, Fed. Rep. Ger.
SOURCE: Justus Liebigs Ann. Chem. (1967), 702, 112-30
DOCUMENT TYPE: Journal
LANGUAGE: German

GI For diagram(s), see printed CA Issue.

AB The dye obtained by lactam ring closure of PhCOCH2CH2CO2H (I) has the structure (II) of a phenylpyrrole-isoindigo (P-II) proposed by Kugel, and is identical with the compd. obtained from the O analog, the Pechmann dye III. In addn. to P-II, 4-(3-carboxy-1-phenylpropylidene)-2-phenyl-2-pyrrolin-5-one is formed by condensation of 2-phenyl-2-pyrrolin-5-one with I, which can also be converted into P-II via a readily proceeding retrocrotonization-retroaldol reaction. New methods for the synthesis of pyrrole-indole-isoindigo derivs. (e.g. IV, X = O, NH, and NMe) are described. The pyrrolylpyrrolinones V (R = CO2Et) (VI) and V (R = H) (VII) and the pyrrolylpyrrole-isoindigo derivs. VIII (R = CO2Et) (IX) and VIII (R = H) (X) prepd. from VI and VII were obtained; IX and X are derivs. of an .alpha., .beta., .alpha.-linked tetrapyrrole.

IT **15966-93-5P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(prepn. of)

RN 15966-93-5 CAPLUS
CN 1H-Pyrrole-3-carboxylic acid, 5-[(1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl-, ethyl ester (9CI) (CA INDEX NAME)



09897755

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:SSSPTA1613SXW

PASSWORD:
TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * * * * * * Welcome to STN International * * * * * * * * * *

NEWS 1		Web Page URLs for STN Seminar Schedule - N. America
NEWS 2	Jan 25	BLAST(R) searching in REGISTRY available in STN on the Web
NEWS 3	Jan 29	FSTA has been reloaded and moves to weekly updates
NEWS 4	Feb 01	DKILIT now produced by FIZ Karlsruhe and has a new update frequency
NEWS 5	Feb 19	Access via Tymnet and SprintNet Eliminated Effective 3/31/02
NEWS 6	Mar 08	Gene Names now available in BIOSIS
NEWS 7	Mar 22	TOXLIT no longer available
NEWS 8	Mar 22	TRCTHERMO no longer available
NEWS 9	Mar 28	US Provisional Priorities searched with P in CA/CAplus and USPATFULL
NEWS 10	Mar 28	LIPINSKI/CALC added for property searching in REGISTRY
NEWS 11	Apr 02	PAPERCHEM no longer available on STN. Use PAPERCHEM2 instead.
NEWS 12	Apr 08	"Ask CAS" for self-help around the clock
NEWS 13	Apr 09	BEILSTEIN: Reload and Implementation of a New Subject Area
NEWS 14	Apr 09	ZDB will be removed from STN
NEWS 15	Apr 19	US Patent Applications available in IFICDB, IFIPAT, and IFIUDB
NEWS 16	Apr 22	Records from IP.com available in CAPLUS, HCAPLUS, and ZCAPLUS
NEWS 17	Apr 22	BIOSIS Gene Names now available in TOXCENTER
NEWS 18	Apr 22	Federal Research in Progress (FEDRIP) now available
NEWS 19	Jun 03	New e-mail delivery for search results now available
NEWS 20	Jun 10	MEDLINE Reload
NEWS 21	Jun 10	PCTFULL has been reloaded

NEWS EXPRESS	February 1 CURRENT WINDOWS VERSION IS V6.0d, CURRENT MACINTOSH VERSION IS V6.0a(ENG) AND V6.0Ja(JP), AND CURRENT DISCOVER FILE IS DATED 05 FEBRUARY 2002
NEWS HOURS	STN Operating Hours Plus Help Desk Availability
NEWS INTER	General Internet Information
NEWS LOGIN	Welcome Banner and News Items
NEWS PHONE	Direct Dial and Telecommunication Network Access to STN
NEWS WWW	CAS World Wide Web Site (general information)

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

* * * * * * * * * * * * * * STN Columbus * * * * * * * * * * * * * *

09897755

FILE 'HOME' ENTERED AT 16:30:47 ON 10 JUN 2002

=> fil reg
COST IN U.S. DOLLARS

	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	0.21	0.21

FILE 'REGISTRY' ENTERED AT 16:30:53 ON 10 JUN 2002
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2002 American Chemical Society (ACS)

STRUCTURE FILE UPDATES: 7 JUN 2002 HIGHEST RN 427375-75-5
DICTIONARY FILE UPDATES: 7 JUN 2002 HIGHEST RN 427375-75-5

TSCA INFORMATION NOW CURRENT THROUGH January 7, 2002

Please note that search-term pricing does apply when conducting SmartSELECT searches.

Crossover limits have been increased. See HELP CROSSOVER for details.

Calculated physical property data is now available. See HELP PROPERTIES for more information. See STNote 27, Searching Properties in the CAS Registry File, for complete details:
http://www.cas.org/ONLINE/STN/STNOTES/stnotes27.pdf

=>
Uploading 09897755.str

L1 STRUCTURE UPLOADED

=> d
L1 HAS NO ANSWERS
L1 STR



G1 O,S

Structure attributes must be viewed using STN Express query preparation.

=> s l1 sss sam
SAMPLE SEARCH INITIATED 16:31:09 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED - 633 TO ITERATE

100.0% PROCESSED 633 ITERATIONS 50 ANSWERS
INCOMPLETE SEARCH (SYSTEM LIMIT EXCEEDED)

09897755

SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **COMPLETE**
BATCH **COMPLETE**
PROJECTED ITERATIONS: 11151 TO 14169
PROJECTED ANSWERS: 2635 TO 4203

L2 50 SEA SSS SAM L1

=> sl 1 full
SL IS NOT A RECOGNIZED COMMAND
The previous command name entered was not recognized by the system.
For a list of commands available to you in the current file, enter
"HELP COMMANDS" at an arrow prompt (=>).

=> s l1 full
FULL SEARCH INITIATED 16:31:25 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED - 13065 TO ITERATE

100.0% PROCESSED 13065 ITERATIONS 3510 ANSWERS
SEARCH TIME: 00.00.03

L3 3510 SEA SSS FUL L1

=> fil caplus
COST IN U.S. DOLLARS SINCE FILE ENTRY TOTAL SESSION
FULL ESTIMATED COST 140.66 140.87

FILE 'CAPLUS' ENTERED AT 16:31:48 ON 10 JUN 2002
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2002 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is
held by the publishers listed in the PUBLISHER (PB) field (available
for records published or updated in Chemical Abstracts after December
26, 1996), unless otherwise indicated in the original publications.
The CA Lexicon is the copyrighted intellectual property of the
American Chemical Society and is provided to assist you in searching
databases on STN. Any dissemination, distribution, copying, or storing
of this information, without the prior written consent of CAS, is
strictly prohibited.

FILE COVERS 1907 - 10 Jun 2002 VOL 136 ISS 24
FILE LAST UPDATED: 7 Jun 2002 (20020607/ED)

This file contains CAS Registry Numbers for easy and accurate
substance identification.

CAS roles have been modified effective December 16, 2001. Please
check your SDI profiles to see if they need to be revised. For
information on CAS roles, enter HELP ROLES at an arrow prompt or use
the CAS Roles thesaurus (/RL field) in this file.

=> s l3 full
L4 390 L3

=> s l4 and tyrosine?

09897755

115982 TYROSINE?
L5 66 L4 AND TYROSINE?

=> d l5 56-66 ibib abs hitstr

L5 ANSWER 56 OF 66 CAPLUS COPYRIGHT 2002 ACS
ACCESSION NUMBER: 1997:322412 CAPLUS
DOCUMENT NUMBER: 127:44439
TITLE: Structure of the **tyrosine** kinase domain of fibroblast growth factor receptor in complex with inhibitors
AUTHOR(S): Mohammadi, Moosa; McMahon, Gerald; Sun, Li; Tang, Cho; Hirth, Peter; Yeh, Brian K.; Hubbard, Stevan R.; Schlessinger, Joseph
CORPORATE SOURCE: Dep. Pharmacology, New York Univ. Med. Center, New York, NY, 10016, USA
SOURCE: Science (Washington, D. C.) (1997), 276(5314), 955-960
CODEN: SCIEAS; ISSN: 0036-8075
PUBLISHER: American Association for the Advancement of Science
DOCUMENT TYPE: Journal
LANGUAGE: English
AB A new class of protein **tyrosine** kinase inhibitors was identified that is based on an oxindole core (indolinones). Two compds. from this class inhibited the kinase activity of fibroblast growth factor receptor 1 (FGFR1) and showed differential specificity toward others receptor **tyrosine** kinases. Crystal structures of the **tyrosine** kinase domain of FGFR1 in complex with the two compds. were detd. The oxindole occupies the sites in which the adenine of ATP binds, whereas the moieties that extend from the oxindole contact residues in the hinge region between the two kinase lobes. The more specific inhibitor of FGFR1 induces a conformational change in the nucleotide-binding loop. This structural information will facilitate the design of new inhibitors for use in the treatment of cancer and other diseases in which cell signaling by **tyrosine** kinases plays a crucial role in disease pathogenesis.
IT **186611-14-3**, SU 5402
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(inhibitor; structure of **tyrosine** kinase domain of fibroblast growth factor receptor in complex with inhibitors)
RN 186611-14-3 CAPLUS
CN 1H-Pyrrole-3-propanoic acid, 5-[(1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-4-methyl- (9CI) (CA INDEX NAME)



L5 ANSWER 57 OF 66 CAPLUS COPYRIGHT 2002 ACS
ACCESSION NUMBER: 1997:140244 CAPLUS
DOCUMENT NUMBER: 126:139901
TITLE: Indolinone compounds capable of modulating **tyrosine** kinase signal transduction

09897755

INVENTOR(S): Tang, Peng Cho; Sun, Li; Mcmahon, Gerald
PATENT ASSIGNEE(S): Sugen, Inc., USA
SOURCE: PCT Int. Appl., 133 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 8
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9640116	A1	19961219	WO 1996-US8903	19960605
W: AL, AM, AU, AZ, BB, BG, BR, BY, CA, CN, CZ, EE, FI, GE, HU, IL, IS, JP, KG, KP, KR, KZ, LK, LR, LS, LT, LV, MD, MG, MK, MN, MX, NO, NZ, PL, RO, RU, SG, SI, SK, TJ, TM, TR, TT, UA, UZ, VN, AM, AZ, BY				
RW: KE, LS, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
US 5880141	A	19990309	US 1995-485323	19950607
CA 2192797	AA	19961219	CA 1996-2192797	19960605
AU 9660441	A1	19961230	AU 1996-60441	19960605
AU 706597	B2	19990617		
EP 769947	A1	19970502	EP 1996-918093	19960605
EP 769947	B1	20010502		
R: AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE				
BR 9606410	A	19971230	BR 1996-6410	19960605
JP 10504323	T2	19980428	JP 1996-501363	19960605
EP 934931	A2	19990811	EP 1999-103667	19960605
EP 934931	A3	19991020		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI				
JP 2000026412	A2	20000125	JP 1999-159567	19960605
AT 200863	E	20010515	AT 1996-918093	19960605
ES 2159741	T3	20011016	ES 1996-918093	19960605
JP 3231044	B2	20011119	JP 1997-501363	19960605
NO 9605377	A	19970212	NO 1996-5377	19961213

PRIORITY APPLN. INFO.:
US 1995-485323 A 19950607
EP 1996-918093 A3 19960605
JP 1997-501363 A3 19960605
WO 1996-US8903 W 19960605

OTHER SOURCE(S): MARPAT 126:139901

AB The present invention relates to org. mols. capable of modulating **tyrosine** kinase signal transduction in order to regulate, modulate and/or inhibit abnormal cell proliferation. Representatives of the 5 different classes of compds. described are SU 4932 [3-(2-chloro-4-hydroxybenzylidenyl)-2-indolinone], SU 4312 [3-(4-dimethylaminobenzylidenyl)-2-indolinone], SU 5416 {3-[(2,4-dimethylpyrrol-5-yl)methylene]-2-indolinone}, SU 5204 [3-(2-ethoxybenzylidenyl)-2-indolinone], and SU 4942 [3-(4-bromobenzylidenyl)-2-indolinone]. Diseases which these compds. and their pharmaceutically acceptable prepns. may be effective against include arthritis, hepatic cirrhosis, diabetic nephropathy and psoriasis.

IT **2731-46-6P**, SU 5432 **3367-90-6P**, SU 5212
15966-93-5P, SU 5408 **62540-08-3P**, SU 5208
64259-01-4P, SU 4798 **64259-03-6P**, SU 5438
64259-04-7P, SU 5409 **64259-05-8P**, SU 5430
91822-51-4P, SU 4314 **186610-92-4P**, SU 5401
186610-93-5P, SU 5404 **186610-94-6P**, SU 5406

186610-96-8P, SU 5419 **186610-97-9P**, SU 5424
186610-98-0P, SU 5427 **186611-12-1P**, SU 5217
186611-14-3P, SU 5402 **186611-15-4P**, SU 5403
186611-16-5P, SU 5405 **186611-17-6P**, SU 5407
186611-18-7P, SU 5410 **186611-19-8P**, SU 5418
186611-20-1P, SU 5420 **186611-21-2P**, SU 5421
186611-22-3P, SU 5422 **186611-23-4P**, SU 5423
186611-24-5P, SU 5425 **186611-25-6P**, SU 5426
186611-26-7P, SU 5428 **186611-27-8P**, SU 5431
186611-28-9P, SU 5451 **186611-29-0P**, SU 5453
186611-30-3P, SU 5454 **186611-31-4P**, SU 5455
186611-32-5P, SU 5456 **186611-33-6P**, SU 5459
186611-34-7P, SU 5460 **186611-35-8P**, SU 5461
186611-36-9P, SU 5462 **186611-37-0P**, SU 5463
186611-38-1P, SU 5464 **186611-39-2P**, SU 5465
186611-41-6P, SU 5468 **186611-42-7P**, SU 5469
186611-43-8P, SU 5472 **186611-44-9P**, SU 5473
186611-45-0P, SU 5474 **186611-46-1P**, SU 5475
186611-47-2P, SU 5476 **186611-48-3P**, SU 5477
186611-49-4P, SU 5478 **186611-50-7P**, SU 5479
186611-53-0P, SU 5612 **186611-54-1P**, SU 5613
186611-56-3P, SU 5614 **186611-57-4P**, SU 5615
186611-58-5P, SU 5616 **186611-59-6P**, SU 5617
186611-60-9P, SU 5618 **186611-61-0P**, SU 5619
186611-62-1P, SU 5620 **186611-63-2P**, SU 5621
186611-65-4P, SU 5624 **186611-66-5P**, SU 5625
186611-67-6P, SU 5626 **186611-68-7P**, SU 5627
186611-69-8P, SU 5628 **186611-71-2P**, SU 5629
186611-73-4P, SU 5630 **186611-75-6P**, SU 5631
186611-77-8P, SU 5632 **186611-78-9P**, SU 5633
186611-79-0P, CS 7127 **186611-80-3P**, CS 7128
186611-81-4P, CS 7129 **186611-82-5P**, CS 7130
186611-83-6P, CS 7131 **186611-84-7P**, CS 7132
186611-85-8P, CS 7133 **186611-86-9P**, CS 7135
186611-87-0P, CS 7136 **186611-88-1P**, CS 7137
186611-89-2P, CS 7138 **186611-90-5P**, CS 7139
186611-91-6P, CS 7140 **186611-92-7P**, CS 7141
186611-93-8P, CS 7142 **186611-94-9P**, CS 7143
186611-95-0P, CS 7144 **186611-96-1P**, CS 7145
186611-97-2P, CS 7146 **186611-98-3P**, CS 7147
204005-46-9P, SU 5416
RL: BAC (Biological activity or effector, except adverse); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of indolinones capable of modulating **tyrosine** kinase signal transduction)

RN 2731-46-6 CAPLUS
CN 2H-Indol-2-one, 1,3-dihydro-3-[(5-nitro-2-furanyl)methylene]- (9CI) (CA INDEX NAME)



RN 3367-90-6 CAPLUS
CN 2H-Indol-2-one, 1,3-dihydro-3-(4-pyridinylmethylene)- (9CI) (CA INDEX

NAME)



RN 15966-93-5 CAPLUS
CN 1H-Pyrrole-3-carboxylic acid, 5-[(1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl-, ethyl ester (9CI) (CA INDEX NAME)



RN 62540-08-3 CAPLUS
CN 2H-Indol-2-one, 1,3-dihydro-3-(2-thienylmethylene)- (9CI) (CA INDEX NAME)



RN 64259-01-4 CAPLUS
CN 2H-Indol-2-one, 3-(2-furanylmethylene)-1,3-dihydro- (9CI) (CA INDEX NAME)



RN 64259-03-6 CAPLUS
CN 2H-Indol-2-one, 3-[(5-bromo-2-furanyl)methylene]-1,3-dihydro- (9CI) (CA INDEX NAME)



RN 64259-04-7 CAPLUS
CN 2H-Indol-2-one, 1,3-dihydro-3-[(5-iodo-2-furanyl)methylene]- (9CI) (CA INDEX NAME)



RN 64259-05-8 CAPLUS
CN 2H-Indol-2-one, 1,3-dihydro-3-[(5-methyl-2-furanyl)methylene]- (9CI) (CA INDEX NAME)



RN 91822-51-4 CAPLUS
CN 2H-Indol-2-one, 1,3-dihydro-3-(1H-pyrrol-2-ylmethylene)- (9CI) (CA INDEX NAME)



RN 186610-92-4 CAPLUS
CN 2H-Indol-2-one, 1,3-dihydro-3-[(4-methyl-2-thienyl)methylene]- (9CI) (CA INDEX NAME)



RN 186610-93-5 CAPLUS
CN 2H-Indol-2-one, 1,3-dihydro-3-[(3-methyl-1H-pyrrol-2-yl)methylene]- (9CI) (CA INDEX NAME)



RN 186610-94-6 CAPLUS
CN 2H-Indol-2-one, 3-[(3,4-dimethyl-1H-pyrrol-2-yl)methylene]-1,3-dihydro- (9CI) (CA INDEX NAME)



RN 186610-96-8 CAPLUS
CN 2H-Indol-2-one, 1,3-dihydro-3-[[5-(methylthio)-2-thienyl]methylene]- (9CI) (CA INDEX NAME)



RN 186610-97-9 CAPLUS
CN 2H-Indol-2-one, 1,3-dihydro-3-[(5-methyl-2-thienyl)methylene]- (9CI) (CA INDEX NAME)



RN 186610-98-0 CAPLUS
CN 2H-Indol-2-one, 1,3-dihydro-3-[(3-methyl-2-thienyl)methylene]- (9CI) (CA INDEX NAME)



RN 186611-12-1 CAPLUS
CN 2H-Indol-2-one, 3-[[5-[3,5-bis(trifluoromethyl)phenyl]-2-furanyl]methylene]-1,3-dihydro- (9CI) (CA INDEX NAME)



RN 186611-14-3 CAPLUS
CN 1H-Pyrrole-3-propanoic acid, 5-[(1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-4-methyl- (9CI) (CA INDEX NAME)



RN 186611-15-4 CAPLUS
CN 2H-Indol-2-one, 3-[(3,4-dibromo-5-methyl-1H-pyrrol-2-yl)methylene]-1,3-dihydro- (9CI) (CA INDEX NAME)



RN 186611-16-5 CAPLUS
CN 1H-Pyrrole-2-carboxaldehyde, 5-[(1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-3,4-dimethyl- (9CI) (CA INDEX NAME)



RN 186611-17-6 CAPLUS
CN 1H-Pyrrole-3-propanoic acid, 2-[(1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-4-methyl-, methyl ester (9CI) (CA INDEX NAME)



RN 186611-18-7 CAPLUS
CN 3-Furancarboxylic acid, 5-[(1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2-methyl-, ethyl ester (9CI) (CA INDEX NAME)



RN 186611-19-8 CAPLUS
CN 2H-Indol-2-one, 3-[(3-bromo-2-thienyl)methylene]-1,3-dihydro- (9CI) (CA INDEX NAME)



RN 186611-20-1 CAPLUS
CN 2H-Indol-2-one, 3-[(5-chloro-2-thienyl)methylene]-1,3-dihydro- (9CI) (CA INDEX NAME)



RN 186611-21-2 CAPLUS
CN 2H-Indol-2-one, 3-[(4,5-dimethyl-2-furanyl)methylene]-1,3-dihydro- (9CI) (CA INDEX NAME)



RN 186611-22-3 CAPLUS
CN 2H-Indol-2-one, 1,3-dihydro-3-[(5-nitro-2-thienyl)methylene]- (9CI) (CA INDEX NAME)



RN 186611-23-4 CAPLUS
CN 2-Thiophenecarboxylic acid, 5-[(1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]- (9CI) (CA INDEX NAME)



RN 186611-24-5 CAPLUS
CN 2H-Indol-2-one, 3-[(5-bromo-2-thienyl)methylene]-1,3-dihydro- (9CI) (CA INDEX NAME)



RN 186611-25-6 CAPLUS
CN 2H-Indol-2-one, 3-[(4-bromo-2-thienyl)methylene]-1,3-dihydro- (9CI) (CA INDEX NAME)



RN 186611-26-7 CAPLUS

CN 2-Furansulfonic acid, 5-[(1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-, monosodium salt (9CI) (CA INDEX NAME)



● Na

RN 186611-27-8 CAPLUS
CN 2H-Indol-2-one, 3-[(5-ethyl-2-furanyl)methylene]-1,3-dihydro- (9CI) (CA INDEX NAME)



RN 186611-28-9 CAPLUS
CN 2H-Indol-2-one, 3-[(5-ethyl-2-thienyl)methylene]-1,3-dihydro- (9CI) (CA INDEX NAME)



RN 186611-29-0 CAPLUS
CN 2H-Indol-2-one, 3-[(3-ethyl-4,5-dimethyl-1H-pyrrol-2-yl)methylene]-1,3-dihydro- (9CI) (CA INDEX NAME)



RN 186611-30-3 CAPLUS
CN 1H-Pyrrole-3-propanoic acid, 5-[(1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2-(ethoxycarbonyl)-4-(2-ethoxy-2-oxoethyl)-, ethyl ester (9CI) (CA INDEX NAME)



RN 186611-31-4 CAPLUS
CN 1H-Pyrrole-2-carboxylic acid, 5-[(1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-4-ethyl-3-methyl- (9CI) (CA INDEX NAME)



RN 186611-32-5 CAPLUS
CN 2H-Indol-2-one, 3-[(3,5-diiodo-4-methyl-1H-pyrrol-2-yl)methylene]-1,3-dihydro- (9CI) (CA INDEX NAME)



RN 186611-33-6 CAPLUS
CN 1H-Pyrrole-3-acetic acid, 2-chloro-5-[(1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-4-(methoxycarbonyl)-, methyl ester (9CI) (CA INDEX NAME)



RN 186611-34-7 CAPLUS
CN 1H-Pyrrole-2-carboxylic acid, 4-acetyl-5-[(1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-3-methyl-, ethyl ester (9CI) (CA INDEX NAME)



RN 186611-35-8 CAPLUS
CN 2H-Indol-2-one, 3-[[1-(3,5-dichlorophenyl)-1H-pyrrol-2-yl]methylene]-1,3-dihydro- (9CI) (CA INDEX NAME)



RN 186611-36-9 CAPLUS
CN 2H-Indol-2-one, 3-[[1-(4-chlorophenyl)-1H-pyrrol-2-yl]methylene]-1,3-dihydro- (9CI) (CA INDEX NAME)



RN 186611-37-0 CAPLUS
CN 1H-Pyrrole-3-carboxylic acid, 5-[(1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-4-methyl-, ethyl ester (9CI) (CA INDEX NAME)



RN 186611-38-1 CAPLUS
CN 2H-Indol-2-one, 1,3-dihydro-3-[(1-methyl-1H-pyrrol-2-yl)methylene]- (9CI) (CA INDEX NAME)



RN 186611-39-2 CAPLUS
CN 1H-Pyrrole-3-propanoic acid, 2-[(1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-5-(ethoxycarbonyl)-4-(2-ethoxy-2-oxoethyl)-, ethyl ester (9CI) (CA INDEX NAME)



RN 186611-41-6 CAPLUS
CN 2H-Indol-2-one, 1,3-dihydro-3-[(4-methyl-1H-imidazol-2-yl)methylene]- (9CI) (CA INDEX NAME)



RN 186611-42-7 CAPLUS
CN 2H-Indol-2-one, 1,3-dihydro-3-[(5-methyl-2-thiazolyl)methylene]- (9CI) (CA INDEX NAME)



RN 186611-43-8 CAPLUS
CN 2H-Indol-2-one, 1,3-dihydro-3-[(5-methyl-1H-pyrazol-3-yl)methylene]- (9CI) (CA INDEX NAME)



RN 186611-44-9 CAPLUS
CN 2H-Indol-2-one, 1,3-dihydro-3-(1H-imidazol-4-ylmethylene)- (9CI) (CA INDEX NAME)



RN 186611-45-0 CAPLUS
CN 2H-Indol-2-one, 3-[(4-chloro-1H-pyrazol-3-yl)methylene]-1,3-dihydro- (9CI) (CA INDEX NAME)



RN 186611-46-1 CAPLUS
CN 2H-Indol-2-one, 3-[[4-bromo-1-[(4-chlorophenyl)methyl]-1H-pyrazol-5-yl]methylene]-1,3-dihydro- (9CI) (CA INDEX NAME)



RN 186611-47-2 CAPLUS
CN 2H-Indol-2-one, 3-[(4-chloro-1-methyl-1H-pyrazol-3-yl)methylene]-1,3-dihydro- (9CI) (CA INDEX NAME)



RN 186611-48-3 CAPLUS
CN 2H-Indol-2-one, 3-[(4-ethyl-3,5-dimethyl-1H-pyrrol-2-yl)methylene]-1,3-dihydro- (9CI) (CA INDEX NAME)



RN 186611-49-4 CAPLUS
CN 2H-Indol-2-one, 3-[(5-ethyl-1H-pyrrol-2-yl)methylene]-1,3-dihydro- (9CI) (CA INDEX NAME)



RN 186611-50-7 CAPLUS
CN 2H-Indol-2-one, 3-[[3,5-dimethyl-4-(1-methylethenyl)-1H-pyrrol-2-yl]methylene]-1,3-dihydro- (9CI) (CA INDEX NAME)



RN 186611-53-0 CAPLUS
CN 2H-Indol-2-one, 5-chloro-1,3-dihydro-3-(1H-pyrrol-2-ylmethylene)- (9CI) (CA INDEX NAME)



RN 186611-54-1 CAPLUS
CN 2H-Indol-2-one, 5-chloro-1,3-dihydro-3-[(3-methyl-1H-pyrrol-2-yl)methylene]- (9CI) (CA INDEX NAME)



RN 186611-56-3 CAPLUS
CN 2H-Indol-2-one, 5-chloro-3-[(3,5-dimethyl-1H-pyrrol-2-yl)methylene]-1,3-dihydro- (9CI) (CA INDEX NAME)



RN 186611-57-4 CAPLUS
CN 2H-Indol-2-one, 5-chloro-1,3-dihydro-3-(1H-indol-3-ylmethylene)- (9CI) (CA INDEX NAME)



RN 186611-58-5 CAPLUS
CN 2H-Indol-2-one, 5-chloro-1,3-dihydro-3-(2-thienylmethylene)- (9CI) (CA INDEX NAME)



RN 186611-59-6 CAPLUS

CN 2H-Indol-2-one, 5-chloro-1,3-dihydro-3-[(3-methyl-2-thienyl)methylene]- (9CI) (CA INDEX NAME)



RN 186611-60-9 CAPLUS
CN 2H-Indol-2-one, 5-chloro-1,3-dihydro-3-[(5-methyl-2-thienyl)methylene]- (9CI) (CA INDEX NAME)



RN 186611-61-0 CAPLUS
CN 2H-Indol-2-one, 5-chloro-3-[(5-ethyl-2-thienyl)methylene]-1,3-dihydro- (9CI) (CA INDEX NAME)



RN 186611-62-1 CAPLUS
CN 2H-Indol-2-one, 5-chloro-1,3-dihydro-3-[[5-(methylthio)-2-thienyl]methylene]- (9CI) (CA INDEX NAME)



RN 186611-63-2 CAPLUS
CN 2H-Indol-2-one, 5-chloro-1,3-dihydro-3-(1H-imidazol-2-ylmethylene)- (9CI) (CA INDEX NAME)



RN 186611-65-4 CAPLUS
CN 2H-Indol-2-one, 1,3-dihydro-5-nitro-3-(1H-pyrrol-2-ylmethylene)- (9CI) (CA INDEX NAME)



RN 186611-66-5 CAPLUS
CN 2H-Indol-2-one, 1,3-dihydro-3-[(3-methyl-1H-pyrrol-2-yl)methylene]-5-nitro- (9CI) (CA INDEX NAME)



RN 186611-67-6 CAPLUS
CN 2H-Indol-2-one, 3-[(3,5-dimethyl-1H-pyrrol-2-yl)methylene]-1,3-dihydro-5-nitro- (9CI) (CA INDEX NAME)



RN 186611-68-7 CAPLUS
CN 2H-Indol-2-one, 1,3-dihydro-3-(1H-indol-3-ylmethylene)-5-nitro- (9CI) (CA INDEX NAME)



RN 186611-69-8 CAPLUS
CN 2H-Indol-2-one, 1,3-dihydro-5-nitro-3-(2-thienylmethylene)- (9CI) (CA INDEX NAME)



RN 186611-71-2 CAPLUS
CN 2H-Indol-2-one, 1,3-dihydro-3-[(3-methyl-2-thienyl)methylene]-5-nitro- (9CI) (CA INDEX NAME)



RN 186611-73-4 CAPLUS
CN 2H-Indol-2-one, 1,3-dihydro-3-[(5-methyl-2-thienyl)methylene]-5-nitro- (9CI) (CA INDEX NAME)



RN 186611-75-6 CAPLUS
CN 2H-Indol-2-one, 3-[(5-ethyl-2-thienyl)methylene]-1,3-dihydro-5-nitro- (9CI) (CA INDEX NAME)



RN 186611-77-8 CAPLUS
CN 2H-Indol-2-one, 1,3-dihydro-3-[[5-(methylthio)-2-thienyl]methylene]-5-nitro- (9CI) (CA INDEX NAME)



RN 186611-78-9 CAPLUS
CN 2H-Indol-2-one, 1,3-dihydro-3-(1H-imidazol-2-ylmethylene)-5-nitro- (9CI) (CA INDEX NAME)



RN 186611-79-0 CAPLUS
CN 2H-Indol-2-one, 1,3-dihydro-3-(2-oxazolylmethylene)- (9CI) (CA INDEX NAME)



RN 186611-80-3 CAPLUS
CN 2H-Indol-2-one, 1,3-dihydro-3-(4-oxazolylmethylene)- (9CI) (CA INDEX NAME)



RN 186611-81-4 CAPLUS
CN 2H-Indol-2-one, 1,3-dihydro-3-(5-oxazolylmethylene)- (9CI) (CA INDEX NAME)



RN 186611-82-5 CAPLUS
CN 2H-Indol-2-one, 1,3-dihydro-3-(2-thiazolylmethylene)- (9CI) (CA INDEX NAME)



RN 186611-83-6 CAPLUS
CN 2H-Indol-2-one, 1,3-dihydro-3-(4-thiazolylmethylene)- (9CI) (CA INDEX NAME)



RN 186611-84-7 CAPLUS
CN 2H-Indol-2-one, 1,3-dihydro-3-(5-thiazolylmethylene)- (9CI) (CA INDEX NAME)



RN 186611-85-8 CAPLUS
CN 2H-Indol-2-one, 1,3-dihydro-3-(1H-imidazol-2-ylmethylene)- (9CI) (CA INDEX NAME)



RN 186611-86-9 CAPLUS
CN 2H-Indol-2-one, 1,3-dihydro-3-(1H-pyrazol-3-ylmethylene)- (9CI) (CA INDEX NAME)



RN 186611-87-0 CAPLUS
CN 2H-Indol-2-one, 1,3-dihydro-3-(1H-pyrazol-4-ylmethylene)- (9CI) (CA INDEX NAME)



RN 186611-88-1 CAPLUS

CN 2H-Indol-2-one, 1,3-dihydro-3-(3-isoxazolylmethylene)- (9CI) (CA INDEX NAME)



RN 186611-89-2 CAPLUS
CN 2H-Indol-2-one, 1,3-dihydro-3-(4-isoxazolylmethylene)- (9CI) (CA INDEX NAME)



RN 186611-90-5 CAPLUS
CN 2H-Indol-2-one, 1,3-dihydro-3-(5-isoxazolylmethylene)- (9CI) (CA INDEX NAME)



RN 186611-91-6 CAPLUS
CN 2H-Indol-2-one, 1,3-dihydro-3-(3-isothiazolylmethylene)- (9CI) (CA INDEX NAME)



RN 186611-92-7 CAPLUS
CN 2H-Indol-2-one, 1,3-dihydro-3-(4-isothiazolylmethylene)- (9CI) (CA INDEX NAME)



RN 186611-93-8 CAPLUS
CN 2H-Indol-2-one, 1,3-dihydro-3-(5-isothiazolylmethylene)- (9CI) (CA INDEX NAME)



RN 186611-94-9 CAPLUS
CN 2H-Indol-2-one, 1,3-dihydro-3-(1H-1,2,3-triazol-4-ylmethylene)- (9CI) (CA INDEX NAME)



RN 186611-95-0 CAPLUS
CN 2H-Indol-2-one, 1,3-dihydro-3-(1,3,4-thiadiazol-2-ylmethylene)- (9CI) (CA INDEX NAME)



RN 186611-96-1 CAPLUS
CN 2H-Indol-2-one, 1,3-dihydro-3-[(5-phenyl-1,2,4-oxadiazol-3-yl)methylene]- (9CI) (CA INDEX NAME)



RN 186611-97-2 CAPLUS
CN 2H-Indol-2-one, 1,3-dihydro-3-[(3-phenyl-1,2,4-oxadiazol-5-yl)methylene]- (9CI) (CA INDEX NAME)



RN 186611-98-3 CAPLUS
CN 2H-Indol-2-one, 1,3-dihydro-3-[(4-phenyl-1,2,5-oxadiazol-3-yl)methylene]- (9CI) (CA INDEX NAME)



RN 204005-46-9 CAPLUS
CN 2H-Indol-2-one, 3-[(3,5-dimethyl-1H-pyrrol-2-yl)methylene]-1,3-dihydro- (9CI) (CA INDEX NAME)



L5 ANSWER 58 OF 66 CAPLUS COPYRIGHT 2002 ACS
ACCESSION NUMBER: 1996:746204 CAPLUS
DOCUMENT NUMBER: 126:18783
TITLE: Substituted indolylmethylene-oxindole analogs as **tyrosine** kinase inhibitors
INVENTOR(S): Battistini, Carlo; Ballinari, Dario; Ermoli, Antonella; Penco, Sergio; Vioglio, Sergio
PATENT ASSIGNEE(S): Pharmacia S.P.A., Italy
SOURCE: PCT Int. Appl., 53 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9632380	A1	19961017	WO 1996-EP1165	19960314

W: JP, US
RW: AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE
EP 764152 A1 19970326 EP 1996-907500 19960314
R: DE, ES, FR, GB, IT, SE
JP 10501821 T2 19980217 JP 1996-530667 19960314
US 5849710 A 19981215 US 1996-750208 19961204
PRIORITY APPLN. INFO.: GB 1995-7298 19950407
WO 1996-EP1165 19960314
OTHER SOURCE(S): MARPAT 126:18783
GI



I



II

AB Indol-3-ylmethylene-2-oxindole derivs. I and their pharmaceutically acceptable salts are disclosed [wherein 1 or 2 of R, R1, R2, and R3 = X(CH2)mNH2, X(CH2)mNR4R5, X(CH2)mNHR6, NHC(:NH)NH2, NHC(:NH)NR4R5, NHC(:NH)NHR6, N:CHNH2, N:CHNR4R5, N:CHNHR6, X(CH2)mCOR7, CORa, COR8, YCOY'R9, NHR6, NHR10 group; remaining groups within R and R1-R3 = H, halo, amino, OH, alkyl, alkoxy, CO2H, alkoxycarbonyl, alkanoyloxy, cyano, NR4R5; X = O, S, NH; m = 1-4; 1 of R4 and R5 = H or alkyl, and other = alkyl; or NR4R5 forms satd. monoheterocycle; R6 = alkanoyl, 1- to 3-residue (un)substituted peptidyl; R7 = OH, amino, alkoxy, NR4R5; Ra = amino terminus of 1- to 3-unit peptidyl; R8 = alkoxy, phenylalkoxy, (CH2)nNH2, (CH2)nNR4R5, (CH2)nNHR6; n = 1-2; Y, Y' = NH, O; R9 = Ph, alkyl, phenylalkyl; R10 = mono-, di- or trihydroxyalkyl]. I have **tyrosine** kinase inhibiting activity, and are useful as antiproliferative, antimetastatic, anticancer, antiatheromatous, anti-Alzheimer, and immunomodulating agents. For example, 2-indolinone reacted with BrCH2COBr and AlCl3 to give the 5-(2-bromoacetyl) deriv., which underwent amination with piperidine and then condensation with indole-3-carboxaldehyde, to give title compd. II (FCE 28484). In tests for inhibition of p45 v-abl kinase and K562 leukemia cells in vitro, II had IC50 of 0.78 and 4.82 .mu.M, resp.

IT **168464-17-3P 184021-39-4P 184021-56-5P**
184021-79-2P 184021-85-0P 184021-97-4P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation)
(intermediate; prepn. of (indolylmethylene)oxindole analogs as **tyrosine** kinase inhibitors)

RN 168464-17-3 CAPLUS

CN 2H-Indol-2-one, 5-amino-1,3-dihydro-3-[(5-methoxy-1H-indol-3-yl)methylene]- (9CI) (CA INDEX NAME)



RN 184021-39-4 CAPLUS
CN Carbamic acid, [2,3-dihydro-3-[(5-methoxy-1H-indol-3-yl)methylene]-2-oxo-1H-indol-5-yl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 184021-56-5 CAPLUS
CN 2H-Indol-2-one, 5-[[(2,2-dimethyl-1,3-dioxolan-4-yl)methyl]amino]-1,3-dihydro-3-[(5-methoxy-1H-indol-3-yl)methylene]- (9CI) (CA INDEX NAME)



RN 184021-79-2 CAPLUS
CN Carbamic acid, [3-[(5-bromo-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-1H-indol-5-yl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 184021-85-0 CAPLUS
CN Carbamic acid, [[3-[(5-bromo-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-1H-indol-5-yl]carbonimidoyl]bis-, bis(1,1-dimethylethyl) ester (9CI) (CA INDEX NAME)



RN 184021-97-4 CAPLUS
CN Carbamic acid, [2,3-dihydro-3-[(5-methoxy-1H-indol-3-yl)methylene]-2-oxo-

1H-indol-6-yl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



IT **184020-98-2P**
RL: BAC (Biological activity or effector, except adverse); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of (indolylmethylene)oxindole analogs as **tyrosine** kinase inhibitors)
RN 184020-98-2 CAPLUS
CN Propanamide, 2-amino-N-[2,3-dihydro-3-[(5-methoxy-1H-indol-3-yl)methylene]-2-oxo-1H-indol-5-yl]-, (S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.



IT **181223-99-4P 184020-79-9P 184020-86-8P**
184020-93-7P 184021-06-5P 184021-15-6P
184021-23-6P
RL: BAC (Biological activity or effector, except adverse); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of (indolylmethylene)oxindole analogs as **tyrosine** kinase inhibitors)
RN 181223-99-4 CAPLUS
CN 2H-Indol-2-one, 5-[(2,3-dihydroxypropyl)amino]-1,3-dihydro-3-[(5-methoxy-1H-indol-3-yl)methylene]- (9CI) (CA INDEX NAME)



RN 184020-79-9 CAPLUS
CN Methanimidamide, N'-[2-[(1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-1H-indol-5-yl]-N,N-dimethyl- (9CI) (CA INDEX NAME)



RN 184020-86-8 CAPLUS
CN Guanidine, [3-[(5-bromo-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-1H-indol-5-yl]- (9CI) (CA INDEX NAME)



RN 184020-93-7 CAPLUS
CN Propanamide, 2-amino-N-[2,3-dihydro-3-[(5-methoxy-1H-indol-3-yl)methylene]-2-oxo-1H-indol-6-yl]-, (S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.



RN 184021-06-5 CAPLUS
CN L-Alaninamide, L-.alpha.-glutamyl-N-[2,3-dihydro-3-[(5-methoxy-1H-indol-3-yl)methylene]-2-oxo-1H-indol-5-yl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.



RN 184021-15-6 CAPLUS
CN 2H-Indol-2-one, 1,3-dihydro-3-(1H-indol-3-ylmethylene)-5-(1-piperidinylacetyl)-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 184021-23-6 CAPLUS
CN 2H-Indol-2-one, 5-(aminoacetyl)-1,3-dihydro-3-(1H-indol-3-ylmethylene)-(9CI) (CA INDEX NAME)



IT **184020-69-7P**
RL: BAC (Biological activity or effector, except adverse); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of (indolylmethylene)oxindoles as **tyrosine** kinase inhibitors)
RN 184020-69-7 CAPLUS
CN 2H-Indol-2-one, 1,3-dihydro-3-(1H-indol-3-ylmethylene)-5-(1-piperidinylacetyl)- (9CI) (CA INDEX NAME)



L5 ANSWER 59 OF 66 CAPLUS COPYRIGHT 2002 ACS
ACCESSION NUMBER: 1996:577724 CAPLUS
DOCUMENT NUMBER: 125:221574
TITLE: Preparation of hydrosoluble 3-arylidene-2-oxyindole **tyrosine** kinase inhibitors
INVENTOR(S): Buzzetti, Franco; Brasca, Maria Gabriella; Longo, Antonio; Ballinari, Dario
PATENT ASSIGNEE(S): Pharmacia S.P.A., Italy
SOURCE: PCT Int. Appl., 75 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9622976	A1	19960801	WO 1995-EP5176	19951222
W: AU, CA, JP, US				
RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
CA 2186508	AA	19960801	CA 1995-2186508	19951222
AU 9644363	A1	19960814	AU 1996-44363	19951222
AU 697673	B2	19981015		
EP 752985	A1	19970115	EP 1995-943238	19951222
EP 752985	B1	19990804		
R: CH, DE, ES, FR, GB, IT, LI, SE				
JP 09510993	T2	19971104	JP 1995-522571	19951222
ES 2137562	T3	19991216	ES 1995-943238	19951222
IL 116851	A1	20000601	IL 1996-116851	19960122
US 5840745	A	19981124	US 1996-704760	19960925

PRIORITY APPLN. INFO.: GB 1995-1567 A 19950126
WO 1995-EP5176 W 19951222

OTHER SOURCE(S): MARPAT 125:221574

GI For diagram(s), see printed CA Issue.

AB 3-Arylidene-2-oxindole derivs. [I; m = 0-2; A = (un)substituted bicyclic ring chosen from tetralin, naphthalene, quinoline and indole; R1 = H, alkyl, alkanoyl; one of R2 and R3 is H and the other is (un)substituted alkyl, (un)substituted alkoxycarbonyl, (un)substituted SO3H, (CH2)nN(alkyl)2, etc.; n = 2, 3], useful as **tyrosine** kinase inhibitors for the treatment of tumors, diabetic complications (no data), restenosis (no data), etc. (no data), are prepd. and I-contg. formulations presented. Thus, 3-carbethoxy-3-(5-methoxyindol-3-ylmethylene)-2-oxyndole was prepd. and demonstrated a IC50 of 1.99 .mu.M against v-abl **tyrosine** kinase and a IC50 of 2.34 .mu.M against the growth of K562 chronic myeloid leukemia cells.

IT **181222-47-9P 181222-52-6P 181222-54-8P**
181222-56-0P 181222-58-2P 181222-60-6P
181222-62-8P 181222-64-0P 181222-68-4P
181222-70-8P 181222-72-0P 181222-73-1P
181222-74-2P 181222-75-3P 181222-76-4P
181222-77-5P 181222-78-6P 181222-79-7P
181222-80-0P 181222-81-1P 181222-82-2P
181222-84-4P 181223-06-3P 181223-07-4P
181223-08-5P 181223-09-6P 181223-10-9P
181223-12-1P 181223-14-3P 181223-16-5P
181223-18-7P 181223-20-1P 181223-22-3P
181223-24-5P 181223-26-7P 181223-28-9P
181223-30-3P 181223-32-5P 181223-34-7P
181223-35-8P 181223-37-0P 181223-39-2P
181223-41-6P 181223-43-8P 181223-45-0P
181223-47-2P 181223-48-3P 181223-49-4P
181223-51-8P 181223-52-9P 181223-53-0P
181223-55-2P 181223-56-3P 181223-57-4P
181223-59-6P 181223-60-9P 181223-61-0P
181223-62-1P 181223-63-2P 181223-80-3P
181223-82-5P 181223-83-6P 181223-85-8P
181223-86-9P 181223-87-0P 181223-89-2P
181223-90-5P 181223-91-6P 181223-93-8P
181223-94-9P 181223-96-1P 181223-98-3P
181223-99-4P 181224-00-0P
RL: BAC (Biological activity or effector, except adverse); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of hydrosol. 3-arylidene-2-oxyindole **tyrosine** kinase

inhibitors)

RN 181222-47-9 CAPLUS

CN 1H-Indole-5-carboxylic acid, 3-[(1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-, methyl ester (9CI) (CA INDEX NAME)



RN 181222-52-6 CAPLUS

CN 1-Piperidinepropanamide, N-[2,3-dihydro-3-[(5-methoxy-1H-indol-3-yl)methylene]-2-oxo-1H-indol-5-yl]-, monohydrochloride, (E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



● HCl

RN 181222-54-8 CAPLUS

CN 1-Piperidinepropanamide, N-[2,3-dihydro-3-[(5-methoxy-1H-indol-3-yl)methylene]-2-oxo-1H-indol-5-yl]-, monohydrochloride, (Z)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



● HCl

RN 181222-56-0 CAPLUS

CN Benzenesulfonamide, 4-chloro-N-[3-[(1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-1H-indol-5-yl]- (9CI) (CA INDEX NAME)



RN 181222-58-2 CAPLUS
CN 1H-Indole-5-carboxylic acid, 2,3-dihydro-3-[(5-methoxy-1H-indol-3-yl)methylene]-2-oxo-, ethyl ester (9CI) (CA INDEX NAME)



RN 181222-60-6 CAPLUS
CN 1H-Indole-5-carboxamide, 2,3-dihydro-3-[(5-methoxy-1H-indol-3-yl)methylene]-2-oxo-N-(phenylmethyl)- (9CI) (CA INDEX NAME)



RN 181222-62-8 CAPLUS
CN 1H-Indole-5-sulfonic acid, 2,3-dihydro-3-[(5-methoxy-1H-indol-3-yl)methylene]-2-oxo- (9CI) (CA INDEX NAME)



RN 181222-64-0 CAPLUS
CN 1H-Indole-5-carboximidamide, 2,3-dihydro-3-[(5-methoxy-1H-indol-3-yl)methylene]-2-oxo-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 181222-68-4 CAPLUS
CN 2H-Indol-2-one, 5-[(2,3-dihydroxypropyl)amino]-1,3-dihydro-3-(4-quinolinylmethylene)- (9CI) (CA INDEX NAME)



RN 181222-70-8 CAPLUS
CN 2H-Indol-2-one, 5-[(2,3-dihydroxypropyl)amino]-1,3-dihydro-3-[(5-methoxy-1H-indol-3-yl)methylene]-, (E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 181222-72-0 CAPLUS
CN 2H-Indol-2-one, 5-[(2,3-dihydroxypropyl)amino]-1,3-dihydro-3-[(5-methoxy-1H-indol-3-yl)methylene]-, (Z)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 181222-73-1 CAPLUS
CN Propanamide, N-[2,3-dihydro-2-oxo-3-(4-quinolinylmethylene)-1H-indol-5-yl]-2,3-dihydroxy- (9CI) (CA INDEX NAME)



RN 181222-74-2 CAPLUS
CN Methanesulfonamide, N-[2,3-dihydro-2-oxo-3-(4-quinolinylmethylene)-1H-indol-5-yl]- (9CI) (CA INDEX NAME)



RN 181222-75-3 CAPLUS
CN Guanidine, [2,3-dihydro-2-oxo-3-(4-quinolinylmethylene)-1H-indol-5-yl]- (9CI) (CA INDEX NAME)





RN 181222-76-4 CAPLUS
CN Urea, [2,3-dihydro-2-oxo-3-(4-quinolinylmethylene)-1H-indol-5-yl]- (9CI) (CA INDEX NAME)



RN 181222-77-5 CAPLUS
CN 2H-Indol-2-one, 5-(2,3-dihydroxypropoxy)-1,3-dihydro-3-(4-quinolinylmethylene)- (9CI) (CA INDEX NAME)



RN 181222-78-6 CAPLUS
CN Acetic acid, hydroxy-, 2,3-dihydro-2-oxo-3-(4-quinolinylmethylene)-1H-indol-5-yl ester (9CI) (CA INDEX NAME)



RN 181222-79-7 CAPLUS
CN 2H-Indol-2-one, 1,3-dihydro-5-(phosphonooxy)-3-(4-quinolinylmethylene)-(9CI) (CA INDEX NAME)



RN 181222-80-0 CAPLUS
CN 1H-Indole-5-carboxylic acid, 2,3-dihydro-2-oxo-3-(4-quinolinylmethylene)-, methyl ester (9CI) (CA INDEX NAME)



RN 181222-81-1 CAPLUS
CN 1H-Indole-5-carboximidamide, 2,3-dihydro-2-oxo-3-(4-quinolinylmethylene)-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 181222-82-2 CAPLUS
CN 2H-Indol-2-one, 5-(aminomethyl)-1,3-dihydro-3-(4-quinolinylmethylene)-
(9CI) (CA INDEX NAME)



RN 181222-84-4 CAPLUS
CN 2H-Indol-2-one, 5-(aminomethyl)-1,3-dihydro-3-(4-quinolinylmethylene)-,
monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 181223-06-3 CAPLUS
CN 1H-Indole-5-sulfonic acid, 2,3-dihydro-2-oxo-3-(4-quinolinylmethylene)-
(9CI) (CA INDEX NAME)



RN 181223-07-4 CAPLUS
CN 1H-Indole-5-sulfonamide, 2,3-dihydro-2-oxo-3-(4-quinolinylmethylene)-(9CI) (CA INDEX NAME)



RN 181223-08-5 CAPLUS
CN 2H-Indol-2-one, 5-[bis(2-hydroxyethyl)amino]-1,3-dihydro-3-(4-quinolinylmethylene)- (9CI) (CA INDEX NAME)



RN 181223-09-6 CAPLUS
CN 1-Piperidinepropanamide, N-[2,3-dihydro-2-oxo-3-(4-quinolinylmethylene)-1H-indol-5-yl]- (9CI) (CA INDEX NAME)



RN 181223-10-9 CAPLUS
CN 1H-Indole-5-carboximidamide, 2,3-dihydro-2-oxo-3-(4-quinolinylmethylene)-(9CI) (CA INDEX NAME)



RN 181223-12-1 CAPLUS
CN 2H-Indol-2-one, 1,3-dihydro-5-(hydroxymethyl)-3-(4-quinolinylmethylene)-(9CI) (CA INDEX NAME)



RN 181223-14-3 CAPLUS
CN 1H-Indole-5-sulfonic acid, 2,3-dihydro-3-(1H-indol-3-ylmethylene)-2-oxo-(9CI) (CA INDEX NAME)



RN 181223-16-5 CAPLUS
CN 1H-Indole-5-sulfonamide, 2,3-dihydro-3-(1H-indol-3-ylmethylene)-2-oxo-

(9CI) (CA INDEX NAME)



RN 181223-18-7 CAPLUS
CN 1H-Indole-5-carboxylic acid, 2,3-dihydro-3-(1H-indol-3-ylmethylene)-2-oxo-, methyl ester (9CI) (CA INDEX NAME)



RN 181223-20-1 CAPLUS
CN 2H-Indol-2-one, 5-[bis(2-hydroxyethyl)amino]-1,3-dihydro-3-(1H-indol-3-ylmethylene)- (9CI) (CA INDEX NAME)



RN 181223-22-3 CAPLUS
CN 2H-Indol-2-one, 5-[(2,3-dihydroxypropyl)amino]-1,3-dihydro-3-(1H-indol-3-ylmethylene)- (9CI) (CA INDEX NAME)



RN 181223-24-5 CAPLUS
CN Urea, [2,3-dihydro-3-(1H-indol-3-ylmethylene)-2-oxo-1H-indol-5-yl]- (9CI) (CA INDEX NAME)



RN 181223-26-7 CAPLUS
CN Guanidine, [2,3-dihydro-3-(1H-indol-3-ylmethylene)-2-oxo-1H-indol-5-yl]- (9CI) (CA INDEX NAME)



RN 181223-28-9 CAPLUS
CN Propanamide, N-[2,3-dihydro-3-(1H-indol-3-ylmethylene)-2-oxo-1H-indol-5-yl]-2,3-dihydroxy- (9CI) (CA INDEX NAME)



RN 181223-30-3 CAPLUS
CN 1-Piperidinepropanamide, N-[2,3-dihydro-3-(1H-indol-3-ylmethylene)-2-oxo-1H-indol-5-yl]- (9CI) (CA INDEX NAME)



RN 181223-32-5 CAPLUS
CN Methanesulfonamide, N-[2,3-dihydro-3-(1H-indol-3-ylmethylene)-2-oxo-1H-indol-5-yl]- (9CI) (CA INDEX NAME)



RN 181223-34-7 CAPLUS
CN Acetamide, N-[2,3-dihydro-3-(1H-indol-3-ylmethylene)-2-oxo-1H-indol-5-yl]-

2-hydroxy- (9CI) (CA INDEX NAME)



RN 181223-35-8 CAPLUS
CN 2H-Indol-2-one, 5-(2,3-dihydroxypropoxy)-1,3-dihydro-3-(1H-indol-3-ylmethylene)- (9CI) (CA INDEX NAME)



RN 181223-37-0 CAPLUS
CN 2H-Indol-2-one, 5-(aminomethyl)-1,3-dihydro-3-(1H-indol-3-ylmethylene)- (9CI) (CA INDEX NAME)



RN 181223-39-2 CAPLUS
CN 1H-Indole-5-carboximidamide, 2,3-dihydro-3-(1H-indol-3-ylmethylene)-2-oxo- (9CI) (CA INDEX NAME)



RN 181223-41-6 CAPLUS
CN 2H-Indol-2-one, 1,3-dihydro-5-(hydroxymethyl)-3-(1H-indol-3-ylmethylene)- (9CI) (CA INDEX NAME)



RN 181223-43-8 CAPLUS
CN 2H-Indol-2-one, 1,3-dihydro-3-(1H-indol-3-ylmethylene)-5-(phosphonooxy)-
(9CI) (CA INDEX NAME)



RN 181223-45-0 CAPLUS
CN 1H-Indole-5-sulfonic acid, 3-[(1,2-dihydro-2-oxo-3H-indol-3-
ylidene)methyl]- (9CI) (CA INDEX NAME)



RN 181223-47-2 CAPLUS
CN 1H-Indole-5-sulfonamide, 3-[(1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-
(9CI) (CA INDEX NAME)



RN 181223-48-3 CAPLUS
CN 2H-Indol-2-one, 3-[[5-[bis(2-hydroxyethyl)amino]-1H-indol-3-yl]methylene]-
1,3-dihydro- (9CI) (CA INDEX NAME)



RN 181223-49-4 CAPLUS
CN 2H-Indol-2-one, 3-[[5-[(2,3-dihydroxypropyl)amino]-1H-indol-3-
yl]methylene]-1,3-dihydro- (9CI) (CA INDEX NAME)



RN 181223-51-8 CAPLUS
CN Urea, [3-[(1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-1H-indol-5-yl]- (9CI) (CA INDEX NAME)



RN 181223-52-9 CAPLUS
CN Guanidine, [3-[(1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-1H-indol-5-yl]- (9CI) (CA INDEX NAME)



RN 181223-53-0 CAPLUS
CN Propanamide, N-[3-[(1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-1H-indol-5-yl]-2,3-dihydroxy- (9CI) (CA INDEX NAME)



RN 181223-55-2 CAPLUS
CN 1-Piperidinepropanamide, N-[3-[(1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-1H-indol-5-yl]- (9CI) (CA INDEX NAME)



RN 181223-56-3 CAPLUS
CN Methanesulfonamide, N-[3-[(1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-1H-indol-5-yl]- (9CI) (CA INDEX NAME)



RN 181223-57-4 CAPLUS
CN Acetic acid, hydroxy-, 3-[(1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-1H-indol-5-yl ester (9CI) (CA INDEX NAME)



RN 181223-59-6 CAPLUS
CN 2H-Indol-2-one, 3-[[5-(2,3-dihydroxypropoxy)-1H-indol-3-yl]methylene]-1,3-dihydro- (9CI) (CA INDEX NAME)



RN 181223-60-9 CAPLUS
CN 2H-Indol-2-one, 3-[[5-(aminomethyl)-1H-indol-3-yl]methylene]-1,3-dihydro- (9CI) (CA INDEX NAME)



RN 181223-61-0 CAPLUS
CN 1H-Indole-5-carboximidamide, 3-[(1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]- (9CI) (CA INDEX NAME)



RN 181223-62-1 CAPLUS
CN 2H-Indol-2-one, 1,3-dihydro-3-[[5-(hydroxymethyl)-1H-indol-3-yl]methylene]- (9CI) (CA INDEX NAME)



RN 181223-63-2 CAPLUS
CN 2H-Indol-2-one, 1,3-dihydro-3-[[5-(phosphonooxy)-1H-indol-3-yl]methylene]- (9CI) (CA INDEX NAME)



RN 181223-80-3 CAPLUS
CN 1-Piperidinepropanamide, N-[2,3-dihydro-3-[(5-methoxy-1H-indol-3-yl)methylene]-2-oxo-1H-indol-5-yl]- (9CI) (CA INDEX NAME)



RN 181223-82-5 CAPLUS
CN 1H-Indole-5-carboxylic acid, 2,3-dihydro-2-oxo-3-(4-quinolinylmethylene)-, ethyl ester (9CI) (CA INDEX NAME)



RN 181223-83-6 CAPLUS
CN 1H-Indole-5-carboxylic acid, 3-[(1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-, ethyl ester (9CI) (CA INDEX NAME)



RN 181223-85-8 CAPLUS
CN 1H-Indole-5-carboxylic acid, 2,3-dihydro-2-oxo-3-(4-quinolinylmethylene)-, phenylmethyl ester (9CI) (CA INDEX NAME)



RN 181223-86-9 CAPLUS
CN 1H-Indole-5-carboxylic acid, 2,3-dihydro-3-[(5-methoxy-1H-indol-3-yl)methylene]-2-oxo-, phenylmethyl ester (9CI) (CA INDEX NAME)



RN 181223-87-0 CAPLUS
CN 1H-Indole-5-carboxylic acid, 3-[(1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-, phenylmethyl ester (9CI) (CA INDEX NAME)



RN 181223-89-2 CAPLUS
CN 1H-Indole-5-carboxamide, 2,3-dihydro-2-oxo-N-phenyl-3-(4-quinolinylmethylene)- (9CI) (CA INDEX NAME)



RN 181223-90-5 CAPLUS
CN 1H-Indole-5-carboxamide, 2,3-dihydro-3-[(5-methoxy-1H-indol-3-yl)methylene]-2-oxo-N-phenyl- (9CI) (CA INDEX NAME)



RN 181223-91-6 CAPLUS
CN 1H-Indole-5-carboxamide, 3-[(1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-N-phenyl- (9CI) (CA INDEX NAME)



RN 181223-93-8 CAPLUS
CN 1H-Indole-5-carboxamide, 2,3-dihydro-2-oxo-N-(phenylmethyl)-3-(4-quinolinylmethylene)- (9CI) (CA INDEX NAME)



RN 181223-94-9 CAPLUS
CN 1H-Indole-5-carboxamide, 3-[(1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-N-(phenylmethyl)- (9CI) (CA INDEX NAME)



RN 181223-96-1 CAPLUS
CN 1H-Indole-5-carboxylic acid, 2,3-dihydro-3-[(8-hydroxy-4-quinolinyl)methylene]-2-oxo-, ethyl ester (9CI) (CA INDEX NAME)



RN 181223-98-3 CAPLUS
CN 1H-Indole-5-carboxamide, 2,3-dihydro-3-[(8-hydroxy-4-quinolinyl)methylene]-2-oxo-N-(phenylmethyl)- (9CI) (CA INDEX NAME)



RN 181223-99-4 CAPLUS
CN 2H-Indol-2-one, 5-[(2,3-dihydroxypropyl)amino]-1,3-dihydro-3-[(5-methoxy-1H-indol-3-yl)methylene]- (9CI) (CA INDEX NAME)



RN 181224-00-0 CAPLUS
CN 1H-Indole-5-carboximidamide, 2,3-dihydro-3-[(5-methoxy-1H-indol-3-yl)methylene]-2-oxo- (9CI) (CA INDEX NAME)



IT **181224-02-2 181224-03-3 181224-04-4**
181224-05-5
RL: RCT (Reactant)
(prepn. of hydrosol. 3-arylidene-2-oxyindole **tyrosine** kinase inhibitors)
RN 181224-02-2 CAPLUS
CN 2H-Indol-2-one, 5-amino-1,3-dihydro-3-(4-quinolinylmethylene)- (9CI) (CA INDEX NAME)



RN 181224-03-3 CAPLUS
CN 1H-Indole-5-carboxylic acid, 2,3-dihydro-2-oxo-3-(4-quinolinylmethylene)- (9CI) (CA INDEX NAME)



RN 181224-04-4 CAPLUS
CN 1H-Indole-5-carbonitrile, 2,3-dihydro-2-oxo-3-(4-quinolinylmethylene)- (9CI) (CA INDEX NAME)



RN 181224-05-5 CAPLUS
CN 2H-Indol-2-one, 5-(chloromethyl)-1,3-dihydro-3-(4-quinolinylmethylene)-
(9CI) (CA INDEX NAME)



L5 ANSWER 60 OF 66 CAPLUS COPYRIGHT 2002 ACS
ACCESSION NUMBER: 1996:209666 CAPLUS
DOCUMENT NUMBER: 124:260834
TITLE: Preparation and formulation of substituted azaindolylidene compounds as **tyrosine** kinase inhibitors
INVENTOR(S): Buzzetti, Franco; Brasca, Gabriella Maria; Longo, Antonio; Ballinari, Dario
PATENT ASSIGNEE(S): Pharmacia S.P.A., Italy
SOURCE: PCT Int. Appl., 64 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9600226	A1	19960104	WO 1995-EP2043	19950530
W: AM, AU, BB, BG, BR, BY, CA, CN, CZ, EE, FI, GE, HU, JP, KE, KG, KP, KR, KZ, LK, LR, LT, LV, MD, MG, MN, MW, MX, NO, NZ, PL, RO, RU, SD, SI, SK, TJ, TT, UA, US, UZ, VN				
RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
CA 2168659	AA	19960104	CA 1995-2168659	19950530
AU 9526716	A1	19960119	AU 1995-26716	19950530
EP 715628	A1	19960612	EP 1995-921777	19950530
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, NL, PT, SE				
CN 1129941	A	19960828	CN 1995-190567	19950530
HU 74609	A2	19970128	HU 1996-729	19950530
JP 09502457	T2	19970311	JP 1995-502741	19950530

ZA 9505223	A	19960131	ZA 1995-5223	19950623
US 5663346	A	19970902	US 1996-592297	19960209
FI 9600751	A	19960219	FI 1996-751	19960219
NO 9600713	A	19960222	NO 1996-713	19960222

PRIORITY APPLN. INFO.: GB 1994-12719 19940624
WO 1995-EP2043 19950530

OTHER SOURCE(S): MARPAT 124:260834

GI



I

AB The title compds. I [one of X1 , X2, X3, X4 is N and the others are CH; R is CH:C(CN)CONH2, etc.; R1 is hydrogen, amino, carboxy, cyano, etc.; R2 is H, C1-C6 alkyl, etc.; a proviso is given] are prepd. 5-Cyano-3-[(7-azaindol-3-yl)methylen]-2-oxindole (NMR data given) in vitro showed IC50 of 0.98 mM against p-45 v-abl kinase.

IT **175075-26-0P 175075-28-2P 175075-29-3P**
175075-30-6P 175075-31-7P 175075-32-8P
175075-33-9P 175075-34-0P 175075-35-1P
175075-36-2P 175075-37-3P 175075-38-4P
175075-39-5P 175075-40-8P 175075-41-9P
175075-42-0P 175075-43-1P 175075-44-2P
175075-45-3P 175075-46-4P 175075-48-6P
175075-96-4P 175075-97-5P 175075-98-6P
175075-99-7P 175076-00-3P 175076-01-4P
175076-02-5P 175076-03-6P 175076-04-7P
175076-05-8P 175076-06-9P 175076-07-0P
175076-08-1P 175076-09-2P 175076-10-5P
175076-11-6P 175076-12-7P 175076-13-8P
175076-14-9P 175076-15-0P 175076-16-1P
175076-17-2P 175076-18-3P 175076-19-4P
175076-20-7P 175076-21-8P 175076-22-9P
175076-23-0P 175076-24-1P 175076-25-2P
175076-26-3P 175076-27-4P 175076-28-5P
175076-29-6P 175076-30-9P 175076-31-0P
175076-32-1P 175076-33-2P 175076-34-3P
175076-35-4P 175076-37-6P 175076-39-8P
175076-41-2P 175076-43-4P 175076-44-5P
175076-45-6P 175076-46-7P 175076-47-8P
175076-48-9P 175076-49-0P 175076-50-3P
175076-51-4P 175076-52-5P 175076-53-6P
175076-54-7P 175076-55-8P
RL: BAC (Biological activity or effector, except adverse); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of substituted azaindolylidene compds. as **tyrosine** kinase inhibitors)

RN 175075-26-0 CAPLUS

CN 1H-Indole-5-sulfonamide, 2,3-dihydro-2-oxo-3-(1H-pyrrolo[2,3-b]pyridin-3-

ylmethylene)- (9CI) (CA INDEX NAME)



RN 175075-28-2 CAPLUS
CN 1H-Indole-5-carboxylic acid, 2,3-dihydro-2-oxo-3-(1H-pyrrolo[2,3-b]pyridin-3-ylmethylene)-, ethyl ester (9CI) (CA INDEX NAME)



RN 175075-29-3 CAPLUS
CN 1H-Indole-5-carboxylic acid, 2,3-dihydro-2-oxo-3-(1H-pyrrolo[2,3-b]pyridin-3-ylmethylene)-, phenylmethyl ester (9CI) (CA INDEX NAME)



RN 175075-30-6 CAPLUS
CN 1H-Indole-5-sulfonic acid, 2,3-dihydro-2-oxo-3-(1H-pyrrolo[2,3-b]pyridin-3-ylmethylene)- (9CI) (CA INDEX NAME)



RN 175075-31-7 CAPLUS
CN 2H-Indol-2-one, 5-[(2,3-dihydroxypropyl)amino]-1,3-dihydro-3-(1H-pyrrolo[2,3-b]pyridin-3-ylmethylene)- (9CI) (CA INDEX NAME)



RN 175075-32-8 CAPLUS
CN Propanamide, N-[2,3-dihydro-2-oxo-3-(1H-pyrrolo[2,3-b]pyridin-3-ylmethylene)-1H-indol-5-yl]-2,3-dihydroxy- (9CI) (CA INDEX NAME)



RN 175075-33-9 CAPLUS
CN Methanesulfonamide, N-[2,3-dihydro-2-oxo-3-(1H-pyrrolo[2,3-b]pyridin-3-ylmethylene)-1H-indol-5-yl]- (9CI) (CA INDEX NAME)



RN 175075-34-0 CAPLUS
CN Guanidine, [2,3-dihydro-2-oxo-3-(1H-pyrrolo[2,3-b]pyridin-3-ylmethylene)-1H-indol-5-yl]- (9CI) (CA INDEX NAME)



RN 175075-35-1 CAPLUS
CN Urea, [2,3-dihydro-2-oxo-3-(1H-pyrrolo[2,3-b]pyridin-3-ylmethylene)-1H-indol-5-yl]- (9CI) (CA INDEX NAME)



RN 175075-36-2 CAPLUS
CN 2H-Indol-2-one, 5-(2,3-dihydroxypropoxy)-1,3-dihydro-3-(1H-pyrrolo[2,3-b]pyridin-3-ylmethylene)- (9CI) (CA INDEX NAME)



RN 175075-37-3 CAPLUS
CN Acetic acid, hydroxy-, 2,3-dihydro-2-oxo-3-(1H-pyrrolo[2,3-b]pyridin-3-ylmethylene)-1H-indol-5-yl ester (9CI) (CA INDEX NAME)



RN 175075-38-4 CAPLUS
CN 2H-Indol-2-one, 1,3-dihydro-5-(phosphonooxy)-3-(1H-pyrrolo[2,3-b]pyridin-3-ylmethylene)- (9CI) (CA INDEX NAME)



RN 175075-39-5 CAPLUS
CN 1H-Indole-5-carboxylic acid, 2,3-dihydro-2-oxo-3-(1H-pyrrolo[2,3-b]pyridin-3-ylmethylene)-, methyl ester (9CI) (CA INDEX NAME)



RN 175075-40-8 CAPLUS
CN 1H-Indole-5-carboximidamide, 2,3-dihydro-2-oxo-3-(1H-pyrrolo[2,3-b]pyridin-3-ylmethylene)-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 175075-41-9 CAPLUS
CN 2H-Indol-2-one, 1,3-dihydro-5-[[4-(2-hydroxyethyl)-1-piperazinyl]methyl]-3-(1H-pyrrolo[2,3-b]pyridin-3-ylmethylene)-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 175075-42-0 CAPLUS
CN 1-Piperazineethanol, 4-[[2,3-dihydro-2-oxo-3-(1H-pyrrolo[2,3-b]pyridin-3-ylmethylene)-1H-indol-5-yl]carbonyl]- (9CI) (CA INDEX NAME)



RN 175075-43-1 CAPLUS
CN 1H-Indole-5-carboxamide, 2,3-dihydro-2-oxo-N-(phenylmethyl)-3-(1H-pyrrolo[2,3-b]pyridin-3-ylmethylene)- (9CI) (CA INDEX NAME)



RN 175075-44-2 CAPLUS
CN 1H-Indole-5-sulfonic acid, 2,3-dihydro-2-oxo-3-(1H-pyrrolo[2,3-b]pyridin-3-ylmethylene)-, monosodium salt (9CI) (CA INDEX NAME)



● Na

RN 175075-45-3 CAPLUS
CN 1-Piperidinepropanamide, N-[2,3-dihydro-2-oxo-3-(1H-pyrrolo[2,3-b]pyridin-3-ylmethylene)-1H-indol-5-yl]-, dihydrochloride (9CI) (CA INDEX NAME)



● 2 HCl

RN 175075-46-4 CAPLUS
CN 2H-Indol-2-one, 5-amino-1,3-dihydro-3-(1H-pyrrolo[2,3-b]pyridin-3-ylmethylene)-, bis(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 157561-92-7
CMF C16 H12 N4 O



CM 2

CRN 76-05-1

CMF C2 H F3 O2



RN 175075-48-6 CAPLUS
CN 1H-Indole-5-carboxylic acid, 2,3-dihydro-2-oxo-3-(1H-pyrrolo[2,3-b]pyridin-3-ylmethylene)-, compd. with piperidine (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 175075-47-5
CMF C17 H11 N3 O3



CM 2

CRN 110-89-4
CMF C5 H11 N



RN 175075-96-4 CAPLUS
CN 1H-Indole-5-sulfonic acid, 2,3-dihydro-3-(1H-indol-3-ylmethylene)-2-oxo-, monosodium salt, (Z)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



● Na

RN 175075-97-5 CAPLUS
CN 1H-Indole-5-sulfonic acid, 2,3-dihydro-2-oxo-3-(1H-pyrrolo[2,3-b]pyridin-3-

ylmethylene)-, monosodium salt, (E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



● Na

RN 175075-98-6 CAPLUS
CN 1H-Indole-5-sulfonamide, 2,3-dihydro-3-(1H-indol-3-ylmethylene)-2-oxo-, (Z)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 175075-99-7 CAPLUS
CN 1H-Indole-5-sulfonamide, 2,3-dihydro-2-oxo-3-(1H-pyrrolo[2,3-b]pyridin-3-ylmethylene)-, (E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 175076-00-3 CAPLUS
CN Piperazine, 1-[[2,3-dihydro-3-(1H-indol-3-ylmethylene)-2-oxo-1H-indol-5-yl]sulfonyl]-, (Z)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 175076-01-4 CAPLUS
CN Piperazine, 1-[[2,3-dihydro-2-oxo-3-(1H-pyrrolo[2,3-b]pyridin-3-ylmethylene)-1H-indol-5-yl]sulfonyl]-, (E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 175076-02-5 CAPLUS
CN 1-Piperazineethanol, 4-[[2,3-dihydro-3-(1H-indol-3-ylmethylene)-2-oxo-1H-indol-5-yl]sulfonyl]-, (Z)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 175076-03-6 CAPLUS
CN 1-Piperazineethanol, 4-[[2,3-dihydro-2-oxo-3-(1H-pyrrolo[2,3-b]pyridin-3-ylmethylene)-1H-indol-5-yl]sulfonyl]-, (E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 175076-04-7 CAPLUS
CN 2H-Indol-2-one, 5-[bis(2-hydroxyethyl)amino]-1,3-dihydro-3-(1H-indol-3-

ylmethylene)-, (Z)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 175076-05-8 CAPLUS
CN 2H-Indol-2-one, 5-[bis(2-hydroxyethyl)amino]-1,3-dihydro-3-(1H-pyrrolo[2,3-b]pyridin-3-ylmethylene)-, (E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 175076-06-9 CAPLUS
CN Urea, [2,3-dihydro-3-(1H-indol-3-ylmethylene)-2-oxo-1H-indol-5-yl]-, (Z)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 175076-07-0 CAPLUS
CN Urea, [2,3-dihydro-2-oxo-3-(1H-pyrrolo[2,3-b]pyridin-3-ylmethylene)-1H-indol-5-yl]-, (E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.





RN 175076-08-1 CAPLUS
CN Guanidine, [2,3-dihydro-3-(1H-indol-3-ylmethylene)-2-oxo-1H-indol-5-yl]-, (Z)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 175076-09-2 CAPLUS
CN Guanidine, [2,3-dihydro-2-oxo-3-(1H-pyrrolo[2,3-b]pyridin-3-ylmethylene)-1H-indol-5-yl]-, (E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 175076-10-5 CAPLUS
CN Propanamide, N-[2,3-dihydro-3-(1H-indol-3-ylmethylene)-2-oxo-1H-indol-5-yl]-2,3-dihydroxy-, (Z)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 175076-11-6 CAPLUS
CN Propanamide, N-[2,3-dihydro-2-oxo-3-(1H-pyrrolo[2,3-b]pyridin-3-

ylmethylene)-1H-indol-5-yl]-2,3-dihydroxy-, (E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 175076-12-7 CAPLUS
CN 1-Piperidinepropanamide, N-[2,3-dihydro-3-(1H-indol-3-ylmethylene)-2-oxo-1H-indol-5-yl]-, dihydrochloride, (Z)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



●2 HCl

RN 175076-13-8 CAPLUS
CN 1-Piperidinepropanamide, N-[2,3-dihydro-2-oxo-3-(1H-pyrrolo[2,3-b]pyridin-3-ylmethylene)-1H-indol-5-yl]-, dihydrochloride, (E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



●2 HCl

RN 175076-14-9 CAPLUS
CN Methanesulfonamide, N-[2,3-dihydro-3-(1H-indol-3-ylmethylene)-2-oxo-1H-indol-5-yl]-, (Z)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 175076-15-0 CAPLUS
CN Methanesulfonamide, N-[2,3-dihydro-2-oxo-3-(1H-pyrrolo[2,3-b]pyridin-3-ylmethylene)-1H-indol-5-yl]-, (E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 175076-16-1 CAPLUS
CN 2H-Indol-2-one, 5-(2,3-dihydroxypropoxy)-1,3-dihydro-3-(1H-indol-3-ylmethylene)-, (Z)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 175076-17-2 CAPLUS
CN 2H-Indol-2-one, 5-(2,3-dihydroxypropoxy)-1,3-dihydro-3-(1H-pyrrolo[2,3-b]pyridin-3-ylmethylene)-, (E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 175076-18-3 CAPLUS
CN Propanoic acid, 2,3-dihydroxy-, 2,3-dihydro-3-(1H-indol-3-ylmethylene)-2-oxo-1H-indol-5-yl ester, (Z)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 175076-19-4 CAPLUS
CN Propanoic acid, 2,3-dihydroxy-, 2,3-dihydro-2-oxo-3-(1H-pyrrolo[2,3-b]pyridin-3-ylmethylene)-1H-indol-5-yl ester, (E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 175076-20-7 CAPLUS
CN 2H-Indol-2-one, 1,3-dihydro-3-(1H-indol-3-ylmethylene)-5-(phosphonooxy)-, (Z)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 175076-21-8 CAPLUS
CN 2H-Indol-2-one, 1,3-dihydro-5-(phosphonooxy)-3-(1H-pyrrolo[2,3-b]pyridin-3-ylmethylene)-, (E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 175076-22-9 CAPLUS
CN 2H-Indol-2-one, 5-(aminomethyl)-1,3-dihydro-3-(1H-indol-3-ylmethylene)-, (Z)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 175076-23-0 CAPLUS
CN 2H-Indol-2-one, 5-(aminomethyl)-1,3-dihydro-3-(1H-pyrrolo[2,3-b]pyridin-3-ylmethylene)-, (E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 175076-24-1 CAPLUS
CN 1H-Indole-5-carboximidamide, 2,3-dihydro-3-(1H-indol-3-ylmethylene)-2-oxo-, (Z)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 175076-25-2 CAPLUS
CN 1H-Indole-5-carboximidamide, 2,3-dihydro-2-oxo-3-(1H-pyrrolo[2,3-b]pyridin-3-ylmethylene)-, (E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 175076-26-3 CAPLUS
CN 2H-Indol-2-one, 5-[(2,3-dihydroxypropyl)amino]-1,3-dihydro-3-(1H-indol-3-ylmethylene)-, (Z)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 175076-27-4 CAPLUS
CN 2H-Indol-2-one, 5-[(2,3-dihydroxypropyl)amino]-1,3-dihydro-3-(1H-pyrrolo[2,3-b]pyridin-3-ylmethylene)-, (E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 175076-28-5 CAPLUS
CN 1H-Indole-5-carboxylic acid, 2,3-dihydro-3-(1H-indol-3-ylmethylene)-2-oxo-, methyl ester, (Z)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 175076-29-6 CAPLUS
CN 1H-Indole-5-carboxylic acid, 2,3-dihydro-2-oxo-3-(1H-pyrrolo[2,3-b]pyridin-3-ylmethylene)-, methyl ester, (E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 175076-30-9 CAPLUS
CN 2H-Indol-2-one, 1,3-dihydro-5-[[4-(2-hydroxyethyl)-1-piperazinyl]methyl]-3-(1H-indol-3-ylmethylene)-, (Z)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 175076-31-0 CAPLUS
CN 2H-Indol-2-one, 1,3-dihydro-5-[[4-(2-hydroxyethyl)-1-piperazinyl]methyl]-3-(1H-pyrrolo[2,3-b]pyridin-3-ylmethylene)-, (E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 175076-32-1 CAPLUS
CN 1-Piperazineethanol, 4-[[2,3-dihydro-3-(1H-indol-3-ylmethylene)-2-oxo-1H-indol-5-yl]carbonyl]-, (Z)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 175076-33-2 CAPLUS
CN 1-Piperazineethanol, 4-[[2,3-dihydro-2-oxo-3-(1H-pyrrolo[2,3-b]pyridin-3-ylmethylene)-1H-indol-5-yl]carbonyl]-, (E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 175076-34-3 CAPLUS
CN Acetic acid, hydroxy-, 2,3-dihydro-3-(1H-indol-3-ylmethylene)-2-oxo-1H-indol-5-yl ester, (Z)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 175076-35-4 CAPLUS
CN Acetic acid, hydroxy-, 2,3-dihydro-2-oxo-3-(1H-pyrrolo[2,3-b]pyridin-3-ylmethylene)-1H-indol-5-yl ester, (E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 175076-37-6 CAPLUS
CN 2H-Indol-2-one, 5-amino-1,3-dihydro-3-(1H-indol-3-ylmethylene)-, (Z)-, bis(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 175076-36-5
CMF C17 H13 N3 O
CDES 2:Z

Double bond geometry as shown.



CM 2

CRN 76-05-1
CMF C2 H F3 O2



RN 175076-39-8 CAPLUS
CN 2H-Indol-2-one, 5-amino-1,3-dihydro-3-(1H-pyrrolo[2,3-b]pyridin-3-ylmethylene)-, (E)-, bis(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 175076-38-7
CMF C16 H12 N4 O
CDES 2:E

Double bond geometry as shown.



CM 2

CRN 76-05-1
CMF C2 H F3 O2



RN 175076-41-2 CAPLUS
CN 1H-Indole-5-carboxylic acid, 2,3-dihydro-3-(1H-indol-3-ylmethylene)-2-oxo-, (Z)-, compd. with piperidine (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 175076-40-1
CMF C18 H12 N2 O3
CDES 2:Z

Double bond geometry as shown.



CM 2

CRN 110-89-4
CMF C5 H11 N



RN 175076-43-4 CAPLUS
CN 1H-Indole-5-carboxylic acid, 2,3-dihydro-2-oxo-3-(1H-pyrrolo[2,3-b]pyridin-3-ylmethylene)-, (E)-, compd. with piperidine (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 175076-42-3
CMF C17 H11 N3 O3
CDES 2:E

Double bond geometry as shown.



CM 2

CRN 110-89-4
CMF C5 H11 N



RN 175076-44-5 CAPLUS
CN 1H-Indole-5-carbonitrile, 2,3-dihydro-3-(1H-indol-3-ylmethylene)-2-oxo-, (Z)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 175076-45-6 CAPLUS
CN 1H-Indole-5-carbonitrile, 2,3-dihydro-2-oxo-3-(1H-pyrrolo[2,3-b]pyridin-3-ylmethylene)-, (E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 175076-46-7 CAPLUS
CN 1H-Indole-5-carboxylic acid, 2,3-dihydro-3-(1H-indol-3-ylmethylene)-2-oxo-, ethyl ester, (Z)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 175076-47-8 CAPLUS
CN 1H-Indole-5-carboxylic acid, 2,3-dihydro-2-oxo-3-(1H-pyrrolo[2,3-b]pyridin-3-ylmethylene)-, ethyl ester, (E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 175076-48-9 CAPLUS
CN 1H-Indole-5-carboxylic acid, 2,3-dihydro-3-(1H-indol-3-ylmethylene)-2-oxo-, phenylmethyl ester, (Z)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 175076-49-0 CAPLUS
CN 1H-Indole-5-carboxylic acid, 2,3-dihydro-2-oxo-3-(1H-pyrrolo[2,3-b]pyridin-3-ylmethylene)-, phenylmethyl ester, (E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 175076-50-3 CAPLUS
CN 1H-Indole-5-carboxylic acid, 2,3-dihydro-3-(1H-indol-3-ylmethylene)-2-oxo-, 2-phenylethyl ester, (Z)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 175076-51-4 CAPLUS
CN 1H-Indole-5-carboxylic acid, 2,3-dihydro-2-oxo-3-(1H-pyrrolo[2,3-b]pyridin-3-ylmethylene)-, 2-phenylethyl ester, (E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 175076-52-5 CAPLUS
CN 1H-Indole-5-carboxamide, 2,3-dihydro-3-(1H-indol-3-ylmethylene)-2-oxo-N-phenyl-, (Z)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 175076-53-6 CAPLUS
CN 1H-Indole-5-carboxamide, 2,3-dihydro-2-oxo-N-phenyl-3-(1H-pyrrolo[2,3-b]pyridin-3-ylmethylene)-, (E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 175076-54-7 CAPLUS
CN 1H-Indole-5-carboxamide, 2,3-dihydro-3-(1H-indol-3-ylmethylene)-2-oxo-N-(phenylmethyl)-, (Z)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 175076-55-8 CAPLUS
CN 1H-Indole-5-carboxamide, 2,3-dihydro-2-oxo-N-(phenylmethyl)-3-(1H-pyrrolo[2,3-b]pyridin-3-ylmethylene)-, (E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



IT **157561-91-6 157561-92-7 175075-27-1**
175075-47-5 175075-49-7 175075-50-0
RL: RCT (Reactant)
(prepn. of substituted azaindolylidene compds. as **tyrosine** kinase inhibitors)
RN 157561-91-6 CAPLUS
CN 2H-Indol-2-one, 1,3-dihydro-5-hydroxy-3-(1H-pyrrolo[2,3-b]pyridin-3-ylmethylene)- (9CI) (CA INDEX NAME)



RN 157561-92-7 CAPLUS
CN 2H-Indol-2-one, 5-amino-1,3-dihydro-3-(1H-pyrrolo[2,3-b]pyridin-3-ylmethylene)- (9CI) (CA INDEX NAME)



RN 175075-27-1 CAPLUS
CN 1H-Indole-5-carbonitrile, 2,3-dihydro-2-oxo-3-(1H-pyrrolo[2,3-b]pyridin-3-ylmethylene)- (9CI) (CA INDEX NAME)



RN 175075-47-5 CAPLUS
CN 1H-Indole-5-carboxylic acid, 2,3-dihydro-2-oxo-3-(1H-pyrrolo[2,3-b]pyridin-3-ylmethylene)- (9CI) (CA INDEX NAME)



RN 175075-49-7 CAPLUS
CN 2H-Indol-2-one, 5-(chloromethyl)-1,3-dihydro-3-(1H-pyrrolo[2,3-b]pyridin-3-ylmethylene)- (9CI) (CA INDEX NAME)



RN 175075-50-0 CAPLUS
CN 1-Piperidinepropanamide, N-[2,3-dihydro-2-oxo-3-(1H-pyrrolo[2,3-b]pyridin-3-ylmethylene)-1H-indol-5-yl]- (9CI) (CA INDEX NAME)



L5 ANSWER 61 OF 66 CAPLUS COPYRIGHT 2002 ACS
ACCESSION NUMBER: 1995:828284 CAPLUS
DOCUMENT NUMBER: 123:227985
TITLE: Arylidene and heteroarylidene oxindole derivatives as **tyrosine** kinase inhibitors
INVENTOR(S): Buzzetti, Franco; Longo, Antonio; Brasca, Maria Gabriella; Orzi, Fabrizio; Crugnola, Angelo; Ballinari, Dario; Mariani, Mariangela
PATENT ASSIGNEE(S): Farmitalia Carlo Erba S.r.l., Italy
SOURCE: PCT Int. Appl., 62 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9501349	A1	19950112	WO 1994-EP1715	19940526
W: AU, BB, BG, BR, BY, CA, CN, CZ, FI, HU, JP, KP, KR, KZ, LK, LV, MG, MN, MW, NO, NZ, PL, RO, RU, SD, SK, UA, UZ, VN				
RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
CA 2142472	AA	19950112	CA 1994-2142472	19940526
AU 9469719	A1	19950124	AU 1994-69719	19940526
AU 679754	B2	19970710		
EP 658159	A1	19950621	EP 1994-918379	19940526
EP 658159	B1	20000823		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, NL, PT, SE				
CN 1111454	A	19951108	CN 1994-190452	19940526
JP 08500847	T2	19960130	JP 1994-503150	19940526
HU 72047	A2	19960328	HU 1995-954	19940526
EP 987263	A2	20000322	EP 1999-203366	19940526
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, NL, SE, PT, IE				
AT 195734	E	20000915	AT 1994-918379	19940526
ES 2152317	T3	20010201	ES 1994-918379	19940526
US 5656654	A	19970812	US 1994-263666	19940622
ZA 9404730	A	19950713	ZA 1994-4730	19940630
FI 9500859	A	19950224	FI 1995-859	19950224

PRIORITY APPLN. INFO.: GB 1993-13638 A 19930701

09897755

EP 1994-918379 A3 19940526
WO 1994-EP1715 W 19940526

OTHER SOURCE(S): MARPAT 123:227985

GI



I



II

AB Title derivs. I [Y = naphthalene, tetralin, quinoline or isoquinoline system; R = H, plus oxo when Y is tetralin; R1, R2 independently = H, C1-6 alkyl or C2-6 alkanoyl; m = 0-2; n = 0-3; R3 independently = H, halo, cyano, C1-6 alkyl, carboxy, nitro or NR6R7 where R6, R7 independently = H, C1-6 alkyl; R5 = H, C1-6 alkyl] and their pharmaceutically acceptable salts, which are useful as **tyrosine** kinase inhibitors, are claimed. The E- and Z-isomers of approx. 85 compds. are specifically claimed. Several synthetic examples are given. For example, condensation of 8-hydroxyquinoline-5-carboxaldehyde with 5-hydroxy-2-oxindole in EtOH in the presence of piperidine at 60-70.degree. gave 60% title compd. II (R8 = OH). Among test results for 10 selected I for inhibition of p45 v-abl kinase in vitro, and for inhibition of cultured K562 human leukemia cell growth, II (R8 = Br) had IC50 values of 2.6 and 0.62 .mu.M, resp.

IT **149492-63-7P 168463-26-1P 168463-27-2P**
168463-28-3P 168463-29-4P 168463-30-7P
168463-31-8P 168463-32-9P 168463-33-0P
168463-34-1P 168463-35-2P 168463-36-3P
168463-37-4P 168463-38-5P 168463-41-0P
168463-42-1P 168463-43-2P 168463-44-3P
168463-45-4P 168463-46-5P 168463-47-6P
168463-48-7P 168463-49-8P 168463-50-1P
168463-58-9P 168463-59-0P 168463-60-3P
168463-61-4P 168463-68-1P 168463-69-2P
168463-70-5P 168463-71-6P 168463-72-7P
168463-73-8P 168463-74-9P 168463-75-0P
168463-76-1P 168463-77-2P 168463-78-3P
168463-79-4P 168463-80-7P 168463-81-8P
168463-84-1P 168463-85-2P 168463-86-3P
168463-87-4P 168463-88-5P 168463-89-6P
168463-90-9P 168463-91-0P 168463-92-1P

168463-93-2P 168464-10-6P, FCE 27518
168464-11-7P, FCE 27566 **168464-12-8P**, FCE 27565
168464-13-9P, FCE 27866 **168464-14-0P**, FCE 27564
168464-15-1P, FCE 27996 **168464-16-2P**, FCE 28359
168464-17-3P, FCE 28436
RL: BAC (Biological activity or effector, except adverse); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(invention compd.; prepn. of (hetero)arylidene oxindole derivs. as **tyrosine** kinase inhibitors)

RN 149492-63-7 CAPLUS
CN 2H-Indol-2-one, 1,3-dihydro-5-hydroxy-3-[(8-hydroxy-5-quinolinyl)methylene]-, (E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 168463-26-1 CAPLUS
CN 2H-Indol-2-one, 1,3-dihydro-5-hydroxy-3-(5-quinolinylmethylene)-, (E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 168463-27-2 CAPLUS
CN 2H-Indol-2-one, 5-amino-1,3-dihydro-3-(5-quinolinylmethylene)-, (E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 168463-28-3 CAPLUS
CN 1H-Indole-5-carboxylic acid, 2,3-dihydro-2-oxo-3-(5-quinolinylmethylene)-, (E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 168463-29-4 CAPLUS
CN 2H-Indol-2-one, 1,3-dihydro-5-hydroxy-3-(4-quinolinylmethylene)-, (E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 168463-30-7 CAPLUS
CN 2H-Indol-2-one, 5-amino-1,3-dihydro-3-(4-quinolinylmethylene)-, (E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 168463-31-8 CAPLUS
CN 1H-Indole-5-carboxylic acid, 2,3-dihydro-2-oxo-3-(4-quinolinylmethylene)-, (E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 168463-32-9 CAPLUS
CN 2H-Indol-2-one, 5-amino-1,3-dihydro-3-[(8-hydroxy-5-quinolinyl)methylene]-, (E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 168463-33-0 CAPLUS
CN 1H-Indole-5-carboxylic acid, 2,3-dihydro-3-[(8-hydroxy-5-quinolinyl)methylene]-2-oxo-, (E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 168463-34-1 CAPLUS
CN 2H-Indol-2-one, 1,3-dihydro-5-hydroxy-3-[(8-hydroxy-4-quinolinyl)methylene]-, (E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 168463-35-2 CAPLUS
CN 2H-Indol-2-one, 5-amino-1,3-dihydro-3-[(8-hydroxy-4-quinolinyl)methylene]-, (E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.





RN 168463-36-3 CAPLUS
CN 1H-Indole-5-carboxylic acid, 2,3-dihydro-3-[(8-hydroxy-4-quinolinyl)methylene]-2-oxo-, (E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 168463-37-4 CAPLUS
CN 2H-Indol-2-one, 5-bromo-1,3-dihydro-3-[(8-hydroxy-5-quinolinyl)methylene]-, (E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 168463-38-5 CAPLUS
CN 2H-Indol-2-one, 5-fluoro-1,3-dihydro-3-[(8-hydroxy-5-quinolinyl)methylene]-, (E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 168463-41-0 CAPLUS
CN 2H-Indol-2-one, 1,3-dihydro-3-[(8-hydroxy-7-quinolinyl)methylene]-, (E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 168463-42-1 CAPLUS
CN 2H-Indol-2-one, 1,3-dihydro-3-[(5-hydroxy-4-quinolinyl)methylene]-, (E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 168463-43-2 CAPLUS
CN 2H-Indol-2-one, 1,3-dihydro-3-[(8-hydroxy-4-quinolinyl)methylene]-, (E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 168463-44-3 CAPLUS
CN 2H-Indol-2-one, 1,3-dihydro-5-hydroxy-3-[(5-methoxy-1H-indol-3-yl)methylene]-, (E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 168463-45-4 CAPLUS
CN 2H-Indol-2-one, 5-amino-1,3-dihydro-3-[(5-methoxy-1H-indol-3-yl)methylene]-, (E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 168463-46-5 CAPLUS
CN 2H-Indol-2-one, 1,3-dihydro-5-hydroxy-3-[(2-methyl-1H-indol-3-yl)methylene]-, (E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 168463-47-6 CAPLUS
CN 2H-Indol-2-one, 1,3-dihydro-3-[(2-methyl-1H-indol-3-yl)methylene]-, (E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 168463-48-7 CAPLUS
CN 1H-Indole-5-carbonitrile, 3-[(1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-, (E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 168463-49-8 CAPLUS
CN 2H-Indol-2-one, 1,3-dihydro-3-[(5-hydroxy-1H-indol-3-yl)methylene]-, (E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 168463-50-1 CAPLUS
CN 2H-Indol-2-one, 1,3-dihydro-3-[(5-methoxy-1H-indol-3-yl)methylene]-, (E)-

(9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 168463-58-9 CAPLUS
CN 2H-Indol-2-one, 1,3-dihydro-5-hydroxy-3-[(8-hydroxy-5-quinolinyl)methylene]- (9CI) (CA INDEX NAME)



RN 168463-59-0 CAPLUS
CN 2H-Indol-2-one, 1,3-dihydro-3-[(8-hydroxy-7-quinolinyl)methylene]- (9CI) (CA INDEX NAME)



RN 168463-60-3 CAPLUS
CN 2H-Indol-2-one, 1,3-dihydro-5-hydroxy-3-[(2-methyl-1H-indol-3-yl)methylene]- (9CI) (CA INDEX NAME)



RN 168463-61-4 CAPLUS

CN 2H-Indol-2-one, 5-fluoro-1,3-dihydro-3-[(8-hydroxy-5-quinolinyl)methylene]- (9CI) (CA INDEX NAME)



RN 168463-68-1 CAPLUS
CN 2H-Indol-2-one, 1,3-dihydro-5-hydroxy-3-(5-quinolinylmethylene)-, (Z)- (9CI) (CA INDEX NAME)

Double bond geometry as described by E or Z.



RN 168463-69-2 CAPLUS
CN 2H-Indol-2-one, 5-amino-1,3-dihydro-3-(5-quinolinylmethylene)-, (Z)- (9CI) (CA INDEX NAME)

Double bond geometry as described by E or Z.



RN 168463-70-5 CAPLUS
CN 1H-Indole-5-carboxylic acid, 2,3-dihydro-2-oxo-3-(5-quinolinylmethylene)-, (Z)- (9CI) (CA INDEX NAME)

Double bond geometry as described by E or Z.



RN 168463-71-6 CAPLUS
CN 2H-Indol-2-one, 1,3-dihydro-5-hydroxy-3-(4-quinolinylmethylene)-, (Z)- (9CI) (CA INDEX NAME)

Double bond geometry as described by E or Z.



RN 168463-72-7 CAPLUS
CN 2H-Indol-2-one, 5-amino-1,3-dihydro-3-(4-quinolinylmethylene)-, (Z)- (9CI) (CA INDEX NAME)

Double bond geometry as described by E or Z.



RN 168463-73-8 CAPLUS
CN 1H-Indole-5-carboxylic acid, 2,3-dihydro-2-oxo-3-(4-quinolinylmethylene)-, (Z)- (9CI) (CA INDEX NAME)

Double bond geometry as described by E or Z.



RN 168463-74-9 CAPLUS
CN 2H-Indol-2-one, 1,3-dihydro-5-hydroxy-3-[(8-hydroxy-5-quinolinyl)methylene]-, (Z)- (9CI) (CA INDEX NAME)

Double bond geometry as described by E or Z.



RN 168463-75-0 CAPLUS
CN 2H-Indol-2-one, 5-amino-1,3-dihydro-3-[(8-hydroxy-5-quinolinyl)methylene]-, (Z)- (9CI) (CA INDEX NAME)

Double bond geometry as described by E or Z.



RN 168463-76-1 CAPLUS
CN 1H-Indole-5-carboxylic acid, 2,3-dihydro-3-[(8-hydroxy-5-quinolinyl)methylene]-2-oxo-, (Z)- (9CI) (CA INDEX NAME)

Double bond geometry as described by E or Z.



RN 168463-77-2 CAPLUS
CN 2H-Indol-2-one, 1,3-dihydro-5-hydroxy-3-[(8-hydroxy-4-quinolinyl)methylene]-, (Z)- (9CI) (CA INDEX NAME)

Double bond geometry as described by E or Z.



RN 168463-78-3 CAPLUS
CN 2H-Indol-2-one, 5-amino-1,3-dihydro-3-[(8-hydroxy-4-quinolinyl)methylene]-, (Z)- (9CI) (CA INDEX NAME)

Double bond geometry as described by E or Z.



RN 168463-79-4 CAPLUS
CN 1H-Indole-5-carboxylic acid, 2,3-dihydro-3-[(8-hydroxy-4-quinolinyl)methylene]-2-oxo-, (Z)- (9CI) (CA INDEX NAME)

Double bond geometry as described by E or Z.



RN 168463-80-7 CAPLUS
CN 2H-Indol-2-one, 5-bromo-1,3-dihydro-3-[(8-hydroxy-5-quinolinyl)methylene]-, (Z)- (9CI) (CA INDEX NAME)

Double bond geometry as described by E or Z.



RN 168463-81-8 CAPLUS
CN 2H-Indol-2-one, 5-fluoro-1,3-dihydro-3-[(8-hydroxy-5-quinolinyl)methylene]-, (Z)- (9CI) (CA INDEX NAME)

Double bond geometry as described by E or Z.



RN 168463-84-1 CAPLUS
CN 2H-Indol-2-one, 1,3-dihydro-3-[(8-hydroxy-7-quinolinyl)methylene]-, (Z)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 168463-85-2 CAPLUS
CN 2H-Indol-2-one, 1,3-dihydro-3-[(5-hydroxy-4-quinolinyl)methylene]-, (Z)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 168463-86-3 CAPLUS
CN 2H-Indol-2-one, 1,3-dihydro-3-[(8-hydroxy-4-quinolinyl)methylene]-, (Z)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 168463-87-4 CAPLUS
CN 2H-Indol-2-one, 1,3-dihydro-5-hydroxy-3-[(5-methoxy-1H-indol-3-yl)methylene]-, (Z)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 168463-88-5 CAPLUS
CN 2H-Indol-2-one, 5-amino-1,3-dihydro-3-[(5-methoxy-1H-indol-3-yl)methylene]-, (Z)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 168463-89-6 CAPLUS
CN 2H-Indol-2-one, 1,3-dihydro-5-hydroxy-3-[(2-methyl-1H-indol-3-yl)methylene]-, (Z)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 168463-90-9 CAPLUS
CN 2H-Indol-2-one, 1,3-dihydro-3-[(2-methyl-1H-indol-3-yl)methylene]-, (Z)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 168463-91-0 CAPLUS
CN 1H-Indole-5-carbonitrile, 3-[(1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-, (Z)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 168463-92-1 CAPLUS
CN 2H-Indol-2-one, 1,3-dihydro-3-[(5-hydroxy-1H-indol-3-yl)methylene]-, (Z)-
(9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 168463-93-2 CAPLUS
CN 2H-Indol-2-one, 1,3-dihydro-3-[(5-methoxy-1H-indol-3-yl)methylene]-, (Z)-
(9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 168464-10-6 CAPLUS
CN 2H-Indol-2-one, 5-amino-1,3-dihydro-3-[(8-hydroxy-5-quinolinyl)methylene]-
(9CI) (CA INDEX NAME)



RN 168464-11-7 CAPLUS
CN 2H-Indol-2-one, 1,3-dihydro-3-[(2-methyl-1H-indol-3-yl)methylene]- (9CI)
(CA INDEX NAME)



RN 168464-12-8 CAPLUS
CN 1H-Indole-5-carbonitrile, 3-[(1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]- (9CI) (CA INDEX NAME)



RN 168464-13-9 CAPLUS
CN 2H-Indol-2-one, 1,3-dihydro-3-[(5-hydroxy-1H-indol-3-yl)methylene]- (9CI) (CA INDEX NAME)



RN 168464-14-0 CAPLUS
CN 2H-Indol-2-one, 1,3-dihydro-3-[(5-methoxy-1H-indol-3-yl)methylene]- (9CI) (CA INDEX NAME)



RN 168464-15-1 CAPLUS
CN 2H-Indol-2-one, 5-bromo-1,3-dihydro-3-[(8-hydroxy-5-quinolinyl)methylene]- (9CI) (CA INDEX NAME)



RN 168464-16-2 CAPLUS
CN 2H-Indol-2-one, 1,3-dihydro-5-hydroxy-3-[(5-methoxy-1H-indol-3-yl)methylene]- (9CI) (CA INDEX NAME)



RN 168464-17-3 CAPLUS
CN 2H-Indol-2-one, 5-amino-1,3-dihydro-3-[(5-methoxy-1H-indol-3-yl)methylene]- (9CI) (CA INDEX NAME)



L5 ANSWER 62 OF 66 CAPLUS COPYRIGHT 2002 ACS
ACCESSION NUMBER: 1995:518515 CAPLUS
DOCUMENT NUMBER: 123:227945
TITLE: Synthesis and configuration of some new bicyclic 3-arylidene-and 3-heteroarylidene-2-oxindoles
AUTHOR(S): Buzzetti, Franco; Pinciroli, Vittorio; BRasca, M. Gabriella; Crugnola, Angelo; Fustinoni, Silvia; Longo, Antonio
CORPORATE SOURCE: Pharmacia, Farmitalia Carlo Erba S.R.L., Ricerca e Sviluppo, Milano, I-20159, Italy
SOURCE: Gazz. Chim. Ital. (1995), 125(2), 69-75
CODEN: GCITA9; ISSN: 0016-5603
DOCUMENT TYPE: Journal
LANGUAGE: English

AB The synthesis of a novel bicyclic 3-arylidene- and 3-heteroarylidene-2-oxindoles was described. Compds. 1-16 have been prepd. by condensation of 2-oxindole with a (hetero)arom. aldehyde belonging to the naphthtalene, tetralin, quinoline or indole series. Said indolones are expected to possessing **tyrosine** kinase inhibitory activity (no data). The singel E or Z isomers could be partially transformed into their isomers by acid or basic catalysis. The E/Z configuration assignment was achieved by

1H NMR spectroscopy on the basis of chem. shifts and NOE data obtained from NOESY spectra.

IT **149492-60-4P 149492-61-5P 149492-62-6P 149492-64-8P 168141-97-7P 168142-05-0P 168142-06-1P 168142-07-2P 168142-08-3P 168142-09-4P 168142-10-7P 168142-16-3P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(prepn. and configuration of (arylidene)indolones)

RN 149492-60-4 CAPLUS
CN 2H-Indol-2-one, 1,3-dihydro-3-[(4-hydroxy-2-quinolinyl)methylene]-, (Z)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 149492-61-5 CAPLUS
CN 2H-Indol-2-one, 1,3-dihydro-3-(4-quinolinylmethylene)-, (E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 149492-62-6 CAPLUS
CN 2H-Indol-2-one, 1,3-dihydro-3-[(8-hydroxy-5-quinolinyl)methylene]-, (E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 149492-64-8 CAPLUS
CN 2H-Indol-2-one, 1,3-dihydro-3-(1H-indol-3-ylmethylene)-, (Z)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 168141-97-7 CAPLUS
CN 2H-Indol-2-one, 3-[(5-amino-1H-indol-3-yl)methylene]-1,3-dihydro-, (Z)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 168142-05-0 CAPLUS
CN 1H-Indole-5-carboxylic acid, 3-[(1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-, (Z)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 168142-06-1 CAPLUS
CN 2H-Indol-2-one, 1,3-dihydro-3-[(5-nitro-1H-indol-3-yl)methylene]-, (Z)-

(9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 168142-07-2 CAPLUS
CN 2H-Indol-2-one, 1,3-dihydro-3-(3-quinolinylmethylene)-, (E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 168142-08-3 CAPLUS
CN 2H-Indol-2-one, 1,3-dihydro-3-(3-quinolinylmethylene)-, (Z)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 168142-09-4 CAPLUS
CN 2H-Indol-2-one, 1,3-dihydro-3-[(5,6,7,8-tetrahydro-2-quinolinyl)methylene]-, (E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 168142-10-7 CAPLUS
CN 2H-Indol-2-one, 1,3-dihydro-3-[(8-hydroxy-5-quinolinyl)methylene]-, (Z)-

(9CI) (CA INDEX NAME)

Double bond geometry as described by E or Z.



RN 168142-16-3 CAPLUS
CN 2H-Indol-2-one, 1,3-dihydro-3-(4-quinolinylmethylene)-, (Z)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



L5 ANSWER 63 OF 66 CAPLUS COPYRIGHT 2002 ACS
ACCESSION NUMBER: 1994:557633 CAPLUS
DOCUMENT NUMBER: 121:157633
TITLE: Preparation and formulation of azaindoles as **tyrosine** kinase inhibitors
INVENTOR(S): Buzetti, Franco; Crugnola, Angelo; Ballinari, Dario; Greco, Felicita
PATENT ASSIGNEE(S): Farmitalia Carlo Erba S.R.L., Italy
SOURCE: PCT Int. Appl., 39 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9414808	A1	19940707	WO 1993-EP3536	19931215
W: AU, BB, BG, BR, BY, CA, CZ, FI, HU, JP, KP, KR, KZ, LK, MG, MN, MW, NO, NZ, PL, RO, RU, SK, UA, VN				
RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
CA 2126228	AA	19940707	CA 1993-2126228	19931215
AU 9458105	A1	19940719	AU 1994-58105	19931215

AU 670488	B2	19960718			
EP 626963	A1	19941207	EP 1994-903774	19931215	
EP 626963	B1	19990609			
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, NL, PT, SE					
HU 67431	A2	19950428	HU 1994-1950	19931215	
JP 07504208	T2	19950511	JP 1993-514761	19931215	
AT 181074	E	19990615	AT 1994-903774	19931215	
ES 2134926	T3	19991016	ES 1994-903774	19931215	
IL 108087	A1	19970930	IL 1993-108087	19931220	
ZA 9309578	A	19940811	ZA 1993-9578	19931221	
CN 1093707	A	19941019	CN 1993-112970	19931222	
US 5397787	A	19950314	US 1993-171154	19931222	
FI 9403838	A	19940819	FI 1994-3838	19940819	
PRIORITY APPLN. INFO.:			GB 1992-26855	19921223	
			WO 1993-EP3536	19931215	

OTHER SOURCE(S): MARPAT 121:157633

GI



I

AB Title compds. [I; R2 = H, alkyl, alkanoyl; 1 of X1-X4 = N and the others are CH; any C may be substituted by R or R1; R = CH:C(CN)R6, (un)substituted 2-oxo-3-indolylidenemethylene; R1 = H, halo, alkyl(oxy), NO2, (di)(alkyl)amino; R6 = CONH2, CONH(CH2)nPh, CSNH2, cyano; n = 0-5] were prepd. Thus, 7-azaindole was formylated and the product refluxed with 2-oxindole in EtOH contg. piperidine to give (Z)-3-[(7-azaindol-3-yl)methylene]-2-oxindole which had IC50 of 0.05 .mu.M against p45 v-abl kinase in vitro.

IT **157561-89-2P 157561-91-6P 157561-92-7P**
157561-93-8P 157561-94-9P 157561-95-0P
157561-96-1P 157562-04-4P 157562-05-5P
157562-10-2P 157562-11-3P 157562-16-8P
157562-17-9P
RL: SPN (Synthetic preparation); PREP (Preparation)
(prepn. of, as **tyrosine** kinase inhibitor)

RN 157561-89-2 CAPLUS

CN 2H-Indol-2-one, 1,3-dihydro-3-(1H-pyrrolo[2,3-b]pyridin-3-ylmethylene)-, (Z)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 157561-91-6 CAPLUS

CN 2H-Indol-2-one, 1,3-dihydro-5-hydroxy-3-(1H-pyrrolo[2,3-b]pyridin-3-ylmethylene)- (9CI) (CA INDEX NAME)



RN 157561-92-7 CAPLUS
CN 2H-Indol-2-one, 5-amino-1,3-dihydro-3-(1H-pyrrolo[2,3-b]pyridin-3-ylmethylene)- (9CI) (CA INDEX NAME)



RN 157561-93-8 CAPLUS
CN 2H-Indol-2-one, 1,3-dihydro-3-[(1-methyl-1H-pyrrolo[2,3-b]pyridin-3-yl)methylene]-, (Z)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 157561-94-9 CAPLUS
CN 1H-Pyrrolo[2,3-b]pyridine, 1-acetyl-3-[(1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-, (Z)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 157561-95-0 CAPLUS
CN 2H-Indol-2-one, 3-[[4-(dimethylamino)-1-methyl-1H-pyrrolo[3,2-c]pyridin-3-yl]methylene]-1,3-dihydro- (9CI) (CA INDEX NAME)



RN 157561-96-1 CAPLUS
CN 2H-Indol-2-one, 1,3-dihydro-3-[(4-methoxy-1-methyl-1H-pyrrolo[3,2-c]pyridin-3-yl)methylene]- (9CI) (CA INDEX NAME)



RN 157562-04-4 CAPLUS
CN 2H-Indol-2-one, 1,3-dihydro-3-(1H-pyrrolo[2,3-c]pyridin-3-ylmethylene)- (9CI) (CA INDEX NAME)



RN 157562-05-5 CAPLUS
CN 2H-Indol-2-one, 1,3-dihydro-5-hydroxy-3-(1H-pyrrolo[2,3-c]pyridin-3-ylmethylene)- (9CI) (CA INDEX NAME)



RN 157562-10-2 CAPLUS
CN 2H-Indol-2-one, 1,3-dihydro-3-(1H-pyrrolo[3,2-c]pyridin-3-ylmethylene)- (9CI) (CA INDEX NAME)



RN 157562-11-3 CAPLUS
CN 2H-Indol-2-one, 1,3-dihydro-5-hydroxy-3-(1H-pyrrolo[3,2-c]pyridin-3-ylmethylene)- (9CI) (CA INDEX NAME)



RN 157562-16-8 CAPLUS
CN 2H-Indol-2-one, 1,3-dihydro-3-(1H-pyrrolo[3,2-b]pyridin-3-ylmethylene)- (9CI) (CA INDEX NAME)



RN 157562-17-9 CAPLUS
CN 2H-Indol-2-one, 1,3-dihydro-5-hydroxy-3-(1H-pyrrolo[3,2-b]pyridin-3-ylmethylene)- (9CI) (CA INDEX NAME)



IT **157562-18-0 157562-19-1 157562-20-4**
RL: RCT (Reactant)
(reaction of, in prepn. of **tyrosine** kinase inhibitor)
RN 157562-18-0 CAPLUS
CN 2H-Indol-2-one, 1,3-dihydro-5-methoxy-3-(1H-pyrrolo[2,3-b]pyridin-3-ylmethylene)- (9CI) (CA INDEX NAME)



RN 157562-19-1 CAPLUS
CN 2H-Indol-2-one, 1,3-dihydro-5-nitro-3-(1H-pyrrolo[2,3-b]pyridin-3-ylmethylene)- (9CI) (CA INDEX NAME)



RN 157562-20-4 CAPLUS
CN 2H-Indol-2-one, 3-[(4-chloro-1-methyl-1H-pyrrolo[3,2-c]pyridin-3-yl)methylene]-1,3-dihydro- (9CI) (CA INDEX NAME)



L5 ANSWER 64 OF 66 CAPLUS COPYRIGHT 2002 ACS
ACCESSION NUMBER: 1993:508407 CAPLUS
DOCUMENT NUMBER: 119:108407
TITLE: Cinnamamide analogs as inhibitors of protein **tyrosine** kinases
AUTHOR(S): Buzzetti, Franco; Brasca, M. Gabriella; Crugnola, Angelo; Fustinoni, Silvia; Longo, Antonio; Penco, Sergio; Dalla Zonca, Paolo; Comoglio, Paolo M.
CORPORATE SOURCE: Farmitalia Carlo Erba SRL, Milan, 20159, Italy

09897755

SOURCE: Farmaco (1993), 48(5), 615-36
CODEN: FRMCE8
DOCUMENT TYPE: Journal
LANGUAGE: English

AB Protein **tyrosine** kinases (PTK) are important signal transducing enzymes involved in the modulation of normal cellular growth and differentiation and have been assocd. with the etiol. of various human cancers. The development of properly designed inhibitors, which block their function by interfering with the substrate binding, may therefore offer an unique target for selective anticancer chemotherapy. Here, the authors describe synthesis and biochem. testing of a novel series of non-peptide PTK inhibitors which have as characteristic active pharmacophore the cinnamamide moiety. For testing, the authors used an exogenous substrate kinase assay based on the phosphorylation of (Val5)-angiotensin II with radiolabeled ATP by the catalytic domain of the PTK encoded by the v-abl oncogene (p45 v-abl). The most potent compds. were found in the class of 3-arylidene-2-oxindoles (II) with IC50 values in the 1 .mu.M range. Among these, the 2-tetralylmethylene-, 4-quinolylmethylene-, 5-quinolylmethylene- and 3-indolylmethylene-2-oxindole compds. were selected for further investigation.

IT **137478-40-1P 148563-43-3P 149492-59-1P**
149492-60-4P 149492-61-5P 149492-62-6P
149492-63-7P 149492-64-8P
RL: SPN (Synthetic preparation); PREP (Preparation)
(prepn. of, as protein **tyrosine** kinase inhibitor, structure in relation to)

RN 137478-40-1 CAPLUS
CN 2H-Indol-2-one, 1,3-dihydro-3-(3-quinolinylmethylene)- (9CI) (CA INDEX NAME)



RN 148563-43-3 CAPLUS
CN 2H-Indol-2-one, 1,3-dihydro-5-hydroxy-3-(1H-indol-3-ylmethylene)- (9CI) (CA INDEX NAME)



RN 149492-59-1 CAPLUS
CN 2H-Indol-2-one, 1,3-dihydro-3-(2-quinolinylmethylene)-, (E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 149492-60-4 CAPLUS
CN 2H-Indol-2-one, 1,3-dihydro-3-[(4-hydroxy-2-quinolinyl)methylene]-, (Z)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 149492-61-5 CAPLUS
CN 2H-Indol-2-one, 1,3-dihydro-3-(4-quinolinylmethylene)-, (E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 149492-62-6 CAPLUS
CN 2H-Indol-2-one, 1,3-dihydro-3-[(8-hydroxy-5-quinolinyl)methylene]-, (E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 149492-63-7 CAPLUS
CN 2H-Indol-2-one, 1,3-dihydro-5-hydroxy-3-[(8-hydroxy-5-quinolinyl)methylene]-, (E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 149492-64-8 CAPLUS
CN 2H-Indol-2-one, 1,3-dihydro-3-(1H-indol-3-ylmethylene)-, (Z)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



L5 ANSWER 65 OF 66 CAPLUS COPYRIGHT 2002 ACS
ACCESSION NUMBER: 1993:449225 CAPLUS
DOCUMENT NUMBER: 119:49225
TITLE: Methyleneoxindole derivatives and process for their preparation
INVENTOR(S): Buzzetti, Franco; Longo, Antonio; Colombo, Maristella
PATENT ASSIGNEE(S): Farmitalia Carlo Erba Srl, Italy

09897755

SOURCE: PCT Int. Appl., 33 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9301182	A1	19930121	WO 1992-EP1569	19920710
W: AU, CA, FI, HU, JP, KR, RU, US				
RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LU, MC, NL, SE				
IL 102383	A1	19970930	IL 1992-102383	19920702
CA 2091058	AA	19930113	CA 1992-2091058	19920710
EP 525472	A2	19930203	EP 1992-111757	19920710
EP 525472	A3	19930224		
R: PT				
AU 9222777	A1	19930211	AU 1992-22777	19920710
AU 656015	B2	19950119		
ZA 9205169	A	19930428	ZA 1992-5169	19920710
EP 552329	A1	19930728	EP 1992-914619	19920710
EP 552329	B1	20011004		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, NL, SE				
JP 06501494	T2	19940217	JP 1993-501981	19920710
JP 3188701	B2	20010716		
HU 67496	A2	19950428	HU 1993-723	19920710
RU 2072989	C1	19970210	RU 1993-4893	19920710
AT 206420	E	20011015	AT 1992-914619	19920710
US 5409949	A	19950425	US 1993-987280	19930312

PRIORITY APPLN. INFO.: GB 1991-15160 A 19910712
WO 1992-EP1569 A 19920710

OTHER SOURCE(S): MARPAT 119:49225
GI



I



II



III



IV

AB The title compds. I [R = II; R4 = H, OH, C1-6 alkoxy, C2-6 alkanoyloxy, CO2H, NO2, NHR7 (R7 = H, C1-6 alkyl); R5 = H, C1-6 alkyl or halo; R6 = H, C1-6 alkyl; n = 0-2; R1 = H, C1-6 alkyl, C2-6 alkanoyl; R2 = H, C1-6 alkyl, halo, CN, CO2H, NO2, NHR7; R3 = H, C1-6 alkyl, C2-6 alkanoyl] were prepd. by condensation of aldehydes III with oxindoles IV, and were evaluated as **tyrosine** kinase inhibitors. Thus, a soln. of 145

mg 3-indolecarboxaldehyde, 149 mg 5-hydroxy-2-oxindole, and 60 mg piperidine in 10 mL abs. EtOH was heated for 3 h at 60.degree.; workup afforded 60% I (R in 3-position, n = 0, R2 = R3 = R5 = R6 = H, R4 = 5-OH) (V). IC50 (.mu.M) values for V of 0.4 were detd. for both the myelin basic protein phosphorylation assay and the autophosphorylation assay. A 0.150 g tablet formulation contg. 25 mg active substance and lactose, corn starch, talc powder, and magnesium stearate is given.

IT **148563-46-6P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation)
(prepn. and acylation of, as **tyrosine** kinase inhibitor)
RN 148563-46-6 CAPLUS
CN 2H-Indol-2-one, 1,3-dihydro-5-hydroxy-3-[(5-hydroxy-1H-indol-3-yl)methylene]- (9CI) (CA INDEX NAME)



IT **148563-55-7P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(prepn. and deetherification of, as **tyrosine** kinase inhibitor)
RN 148563-55-7 CAPLUS
CN 2H-Indol-2-one, 1,3-dihydro-5-methoxy-3-[(5-methoxy-1H-indol-3-yl)methylene]- (9CI) (CA INDEX NAME)



IT **148563-43-3P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(prepn. and **tyrosine** kinase inhibiting activity of)
RN 148563-43-3 CAPLUS
CN 2H-Indol-2-one, 1,3-dihydro-5-hydroxy-3-(1H-indol-3-ylmethylene)- (9CI) (CA INDEX NAME)



IT **19423-45-1P 22813-84-9P 148563-44-4P**
148563-45-5P 148563-47-7P 148563-48-8P
148563-49-9P 148563-50-2P 148563-51-3P
148563-52-4P 148563-53-5P 148563-54-6P
148563-56-8P 148563-57-9P 148563-58-0P
148563-59-1P
RL: SPN (Synthetic preparation); PREP (Preparation)
(prepn. of, as **tyrosine** kinase inhibitor)
RN 19423-45-1 CAPLUS
CN 2H-Indol-2-one, 1,3-dihydro-3-(1H-indol-3-ylmethylene)-1-methyl- (9CI)
(CA INDEX NAME)



RN 22813-84-9 CAPLUS
CN 2H-Indol-2-one, 1,3-dihydro-3-[(1-methyl-1H-indol-3-yl)methylene]- (9CI)
(CA INDEX NAME)



RN 148563-44-4 CAPLUS
CN 1H-Indole-5-carboxylic acid, 2,3-dihydro-3-(1H-indol-3-ylmethylene)-2-oxo-

(9CI) (CA INDEX NAME)



RN 148563-45-5 CAPLUS
CN 2H-Indol-2-one, 5-amino-1,3-dihydro-3-(1H-indol-3-ylmethylene)- (9CI) (CA INDEX NAME)



RN 148563-47-7 CAPLUS
CN 2H-Indol-2-one, 1,3-dihydro-5-hydroxy-3-[(7-hydroxy-1H-indol-3-yl)methylene]- (9CI) (CA INDEX NAME)



RN 148563-48-8 CAPLUS
CN 2H-Indol-2-one, 3-[(5,7-dihydroxy-1H-indol-3-yl)methylene]-1,3-dihydro- (9CI) (CA INDEX NAME)



RN 148563-49-9 CAPLUS
CN 2H-Indol-2-one, 5-amino-1,3-dihydro-3-[(5-hydroxy-1H-indol-3-yl)methylene]- (9CI) (CA INDEX NAME)



RN 148563-50-2 CAPLUS
CN 2H-Indol-2-one, 3-[(5-amino-1H-indol-3-yl)methylene]-1,3-dihydro-5-hydroxy- (9CI) (CA INDEX NAME)



RN 148563-51-3 CAPLUS
CN 1H-Indole-5-carboxylic acid, 2,3-dihydro-3-[(5-hydroxy-1H-indol-3-yl)methylene]-2-oxo- (9CI) (CA INDEX NAME)



RN 148563-52-4 CAPLUS
CN 1H-Indole-5-carboxylic acid, 3-[(1,2-dihydro-5-hydroxy-2-oxo-3H-indol-3-ylidene)methyl]- (9CI) (CA INDEX NAME)



RN 148563-53-5 CAPLUS
CN 2H-Indol-2-one, 5-amino-1,3-dihydro-3-[(7-hydroxy-1H-indol-3-yl)methylene]- (9CI) (CA INDEX NAME)



RN 148563-54-6 CAPLUS
CN 1H-Indole-5-carboxylic acid, 2,3-dihydro-3-[(7-hydroxy-1H-indol-3-yl)methylene]-2-oxo- (9CI) (CA INDEX NAME)



RN 148563-56-8 CAPLUS
CN 2H-Indol-2-one, 5-(acetyloxy)-3-[[5-(acetyloxy)-1H-indol-3-yl]methylene]-1,3-dihydro- (9CI) (CA INDEX NAME)



RN 148563-57-9 CAPLUS
CN 1H-Indole-5-carboxylic acid, 3-[(1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]- (9CI) (CA INDEX NAME)



RN 148563-58-0 CAPLUS
CN 2H-Indol-2-one, 3-[(5-amino-1H-indol-3-yl)methylene]-1,3-dihydro- (9CI) (CA INDEX NAME)

09897755



RN 148563-59-1 CAPLUS
CN 2H-Indol-2-one, 1,3-dihydro-3-[(5-nitro-1H-indol-3-yl)methylene]- (9CI) (CA INDEX NAME)



L5 ANSWER 66 OF 66 CAPLUS COPYRIGHT 2002 ACS
ACCESSION NUMBER: 1991:679621 CAPLUS
DOCUMENT NUMBER: 115:279621
TITLE: Preparation of (hetero)arylacrylates useful as **tyrosine** kinase inhibitors
INVENTOR(S): Buzzetti, Franco; Longo, Antonio; Colombo, Maristella
PATENT ASSIGNEE(S): Farmitalia Carlo Erba S.r.l., Italy
SOURCE: PCT Int. Appl., 42 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9113055	A2	19910905	WO 1991-EP350	19910226
WO 9113055	A3	19911031		
W: AU, CA, FI, HU, JP, KR, SU, US				
RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LU, NL, SE				
IL 97049	A1	19951031	IL 1991-97049	19910125
CA 2053253	AA	19910829	CA 1991-2053253	19910226
AU 9172412	A1	19910918	AU 1991-72412	19910226
AU 652740	B2	19940908		
EP 470221	A1	19920212	EP 1991-904125	19910226
EP 470221	B1	19951213		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, NL, SE				
HU 59081	A2	19920428	HU 1991-3626	19910226
HU 210791	B	19950728		
JP 04506081	T2	19921022	JP 1991-504222	19910226

JP 3152434	B2	20010403			
EP 662473	A1	19950712	EP 1995-102495	19910226	
EP 662473	B1	19990901			
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, NL, SE					
AT 131470	E	19951215	AT 1991-904125	19910226	
ES 2083569	T3	19960416	ES 1991-904125	19910226	
RU 2091369	C1	19970927	RU 1991-5010251	19910226	
AT 184000	E	19990915	AT 1995-102495	19910226	
ES 2137386	T3	19991216	ES 1995-102495	19910226	
JP 2000204070	A2	20000725	JP 2000-40167	19910226	
ZA 9101441	A	19911127	ZA 1991-1441	19910227	
US 5374652	A	19941220	US 1993-126687	19930927	
US 5488057	A	19960130	US 1994-294350	19940823	
US 5627207	A	19970506	US 1995-455688	19950531	

PRIORITY APPLN. INFO.:

GB 1990-4483	A	19900228
EP 1991-904125	A3	19910226
JP 1991-504222	A3	19910226
WO 1991-EP350	A	19910226
US 1991-768259	B1	19911028
US 1993-126687	A3	19930927
US 1994-294350	A3	19940823

OTHER SOURCE(S): MARPAT 115:279621

GI



I II III

AB Title compds., useful in treatment of cancer and other pathol. proliferative conditions (no data), are prepd. 2-Hydroxy-1-naphthaldehyde, NCCH2CSNH2, HOCH2CH2NEt2, and EtOH were refluxed 30 min to give naphthylthioacrylamide I. Prepd. similarly were quinolineacrylamide II and quinolylmethyleneoxindole III. A capsule and tablet formulation contg. 2-cyano-3-(3-hydroxynaphth-2-yl)acrylamide and 2-cyano-3-(1-hydroxynaphth-2-yl)acrylamide, resp.

IT **137478-38-7P 137478-39-8P 137478-40-1P 137479-18-6P 137479-19-7P 137479-20-0P 137479-21-1P 137501-13-4P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(prepn. of, as **tyrosine** kinase inhibitor)

RN 137478-38-7 CAPLUS

CN 2H-Indol-2-one, 1,3-dihydro-3-(2-quinolinylmethylene)- (9CI) (CA INDEX NAME)



RN 137478-39-8 CAPLUS
CN 2H-Indol-2-one, 1,3-dihydro-3-[(4-hydroxy-2-quinolinyl)methylene]- (9CI) (CA INDEX NAME)



RN 137478-40-1 CAPLUS
CN 2H-Indol-2-one, 1,3-dihydro-3-(3-quinolinylmethylene)- (9CI) (CA INDEX NAME)



RN 137479-18-6 CAPLUS
CN 2H-Indol-2-one, 1,3-dihydro-3-[(7-hydroxy-3-quinolinyl)methylene]- (9CI) (CA INDEX NAME)



RN 137479-19-7 CAPLUS
CN 2H-Indol-2-one, 1,3-dihydro-3-[(8-hydroxy-5-quinolinyl)methylene]- (9CI) (CA INDEX NAME)



RN 137479-20-0 CAPLUS
CN 2H-Indol-2-one, 1,3-dihydro-3-[(7-hydroxy-6-quinolinyl)methylene]- (9CI) (CA INDEX NAME)



RN 137479-21-1 CAPLUS
CN 2H-Indol-2-one, 1,3-dihydro-3-[(8-hydroxy-6-quinolinyl)methylene]- (9CI) (CA INDEX NAME)



RN 137501-13-4 CAPLUS
CN 2H-Indol-2-one, 1,3-dihydro-3-(4-quinolinylmethylene)- (9CI) (CA INDEX NAME)



=> d l5 1-8 ibib abs hitstr

L5 ANSWER 1 OF 66 CAPLUS COPYRIGHT 2002 ACS
ACCESSION NUMBER: 2002:275806 CAPLUS
DOCUMENT NUMBER: 136:304047
TITLE: Effects of combined administration of farnesyl transferase inhibitors and signal transduction inhibitors
INVENTOR(S): Daley, George Q.; Hoover, Russell R.
PATENT ASSIGNEE(S): Whitehead Institute for Biomedical Research, USA
SOURCE: PCT Int. Appl., 30 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002028409	A2	20020411	WO 2001-US31104	20011004

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

PRIORITY APPLN. INFO.: US 2000-238240P P 20001005
US 2000-238813P P 20001006

AB The invention relates to methods of reducing proliferation of cells, enhancing apoptosis of cells or both in an individual in need thereof, comprising administering to the individual a combination of at least one farnesyl transferase inhibitor (FTI), such as an inhibitor or Ras function, and at least one signal transduction inhibitor (STI) in a therapeutically effective amt., wherein proliferation of cells is reduced and/or apoptosis of cells in enhanced in the individual. The invention also discloses a method of reducing proliferation of STI resistant cells, enhancing apoptosis of STI resistant cells, or both in an individual in need thereof, comprising administering to the individual a combination of at least one FTI and at least one STI in a therapeutically effective amt., wherein proliferation of STI resistant cells is reduced and/or apoptosis of STI resistant cells is enhanced in the individual. The invention can be used to treat leukemia (e.g., CML) using this combination of farnesyl transferase inhibitor and signal transduction inhibitor.

IT **204005-46-9**, SU5416
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(effects of combined administration of farnesyl transferase inhibitors and signal transduction inhibitors)

RN 204005-46-9 CAPLUS
CN 2H-Indol-2-one, 3-[(3,5-dimethyl-1H-pyrrol-2-yl)methylene]-1,3-dihydro- (9CI) (CA INDEX NAME)

09897755



L5 ANSWER 2 OF 66 CAPLUS COPYRIGHT 2002 ACS
ACCESSION NUMBER: 2002:131838 CAPLUS
TITLE: The total synthesis of proteasome inhibitors TMC-95A and TMC-95B: discovery of a new method to generate cis-propenyl amides
AUTHOR(S): Lin, Songnian; Danishefsky, Samuel J.
CORPORATE SOURCE: Laboratory for Bioorganic Chemistry, Sloan - Kettering Institute for Cancer Research, New York, NY, 10021, USA
SOURCE: Angewandte Chemie, International Edition (2002), 41(3), 512-515
CODEN: ACIEF5; ISSN: 1433-7851
PUBLISHER: Wiley-VCH Verlag GmbH
DOCUMENT TYPE: Journal
LANGUAGE: English
GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB Total synthesis of proteasome inhibitors TMC-95A and TMC-95B (I; A = S-side chain, B = R-side chain) was accomplished using a stereo-specific generation of the (Z)-propenamide side chain developed for the purpose. Silatropic bond reorganization of 1-silylated-2-propen-1-amides (II; R = Ph, 4-MeO-C6H4, 2-furyl, (CH3)3CCH2-, Boc-Ser(SiiPr3)-) occurred when the compds. were heated at .apprx.110.degree. for from 10 h - 4 days to give the corresponding (Z)-1-propenamides in yields of 52-81%. The total synthesis began with crossed-aldol condensation of 8-iodo-2-oxo-indole and Garner aldehyde (III); the (Z) isomer of the resulting E/Z mixt. of product (IV) could be isomerized to (E) using iodine. L-Lys was elaborated into reactant (V), which was Suzuki-coupled to E-IV, the product coupled with H-Asn-OBut, and the product was converted to the dihydroxy compd., which, after protection/deprotection steps, was macrolactamized to give the core structure. Acylation of free amine with (.+-.)-3-methyl-2-oxo-pentanoic acid gave the mixt. of A/B product precursors, which were then reacted with H2NCH(SiEt3)CH:CH2 and the product subjected to the above thermal rearrangement to give the protected I. Global deprotection followed by RP-HPLC sepn. yielded I, which were characterized by comparison of their high-field NMR spectra with authentic samples.

IT INDEXING IN PROGRESS
IT **421556-66-3P 421556-67-4P 421556-70-9P 421556-71-0P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(prepn. of TMC-95A and -B using a thermal silatropic bond reorganization to generate the Z-propenamide side-chain)
RN 421556-66-3 CAPLUS

CN 3-Oxazolidinecarboxylic acid, 4-[(E)-(1,2-dihydro-7-iodo-2-oxo-3H-indol-3-ylidene)methyl]-2,2-dimethyl-, 1,1-dimethylethyl ester, (4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 421556-67-4 CAPLUS
CN 3-Oxazolidinecarboxylic acid, 4-[(Z)-(1,2-dihydro-7-iodo-2-oxo-3H-indol-3-ylidene)methyl]-2,2-dimethyl-, 1,1-dimethylethyl ester, (4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 421556-70-9 CAPLUS
CN 3-Oxazolidinecarboxylic acid, 4-[(E)-[1,2-dihydro-7-[5-[(2S)-3-methoxy-3-oxo-2-[[(phenylmethoxy)carbonyl]amino]propyl]-2-(phenylmethoxy)phenyl]-2-oxo-3H-indol-3-ylidene]methyl]-2,2-dimethyl-, 1,1-dimethylethyl ester, (4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 421556-71-0 CAPLUS
CN L-Asparagine, 3-[(3E)-3-[[(4S)-3-[(1,1-dimethylethoxy)carbonyl]-2,2-dimethyl-4-oxazolidinyl]methylene]-2,3-dihydro-2-oxo-1H-indol-7-yl]-N-[(phenylmethoxy)carbonyl]-O-(phenylmethyl)-L-tyrosyl-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



REFERENCE COUNT: 24 THERE ARE 24 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 3 OF 66 CAPLUS COPYRIGHT 2002 ACS
ACCESSION NUMBER: 2002:43419 CAPLUS
DOCUMENT NUMBER: 136:259310

09897755

TITLE: The antiangiogenic agents SU5416 and SU6668 increase the antitumor effects of fractionated irradiation

AUTHOR(S): Ning, Shoucheng; Laird, Douglas; Cherrington, Julie M.; Knox, Susan J.

CORPORATE SOURCE: Department of Radiation Oncology, Stanford University Medical Center, Stanford, CA, 94305-5105, USA

SOURCE: Radiation Research (2002), 157(1), 45-51
CODEN: RAREAE; ISSN: 0033-7587

PUBLISHER: Radiation Research Society

DOCUMENT TYPE: Journal

LANGUAGE: English

AB Angiogenesis is crit. for tumor development, growth and metastasis. The vascular endothelial growth factor (VEGF), fibroblast growth factor (FGF) and platelet-derived growth factor (PDGF) and their **tyrosine** kinase receptors are major regulators of angiogenesis. Radiation induces the prodn. of VEGF, FGF and PDGF in many tumor cells. We hypothesized that inhibition of the function of these growth factors could inhibit tumor angiogenesis and thereby enhance the efficacy of radiation therapy. To test this hypothesis, we used the small mol. inhibitors SU5416 (an inhibitor for Vegf receptor) and SU6668 (an inhibitor for Vegf, Fgf and Pdgf receptors) alone and in combination with fractionated irradn. to treat C3H mice bearing SCC VII carcinomas. The SCC VII tumors express Vegf, Fgf2 (also known as bFGF), Pdgf and their assocd. receptors. Animals were given either SU5416 or SU6668 daily before or after irradn. (2 Gy per fraction per day for 5 days). The results from these expts. demonstrate that administration of either SU5416 or SU6668 without radiation delayed tumor growth. Administration of SU5416 at a dose of 25 mg/kg per day (the max. tolerated ED) inhibited tumor growth by 17.9% on day 7 ($P < 0.05$ compared to untreated control mice) and produced an av. tumor growth delay time of 0.5-2.0 days. When combined with fractionated irradn., administration of SU5416 increased the inhibition of tumor growth to 50-53% on day 7 and the tumor growth delay time to 5.7-6.5 days ($P < 0.001$ compared with SU5416 alone; P 0.05 compared with radiation alone). SU6668 alone inhibited tumor growth in a dose-dependent manner. Administration of SU6668 at a dose of 75 mg/kg per day (a suboptimal dose) inhibited tumor growth by 36% on day 7 and produced an av. tumor growth delay time of 3.3 .+-. 1.4 days. The combination of SU6668 with fractionated radiation increased inhibition of tumor growth to 66-70% and the tumor growth delay time from 3.3 days to 11.9 days (P .ltoreq. 0.001 compared with either radiation alone or SU6668 alone). Administration of these agents before or after irradn. produced similar results ($P = 0.40$ for SU5416; $P = 0.98$ for SU6668). SU5416 or SU6668 alone or in combination with radiation was very well tolerated with little or no toxicity. These results suggest that inhibition of Vegf, Fgf and Pdgf receptor function by SU5416 and SU6668 can enhance the efficacy of irradn. The targeting of multiple **tyrosine** kinase receptors by SU6668 is more effective than inhibition of the Vegf receptor alone by SU5416 for the enhancement of tumor cell killing by fractionated irradn.

IT **204005-46-9**, SU5416
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(antiangiogenic agents SU5416 and SU6668 increase antitumor effects of fractionated irradn.)

RN 204005-46-9 CAPLUS

CN 2H-Indol-2-one, 3-[(3,5-dimethyl-1H-pyrrol-2-yl)methylene]-1,3-dihydro- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 41 THERE ARE 41 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 4 OF 66 CAPLUS COPYRIGHT 2002 ACS
ACCESSION NUMBER: 2002:31440 CAPLUS
DOCUMENT NUMBER: 136:102386
TITLE: Preparation and use of 4-heteroaryl-3-heteroarylidenyl-2-indolinones and their use as protein kinase inhibitors
INVENTOR(S): Tang, Peng Cho; Wei, Chung Chen; Huang, Ping; Cui, Jingron
PATENT ASSIGNEE(S): Sugen, Inc., USA
SOURCE: PCT Int. Appl., 164 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002002551	A1	20020110	WO 2001-US20768	20010629

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

PRIORITY APPLN. INFO.: US 2000-215654P P 20000630
OTHER SOURCE(S): MARPAT 136:102386
GI



I



II

AB Title compds. I [R1-2 = H, alkyl, cycloalkyl, aryl, heteroaryl, heteroalicyclic, halo, etc.; Het = (un)substituted arom. heterocycle

contg. at least one and not more than two N atoms, tetrahydro(thio)pyranyl, (thio)morpholino, piperidinyl, piperazinyl, tetrazolyl, etc.; Q = (un)substituted arom. heterocycle contg. not more than two N atoms, 5-membered ring (un)substituted heterocycle contg. N, O or S, e.g., imidazolyl, pyrrolyl, indolyl, etc.] with some exceptions, were prepd. Included are 75 synthetic examples and results for several protein **tyrosine** kinase assays for those compds. For instance, 4-bromoindole was coupled to bis(pinacolato)diborane (DMSO, KOAc, PdCl2(dppf).bul.CH2Cl2, 80.degree.C, 22 h). The resulting dioxaborolane was coupled to 4-bromopyridine.bul.HCl (THF, Pd(PPh3)4, NaOH, 70.degree.C, 6 h) to give the indole which was treated with C5H5N.bul.Br3 (t-BuOH/EtOH/H2O, 1h) followed by zinc (stirred 1 addnl. hour) to give 4-(pyridin-4-yl)-1,3-dyhydroindol-2-one as a yellow solid. Condensation of this intermediate with 5-methylimidazole-4-carboxaldehyde (EtOH, piperidine, 2 days) afforded II. II had IC50 = 4.88 mM for FGFR-1 **tyrosine** kinase and 0.03 mM for cdk2/cyclin A **tyrosine** kinase. I are useful in treating cancer, immunol. disorders, etc.

IT **388116-44-7P 388116-45-8P 388116-46-9P**
388116-47-0P 388116-50-5P 388116-51-6P
388116-52-7P 388116-54-9P 388116-55-0P
388116-56-1P 388116-57-2P, 3-(1H-Indol-2-ylmethylene)-4-(pyridin-4-yl)-1,3-dihydroindol-2-one **388116-58-3P**, 4-(Pyridin-4-yl)-3-(4,5,6,7-tetrahydro-1H-indol-2-ylmethylene)-1,3-dihydroindol-2-one **388116-59-4P**, 3-[5-(2-(Morpholin-4-yl)ethoxy)-1H-indol-2-ylmethylene]-4-(pyridin-4-yl)-1,3-dihydroindol-2-one **388116-60-7P 388116-61-8P 388116-62-9P**
388116-64-1P 388116-65-2P 388116-66-3P
388116-68-5P 388116-70-9P, 3-(5-Methylthiophen-2-ylmethylene)-4-(pyridin-4-yl)-1,3-dihydroindol-2-one **388116-73-2P**
388116-74-3P 388116-76-5P 388116-79-8P
388116-80-1P, 3-[3-Methyl-4-((piperidin-1-yl)carbonyl)pyrrol-2-ylmethylene]-4-(piperidin-4-yl)-1,3-dihydroindol-2-one
388116-81-2P, 3-[3-Methyl-4-(morpholine-4-carbonyl)pyrrol-2-ylmethylene]-4-(piperidin-4-yl)-1,3-dihydroindol-2-one
388116-83-4P 388116-84-5P 388116-85-6P
388116-86-7P, 3-(3,5-Dimethyl-1H-pyrrol-2-ylmethylene)-4-(piperidin-4-yl)-1,3-dihydroindol-2-one **388116-87-8P**
388116-88-9P 388116-89-0P 388116-90-3P
388116-91-4P 388116-92-5P 388116-93-6P,
3-(1H-Indol-2-ylmethylene)-4-(piperidin-4-yl)-1,3-dihydroindol-2-one
388116-94-7P, 4-(Piperidin-4-yl)-3-(4,5,6,7-tetrahydro-1H-indol-2-ylmethylene)-1,3-dihydroindol-2-one **388116-95-8P**,
3-[5-(2-(Morpholin-4-yl)ethoxy)-1H-indol-2-ylmethylene]-4-(piperidin-4-yl)-1,3-dihydroindol-2-one **388116-96-9P 388116-97-0P**
388116-98-1P, 3-[3-(3-Morpholin-4-ylpropyl)-4,5,6,7-tetrahydro-1H-indol-2-ylmethylene]-4-(piperidin-4-yl)-1,3-dihydroindol-2-one
388116-99-2P 388117-00-8P, 3-[(3-Methyl-5-(4-methylpiperazin-1-ylcarbonyl)pyrrol-2-yl)methylene]-4-(piperidin-4-yl)-1,3-dihydroindol-2-one **388117-01-9P 388117-02-0P**
388117-03-1P, 3-(5-Methylthiophen-2-ylmethylene)-4-(piperidin-4-yl)-1,3-dihydroindol-2-one **388117-05-3P 388117-06-4P**
388117-07-5P 388117-08-6P 388117-10-0P
388117-12-2P 388117-14-4P 388117-16-6P,
3-[(3,5-Dimethyl-4-(4-methylpiperazin-1-ylcarbonyl)pyrrol-2-yl)methylene]-4-pyridin-2-yl-1,3-dihydroindol-2-one **388117-17-7P**,
3-[(3,5-Dimethyl-4-(4-methylpiperazin-1-ylcarbonyl)pyrrol-2-yl)methylene]-4-pyrimidin-5-yl-1,3-dihydroindol-2-one **388117-18-8P**,
3-[(3,5-Dimethyl-4-(4-methylpiperazin-1-ylcarbonyl)pyrrol-2-yl)methylene]-4-(thiazol-2-yl)-1,3-dihydroindol-2-one **388117-19-9P**
388117-20-2P 388117-21-3P 388117-22-4P,

4-(6-Aminopyridin-3-yl)-3-[(3,5-dimethyl-4-(4-methylpiperazin-1-ylcarbonyl)pyrrol-2-yl)methylene]-1,3-dihydroindol-2-one **388117-23-5P 388117-24-6P**, 3-[(3,5-Dimethyl-4-(4-methylpiperazin-1-ylcarbonyl)pyrrol-2-yl)methylene]-4-pyridin-3-yl-1,3-dihydroindol-2-one **388117-25-7P 388117-26-8P**, 5-[3-[(3,5-Dimethyl-4-(4-methylpiperazin-1-ylcarbonyl)pyrrol-2-yl)methylene]-2-oxo-2,3-dihydro-1H-indol-4-yl]nicotinic acid **388117-27-9P**, 5-[3-[4-(2-Diethylaminoethylcarbamoyl)-3,5-dimethyl-1H-pyrrol-2-ylmethylene]-2-oxo-2,3-dihydro-1H-indol-4-yl]nicotinic acid **388117-28-0P 388117-29-1P**, 4-(2-Aminopyrimidin-5-yl)-3-[(3,5-dimethyl-4-(4-methylpiperazin-1-ylcarbonyl)pyrrol-2-yl)methylene]-1,3-dihydroindol-2-one **388117-30-4P**
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(drug; prepn. and use of 4-heteroaryl-3-heteroarylidenyl-2-indolinones and their use as protein kinase inhibitors)

RN 388116-44-7 CAPLUS
CN Piperazine, 1-[[5-[[1,2-dihydro-2-oxo-4-(4-pyridinyl)-3H-indol-3-ylidene]methyl]-2,4-dimethyl-1H-pyrrol-3-yl]carbonyl]-4-methyl- (9CI) (CA INDEX NAME)



RN 388116-45-8 CAPLUS
CN 2H-Indol-2-one, 1,3-dihydro-3-[(5-methyl-1H-imidazol-4-yl)methylene]-4-(4-pyridinyl)- (9CI) (CA INDEX NAME)



RN 388116-46-9 CAPLUS
CN Pyrano[3,4-c]pyrrol-4(1H)-one, 1-[[1,2-dihydro-2-oxo-4-(4-pyridinyl)-3H-indol-3-ylidene]methyl]-6,7-dihydro- (9CI) (CA INDEX NAME)



RN 388116-47-0 CAPLUS
CN Piperazine, 1-[[5-[[1,2-dihydro-2-oxo-4-(4-pyridinyl)-3H-indol-3-ylidene]methyl]-4-methyl-1H-pyrrol-3-yl]carbonyl]- (9CI) (CA INDEX NAME)



RN 388116-50-5 CAPLUS
CN 1H-Indole-3-propanoic acid, 2-[[1,2-dihydro-2-oxo-4-(4-pyridinyl)-3H-indol-3-ylidene]methyl]-4,5,6,7-tetrahydro- (9CI) (CA INDEX NAME)



RN 388116-51-6 CAPLUS
CN 1H-Pyrrole-3-propanoic acid, 2-[[1,2-dihydro-2-oxo-4-(4-pyridinyl)-3H-indol-3-ylidene]methyl]-5-methyl- (9CI) (CA INDEX NAME)



RN 388116-52-7 CAPLUS
CN 1H-Pyrrole-3-propanoic acid, 2-[[1,2-dihydro-2-oxo-4-(4-pyridinyl)-3H-indol-3-ylidene]methyl]-5-ethyl- (9CI) (CA INDEX NAME)



RN 388116-54-9 CAPLUS
CN 1H-Pyrrole-3-propanoic acid, 2-[[1,2-dihydro-2-oxo-4-(4-pyridinyl)-3H-indol-3-ylidene]methyl]-4-(ethoxycarbonyl)-5-methyl- (9CI) (CA INDEX NAME)



RN 388116-55-0 CAPLUS
CN 1H-Pyrrole-3-propanoic acid, 5-[[1,2-dihydro-2-oxo-4-(4-pyridinyl)-3H-indol-3-ylidene]methyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)



RN 388116-56-1 CAPLUS
CN 1H-Pyrrole-3-acetic acid, 5-[[1,2-dihydro-2-oxo-4-(4-pyridinyl)-3H-indol-3-ylidene]methyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)



RN 388116-57-2 CAPLUS
CN 2H-Indol-2-one, 1,3-dihydro-3-(1H-indol-2-ylmethylene)-4-(4-pyridinyl)- (9CI) (CA INDEX NAME)



RN 388116-58-3 CAPLUS
CN 2H-Indol-2-one, 1,3-dihydro-4-(4-pyridinyl)-3-[(4,5,6,7-tetrahydro-1H-indol-2-yl)methylene]- (9CI) (CA INDEX NAME)



RN 388116-59-4 CAPLUS
CN 2H-Indol-2-one, 1,3-dihydro-3-[1H-indol-2-yl[2-(4-morpholinyl)ethoxy]methylene]-4-(4-pyridinyl)- (9CI) (CA INDEX NAME)



RN 388116-60-7 CAPLUS
CN 1H-Pyrrole-2-carboxylic acid, 5-[[1,2-dihydro-2-oxo-4-(4-pyridinyl)-3H-indol-3-ylidene]methyl]-4-methyl- (9CI) (CA INDEX NAME)



RN 388116-61-8 CAPLUS
CN 1H-Pyrrole-3-carboxylic acid, 2-[[1,2-dihydro-2-oxo-4-(4-pyridinyl)-3H-indol-3-ylidene]methyl]-5-methyl- (9CI) (CA INDEX NAME)



RN 388116-62-9 CAPLUS
CN 2H-Indol-2-one, 1,3-dihydro-3-[4-(4-morpholinyl)-1-(4,5,6,7-tetrahydro-1H-indol-2-yl)butylidene]-4-(4-pyridinyl)- (9CI) (CA INDEX NAME)



RN 388116-64-1 CAPLUS
CN 1H-Pyrrole-3-carboxamide, N-[2-(diethylamino)ethyl]-5-[[1,2-dihydro-2-oxo-4-(4-pyridinyl)-3H-indol-3-ylidene]methyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)



RN 388116-65-2 CAPLUS
CN Piperazine, 1-[[5-[[1,2-dihydro-2-oxo-4-(4-pyridinyl)-3H-indol-3-ylidene]methyl]-4-methyl-1H-pyrrol-2-yl]carbonyl]-4-methyl- (9CI) (CA INDEX NAME)



RN 388116-66-3 CAPLUS
CN 2H-Isoindole-1-carboxylic acid, 3-[[1,2-dihydro-2-oxo-4-(4-pyridinyl)-3H-indol-3-ylidene]methyl]-4,5,6,7-tetrahydro-, ethyl ester (9CI) (CA INDEX NAME)



RN 388116-68-5 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 5-[[1,2-dihydro-2-oxo-4-(4-pyridinyl)-3H-indol-3-ylidene]methyl]-2-methyl-4-phenyl-N-4-pyridinyl- (9CI) (CA INDEX NAME)



RN 388116-70-9 CAPLUS
CN 2H-Indol-2-one, 1,3-dihydro-3-[(5-methyl-2-thienyl)methylene]-4-(4-pyridinyl)- (9CI) (CA INDEX NAME)



RN 388116-73-2 CAPLUS
CN 1H-Pyrrole-3-propanoic acid, 2-[[1,2-dihydro-2-oxo-4-(4-pyridinyl)-3H-indol-3-ylidene]methyl]-5-(ethoxycarbonyl)-4-methyl- (9CI) (CA INDEX NAME)



RN 388116-74-3 CAPLUS
CN 1H-Pyrrole-3-carboxylic acid, 5-[[1,2-dihydro-2-oxo-4-(4-pyridinyl)-3H-indol-3-ylidene]methyl]-4-(2-hydroxyethyl)- (9CI) (CA INDEX NAME)



RN 388116-76-5 CAPLUS
CN 1H-Pyrrole-3-carboxylic acid, 5-[[1,2-dihydro-2-oxo-4-(4-pyridinyl)-3H-indol-3-ylidene]methyl]-4-(4-methoxyphenyl)-, ethyl ester (9CI) (CA INDEX NAME)



RN 388116-79-8 CAPLUS
CN 2H-Indol-2-one, 1,3-dihydro-3-[(5-methyl-1H-imidazol-4-yl)methylene]-4-(4-piperidinyl)-, monoacetate (9CI) (CA INDEX NAME)

CM 1

CRN 388116-78-7
CMF C18 H20 N4 O



CM 2

CRN 64-19-7
CMF C2 H4 O2



RN 388116-80-1 CAPLUS
CN Piperidine, 1-[[5-[[1,2-dihydro-2-oxo-4-(4-piperidinyl)-3H-indol-3-ylidene]methyl]-4-methyl-1H-pyrrol-3-yl]carbonyl]- (9CI) (CA INDEX NAME)



RN 388116-81-2 CAPLUS
CN Morpholine, 4-[[5-[[1,2-dihydro-2-oxo-4-(4-piperidinyl)-3H-indol-3-ylidene]methyl]-4-methyl-1H-pyrrol-3-yl]carbonyl]- (9CI) (CA INDEX NAME)





RN 388116-83-4 CAPLUS
CN Pyrano[3,4-c]pyrrol-4(1H)-one, 1-[[1,2-dihydro-2-oxo-4-(4-piperidinyl)-3H-indol-3-ylidene]methyl]-6,7-dihydro- (9CI) (CA INDEX NAME)



RN 388116-84-5 CAPLUS
CN 4H-Pyrrolo[3,4-c]pyridin-4-one, 1-[[1,2-dihydro-2-oxo-4-(4-piperidinyl)-3H-indol-3-ylidene]methyl]-2,5,6,7-tetrahydro- (9CI) (CA INDEX NAME)



RN 388116-85-6 CAPLUS
CN 4H-Pyrrolo[3,4-c]pyridin-4-one, 1-[[1,2-dihydro-2-oxo-4-(4-piperidinyl)-3H-indol-3-ylidene]methyl]-2,5,6,7-tetrahydro-5-methyl- (9CI) (CA INDEX NAME)



RN 388116-86-7 CAPLUS
CN 2H-Indol-2-one, 3-[(3,5-dimethyl-1H-pyrrol-2-yl)methylene]-1,3-dihydro-4-(4-piperidinyl)- (9CI) (CA INDEX NAME)



RN 388116-87-8 CAPLUS
CN 1H-Indole-3-propanoic acid, 2-[[1,2-dihydro-2-oxo-4-(4-piperidinyl)-3H-indol-3-ylidene]methyl]-4,5,6,7-tetrahydro- (9CI) (CA INDEX NAME)



RN 388116-88-9 CAPLUS
CN 1H-Pyrrole-3-propanoic acid, 2-[[1,2-dihydro-2-oxo-4-(4-piperidinyl)-3H-indol-3-ylidene]methyl]-5-methyl- (9CI) (CA INDEX NAME)



RN 388116-89-0 CAPLUS
CN 1H-Pyrrole-3-propanoic acid, 2-[[1,2-dihydro-2-oxo-4-(4-piperidinyl)-3H-indol-3-ylidene]methyl]-5-ethyl- (9CI) (CA INDEX NAME)



RN 388116-90-3 CAPLUS
CN 1H-Pyrrole-3-propanoic acid, 2-[[1,2-dihydro-2-oxo-4-(4-piperidinyl)-3H-indol-3-ylidene]methyl]-4-(ethoxycarbonyl)-5-methyl- (9CI) (CA INDEX NAME)



RN 388116-91-4 CAPLUS
CN 1H-Pyrrole-3-propanoic acid, 5-[[1,2-dihydro-2-oxo-4-(4-piperidinyl)-3H-indol-3-ylidene]methyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)



RN 388116-92-5 CAPLUS
CN 1H-Pyrrole-3-acetic acid, 5-[[1,2-dihydro-2-oxo-4-(4-piperidinyl)-3H-indol-3-ylidene]methyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)



RN 388116-93-6 CAPLUS
CN 2H-Indol-2-one, 1,3-dihydro-3-(1H-indol-2-ylmethylene)-4-(4-piperidinyl)- (9CI) (CA INDEX NAME)



RN 388116-94-7 CAPLUS
CN 2H-Indol-2-one, 1,3-dihydro-4-(4-piperidinyl)-3-[(4,5,6,7-tetrahydro-1H-indol-2-yl)methylene]- (9CI) (CA INDEX NAME)



RN 388116-95-8 CAPLUS
CN 2H-Indol-2-one, 1,3-dihydro-3-[1H-indol-2-yl[2-(4-morpholinyl)ethoxy]methylene]-4-(4-piperidinyl)- (9CI) (CA INDEX NAME)



RN 388116-96-9 CAPLUS
CN 1H-Pyrrole-2-carboxylic acid, 5-[[1,2-dihydro-2-oxo-4-(4-piperidinyl)-3H-indol-3-ylidene]methyl]-4-methyl- (9CI) (CA INDEX NAME)



RN 388116-97-0 CAPLUS
CN 1H-Pyrrole-3-carboxylic acid, 2-[[1,2-dihydro-2-oxo-4-(4-piperidinyl)-3H-indol-3-ylidene]methyl]-5-methyl- (9CI) (CA INDEX NAME)



RN 388116-98-1 CAPLUS
CN 2H-Indol-2-one, 1,3-dihydro-3-[4-(4-morpholinyl)-1-(4,5,6,7-tetrahydro-1H-indol-2-yl)butylidene]-4-(4-piperidinyl)- (9CI) (CA INDEX NAME)



RN 388116-99-2 CAPLUS
CN 1H-Pyrrole-3-carboxamide, N-[2-(diethylamino)ethyl]-5-[[1,2-dihydro-2-oxo-4-(4-piperidinyl)-3H-indol-3-ylidene]methyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)



RN 388117-00-8 CAPLUS
CN Piperazine, 1-[[5-[[1,2-dihydro-2-oxo-4-(4-piperidinyl)-3H-indol-3-ylidene]methyl]-4-methyl-1H-pyrrol-2-yl]carbonyl]-4-methyl- (9CI) (CA INDEX NAME)



RN 388117-01-9 CAPLUS
CN 2H-Isoindole-1-carboxylic acid, 3-[[1,2-dihydro-2-oxo-4-(4-piperidinyl)-3H-indol-3-ylidene]methyl]-4,5,6,7-tetrahydro-, ethyl ester (9CI) (CA INDEX NAME)



RN 388117-02-0 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 5-[[1,2-dihydro-2-oxo-4-(4-piperidinyl)-3H-indol-3-ylidene]methyl]-2-methyl-4-phenyl-N-4-pyridinyl- (9CI) (CA INDEX NAME)



RN 388117-03-1 CAPLUS
CN 2H-Indol-2-one, 1,3-dihydro-3-[(5-methyl-2-thienyl)methylene]-4-(4-piperidinyl)- (9CI) (CA INDEX NAME)



RN 388117-05-3 CAPLUS
CN 1H-Pyrrole-3-propanoic acid, 2-[[1,2-dihydro-2-oxo-4-(4-piperidinyl)-3H-indol-3-ylidene]methyl]-5-(ethoxycarbonyl)-4-methyl- (9CI) (CA INDEX NAME)



RN 388117-06-4 CAPLUS
CN 1H-Pyrrole-3-carboxylic acid, 5-[[1,2-dihydro-2-oxo-4-(4-piperidinyl)-3H-indol-3-ylidene]methyl]-4-(2-hydroxyethyl)- (9CI) (CA INDEX NAME)



RN 388117-07-5 CAPLUS
CN 1H-Pyrrole-3-carboxylic acid, 5-[[1,2-dihydro-2-oxo-4-(4-piperidinyl)-3H-indol-3-ylidene]methyl]-4-(4-methoxyphenyl)-, ethyl ester (9CI) (CA INDEX NAME)



RN 388117-08-6 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 5-[[1,2-dihydro-2-oxo-4-(4-piperidinyl)-3H-indol-3-ylidene]methyl]-4-methyl-N-(phenylmethyl)- (9CI) (CA INDEX NAME)



RN 388117-10-0 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 5-[[1,2-dihydro-2-oxo-4-(4-piperidinyl)-3H-indol-3-ylidene]methyl]-4-methyl-N-(4-pyridinylmethyl)- (9CI) (CA INDEX NAME)



RN 388117-12-2 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 5-[[1,2-dihydro-2-oxo-4-(4-piperidinyl)-3H-indol-3-ylidene]methyl]-4-methyl-N-[3-(2-oxo-1-pyrrolidinyl)propyl]- (9CI) (CA INDEX NAME)



RN 388117-14-4 CAPLUS
CN 1H-Pyrrole-3-carboxylic acid, 5-[[1,2-dihydro-2-oxo-4-(2-pyridinyl)-3H-indol-3-ylidene]methyl]-2-methyl-4-[3-(4-methyl-1-piperazinyl)propyl]-, ethyl ester (9CI) (CA INDEX NAME)



RN 388117-16-6 CAPLUS
CN Piperazine, 1-[[5-[[1,2-dihydro-2-oxo-4-(2-pyridinyl)-3H-indol-3-ylidene]methyl]-2,4-dimethyl-1H-pyrrol-3-yl]carbonyl]-4-methyl- (9CI) (CA INDEX NAME)



RN 388117-17-7 CAPLUS
CN Piperazine, 1-[[5-[[1,2-dihydro-2-oxo-4-(5-pyrimidinyl)-3H-indol-3-ylidene]methyl]-2,4-dimethyl-1H-pyrrol-3-yl]carbonyl]-4-methyl- (9CI) (CA INDEX NAME)



RN 388117-18-8 CAPLUS
CN Piperazine, 1-[[5-[[1,2-dihydro-2-oxo-4-(2-thiazolyl)-3H-indol-3-ylidene]methyl]-2,4-dimethyl-1H-pyrrol-3-yl]carbonyl]-4-methyl- (9CI) (CA INDEX NAME)



RN 388117-19-9 CAPLUS
CN 1H-Pyrrole-3-carboxylic acid, 5-[[1,2-dihydro-2-oxo-4-(5-pyrimidinyl)-3H-indol-3-ylidene]methyl]-2-methyl-4-[3-(4-methyl-1-piperazinyl)propyl]-, ethyl ester (9CI) (CA INDEX NAME)



RN 388117-20-2 CAPLUS
CN 1H-Pyrrole-3-carboxylic acid, 5-[[1,2-dihydro-2-oxo-4-(2-thiazolyl)-3H-indol-3-ylidene]methyl]-2-methyl-4-[3-(4-methyl-1-piperazinyl)propyl]-, ethyl ester (9CI) (CA INDEX NAME)



RN 388117-21-3 CAPLUS
CN 1H-Pyrrole-3-carboxylic acid, 5-[[4-(6-amino-3-pyridinyl)-1,2-dihydro-2-oxo-3H-indol-3-ylidene]methyl]-2-methyl-4-[3-(4-methyl-1-piperazinyl)propyl]-, ethyl ester (9CI) (CA INDEX NAME)



RN 388117-22-4 CAPLUS
CN Piperazine, 1-[[5-[[4-(6-amino-3-pyridinyl)-1,2-dihydro-2-oxo-3H-indol-3-ylidene]methyl]-2,4-dimethyl-1H-pyrrol-3-yl]carbonyl]-4-methyl- (9CI) (CA

INDEX NAME)



RN 388117-23-5 CAPLUS
CN 1H-Pyrrole-3-carboxylic acid, 5-[[1,2-dihydro-2-oxo-4-(3-pyridinyl)-3H-indol-3-ylidene]methyl]-2-methyl-4-[3-(4-methyl-1-piperazinyl)propyl]-, ethyl ester (9CI) (CA INDEX NAME)



RN 388117-24-6 CAPLUS
CN Piperazine, 1-[[5-[[1,2-dihydro-2-oxo-4-(3-pyridinyl)-3H-indol-3-ylidene]methyl]-2,4-dimethyl-1H-pyrrol-3-yl]carbonyl]-4-methyl- (9CI) (CA INDEX NAME)



RN 388117-25-7 CAPLUS
CN 3-Pyridinecarboxylic acid, 5-[3-[[4-(ethoxycarbonyl)-5-methyl-3-[3-(4-methyl-1-piperazinyl)propyl]-1H-pyrrol-2-yl]methylene]-2,3-dihydro-2-oxo-1H-indol-4-yl]- (9CI) (CA INDEX NAME)



RN 388117-26-8 CAPLUS
CN 3-Pyridinecarboxylic acid, 5-[3-[[3,5-dimethyl-4-[(4-methyl-1-piperazinyl)carbonyl]-1H-pyrrol-2-yl]methylene]-2,3-dihydro-2-oxo-1H-indol-4-yl]- (9CI) (CA INDEX NAME)



RN 388117-27-9 CAPLUS
CN 3-Pyridinecarboxylic acid, 5-[3-[2-[[2-(diethylamino)ethyl]amino]-1-(3,5-dimethyl-1H-pyrrol-2-yl)-2-oxoethylidene]-2,3-dihydro-2-oxo-1H-indol-4-yl]- (9CI) (CA INDEX NAME)



RN 388117-28-0 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 5-[[4-(2-amino-5-pyrimidinyl)-1,2-dihydro-2-oxo-3H-indol-3-ylidene]methyl]-N-[2-(diethylamino)ethyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)



RN 388117-29-1 CAPLUS
CN Piperazine, 1-[[5-[[4-(2-amino-5-pyrimidinyl)-1,2-dihydro-2-oxo-3H-indol-3-ylidene]methyl]-2,4-dimethyl-1H-pyrrol-3-yl]carbonyl]-4-methyl- (9CI) (CA INDEX NAME)



RN 388117-30-4 CAPLUS
CN 1H-Pyrrole-3-carboxamide, N-[2-(diethylamino)ethyl]-5-[[1,2-dihydro-2-oxo-4-(3-pyridinyl)-3H-indol-3-ylidene]methyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)



IT **388116-49-2P**, 3-(3,5-Dimethyl-1H-pyrrol-2-ylmethylene)-4-(pyridin-4-yl)-1,3-dihydroindol-2-one
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. and use of 4-heteroaryl-3-heteroarylidenyl-2-indolinones and their use as protein kinase inhibitors)
RN 388116-49-2 CAPLUS
CN 2H-Indol-2-one, 3-[(3,5-dimethyl-1H-pyrrol-2-yl)methylene]-1,3-dihydro-4-(4-pyridinyl)- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 9 THERE ARE 9 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 5 OF 66 CAPLUS COPYRIGHT 2002 ACS

ACCESSION NUMBER: 2001:917070 CAPLUS
DOCUMENT NUMBER: 136:214530
TITLE: The t(8;22) in chronic myeloid leukemia fuses BCR to FGFR1: transforming activity and specific inhibition of FGFR1 fusion proteins
AUTHOR(S): Demiroglu, Asuman; Steer, E. Joanna; Heath, Carol; Taylor, Kerry; Bentley, Mark; Allen, Steven L.; Koduru, Prasad; Brody, Judith P.; Hawson, Geoffrey; Rodwell, Robyn; Doody, Mary-Lou; Carnicero, Fernando; Reiter, Andreas; Goldman, John M.; Melo, Junia V.; Cross, Nicholas C. P.
CORPORATE SOURCE: Department of Haematology, Imperial College School of Medicine, Hammersmith Hospital, London, UK
SOURCE: Blood (2001), 98(13), 3778-3783
CODEN: BLOOAW; ISSN: 0006-4971
PUBLISHER: American Society of Hematology
DOCUMENT TYPE: Journal
LANGUAGE: English
AB This report describes 2 patients with a clin. and hematol. diagnosis of chronic myeloid leukemia (CML) in chronic phase who had an acquired t(8;22)(p11;q11). Anal. by fluorescence in situ hybridization (FISH) and reverse transcription-polymerase chain reaction (RT-PCR) indicated that both patients were neg. for the BCR-ABL fusion, but suggested that the BCR gene was disrupted. Further FISH indicated a breakpoint within fibroblast growth factor receptor 1 (FGFR1), the receptor **tyrosine** kinase that is known to be disrupted in a distinctive myeloproliferative disorder, most commonly by fusion to ZNF198. RT-PCR confirmed the presence in both cases of an in-frame mRNA fusion between BCR exon 4 and FGFR1 exon 9. Expression of BCR-FGFR1 in the factor-dependent cell line Ba/F3 resulted in interleukin 3-independent clones that grew at a comparable rate to cells transformed with ZNF198-FGFR1. The growth of transformed cells was inhibited by the phosphatidylinositol 3-kinase inhibitor LY294002, the farnesyltransferase inhibitors L744832 and manumycin A, the p38 inhibitors SB202190 and SB203580 but not by the MEK inhibitor PD98059. The growth of BaF3/BCR-FGFR1 and BaF3/ZNF198-FGFR1 was not significantly inhibited by treatment with STI571, but was inhibited by SU5402, a compd. with inhibitory activity against FGFR1. Inhibition with this compd. was assocd. with decreased phosphorylation of ERK1/2 and BCR-FGFR1 or ZNF198-FGFR1, and was dose dependent with an inhibitory concn. of 50% of approx. 5 .mu.M. As expected, growth of BaF3/BCR-ABL was inhibited by STI571 but not by SU5402. The study demonstrates that the BCR-FGFR1 fusion may occur in patients with apparently typical CML. Patients with constitutively active FGFR1 fusion genes may be amenable to treatment with specific FGFR1 inhibitors.

IT **215543-92-3**, SU 5402
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(t(8;22) in chronic myeloid leukemia fuses BCR to FGFR1: transforming activity and specific inhibition of FGFR1 fusion proteins)

RN 215543-92-3 CAPLUS
CN 1H-Pyrrole-3-propanoic acid, 2-[(1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-4-methyl- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 33 THERE ARE 33 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 6 OF 66 CAPLUS COPYRIGHT 2002 ACS
ACCESSION NUMBER: 2001:905718 CAPLUS
DOCUMENT NUMBER: 136:160779
TITLE: Semaxanib (SUGEN)
AUTHOR(S): Sakamoto, Kathleen M.
CORPORATE SOURCE: Department of Pedlatncs and Pathology, UCLA School of Medicine, Los Angeles, CA, 90095-1752, USA
SOURCE: IDrugs (2001), 4(9), 1061-1067
CODEN: IDRUFN; ISSN: 1369-7056
PUBLISHER: Current Drugs Ltd.
DOCUMENT TYPE: Journal; General Review
LANGUAGE: English

AB A review. SUGEN (owned by Pharmacia) is developing semaxanib (SU-5416), the lead in a series of small mol. inhibitors of the flk-1 **tyrosine** kinase receptor (flk-1 RTK), for the potential treatment of solid tumors (via suppression of metastasis and angiogenesis). In July 1999, phase III trials for colorectal and lung cancer were initiated. In Mar. 2001, phase III trials were initiated for the compd. as an addn. to a std. chemotherapy regimen in colorectal cancer; at this time, Pharmacia, as well as the NCI, was conducting clin. studies for numerous other solid and hematol. cancers. By Oct. 2000, oral forms of the compd. were also being evaluated. In July 2000, Pharmacia anticipated US and international filing in 2001. Taiho and SUGEN have agreed a joint development program for SUGEN's angiogenesis inhibitors. In August 1998, the USPTO issued US-05792783 to SUGEN, covering a family of compds., including semaxanib. The patent claims cover the compds. and compn., as well as methods of use in a variety of diseases, including cancer. In August 1998, the USPTO issued US-05792783 to SUGEN, covering a family of compds., including semaxanib. The patent claims cover the compds. and compn., as well as methods of use in a variety of diseases, including cancer.

IT **194413-58-6**, Semaxanib
RL: ADV (Adverse effect, including toxicity); PAC (Pharmacological activity); PKT (Pharmacokinetics); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(semaxanib, an inhibitor of the flk-1 **tyrosine** kinase receptor, for potential treatment of solid tumors in humans)

RN 194413-58-6 CAPLUS
CN 2H-Indol-2-one, 3-[(3,5-dimethyl-1H-pyrrol-2-yl)methylene]-1,3-dihydro-, (3Z)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.





REFERENCE COUNT: 39 THERE ARE 39 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 7 OF 66 CAPLUS COPYRIGHT 2002 ACS
ACCESSION NUMBER: 2001:904107 CAPLUS
DOCUMENT NUMBER: 136:37505
TITLE: Preparation of 3-(2-indolylmethylene)-2-indolinones as protein kinase/phosphatase inhibitors for treatment of proliferative diseases
INVENTOR(S): Tang, Peng Cho; Harris, G. Davis; Li, Xiaoyuan
PATENT ASSIGNEE(S): Sugen, Inc., USA
SOURCE: PCT Int. Appl., 199 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001094312	A2	20011213	WO 2001-US17961	20010604
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
US 2002052369	A1	20020502	US 2001-871700	20010604

PRIORITY APPLN. INFO.: US 2000-209162P P 20000602
OTHER SOURCE(S): MARPAT 136:37505
GI



I



II

AB Title compds. I [wherein R4-R6 and R8-R10 = H; R1, R2, and R3 = independently H, halo, carboxylic acid, trihalomethyl, or (un)substituted ester, amide, alkyl, alkoxy, or (hetero)aryl; R7 = (un)substituted alkyl or alkoxy; or pharmaceutically acceptable salt thereof] were prepd. as modulators of the activity of protein kinases (PKs) and phosphatases. For example, 5-bromo-2-oxindole was coupled with 5-(3-diethylaminopropyl)-1H-indole-2-carbaldehyde (prepn. given) in the presence of piperidine in EtOH to afford II, which inhibited GST-FLK-1, EGF receptor kinase, and PDGF with IC50 values of 0.03 .mu.M, 2.87 .mu.M, and 0.38 .mu.M, resp. I are useful in treating disorders related to abnormal PK activity, such as blood vessel proliferative disorders, mesangial cell proliferative disorders, fibrotic disorders, cancer, diabetes, autoimmune disorders, hyperproliferation disorders, restenosis, fibrosis, psoriasis, von Heppel-Lindau disease, osteoarthritis, rheumatoid arthritis, angiogenesis, inflammatory disorders, immunol. disorders, and cardiovascular disorders (no data). Combinatorial libraries comprising at least five indolinone compds., formed by reacting oxindoles with aldehydes, are also claimed.

IT **258830-88-5P**
RL: CPN (Combinatorial preparation); CRT (Combinatorial reactant); RCT (Reactant); SPN (Synthetic preparation); CMBI (Combinatorial study); PREP (Preparation); RACT (Reactant or reagent)
(prepn. of (indolylmethylene)indolinones as protein kinase/phosphatase inhibitors for treatment of proliferative diseases)

RN 258830-88-5 CAPLUS

CN 1H-Indole-5-sulfonamide, 2,3-dihydro-3-(1H-indol-2-ylmethylene)-N,N-dimethyl-2-oxo- (9CI) (CA INDEX NAME)



IT **258830-79-4P 258830-86-3P 380241-29-2P**
380241-30-5P 380241-31-6P 380241-33-8P
RL: CPN (Combinatorial preparation); PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); CMBI (Combinatorial study); PREP (Preparation); USES (Uses)
(prepn. of (indolylmethylene)indolinones as protein kinase/phosphatase inhibitors for treatment of proliferative diseases)

RN 258830-79-4 CAPLUS
CN 1H-Indole-5-sulfonamide, 2,3-dihydro-3-(1H-indol-2-ylmethylene)-N-methyl-2-oxo- (9CI) (CA INDEX NAME)



RN 258830-86-3 CAPLUS
CN 1H-Indole-5-sulfonamide, 2,3-dihydro-N,N-dimethyl-3-[(2-methyl-1H-indol-3-yl)methylene]-2-oxo- (9CI) (CA INDEX NAME)



RN 380241-29-2 CAPLUS
CN 2H-Indol-2-one, 5-bromo-3-[[5-[2-(diethylamino)ethoxy]-1H-indol-2-yl]methylene]-1,3-dihydro- (9CI) (CA INDEX NAME)



RN 380241-30-5 CAPLUS
CN 2H-Indol-2-one, 3-[[5-[2-(diethylamino)ethoxy]-1H-indol-2-yl]methylene]-1,3-dihydro-6-phenyl- (9CI) (CA INDEX NAME)



RN 380241-31-6 CAPLUS

CN 2H-Indol-2-one, 3-[[5-[2-(diethylamino)ethoxy]-1H-indol-2-yl]methylene]-1,3-dihydro-5-phenyl- (9CI) (CA INDEX NAME)



RN 380241-33-8 CAPLUS
CN 1H-Indole-5-carboxylic acid, 2,3-dihydro-2-oxo-3-[[5-[3-(1-pyrrolidinyl)propyl]-1H-indol-2-yl]methylene]- (9CI) (CA INDEX NAME)



IT **258830-66-9P 380242-44-4P 380242-45-5P**
380242-46-6P 380242-47-7P 380242-48-8P
380242-49-9P 380242-50-2P 380242-51-3P
380242-52-4P 380242-53-5P 380242-54-6P
380242-55-7P 380242-56-8P 380242-57-9P
380242-58-0P 380242-59-1P 380242-60-4P
380242-61-5P 380242-62-6P 380242-63-7P
380242-64-8P 380242-65-9P 380242-66-0P
380242-67-1P 380242-68-2P 380242-69-3P
380242-70-6P 380242-71-7P 380242-72-8P
380242-73-9P 380363-16-6P
RL: CPN (Combinatorial preparation); PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); CMBI (Combinatorial study); PREP (Preparation); USES (Uses)
(prepn. of (indolylmethylene)indolinones as protein kinase/phosphatase inhibitors for treatment of proliferative diseases)

RN 258830-66-9 CAPLUS
CN 1H-Indole-5-sulfonamide, 2,3-dihydro-3-(1H-indol-2-ylmethylene)-2-oxo- (9CI) (CA INDEX NAME)



RN 380242-44-4 CAPLUS
CN 1H-Indole-5-sulfonamide, 3-[[5-[3-(diethylamino)propyl]-1H-indol-2-yl]methylene]-2,3-dihydro-N,N-dimethyl-2-oxo- (9CI) (CA INDEX NAME)



RN 380242-45-5 CAPLUS
CN Piperazine, 1-[[3-[[5-[3-(diethylamino)propyl]-1H-indol-2-yl]methylene]-2,3-dihydro-2-oxo-1H-indol-5-yl]sulfonyl]-4-methyl- (9CI) (CA INDEX NAME)



RN 380242-46-6 CAPLUS
CN Pyrrolidine, 1-[[3-[[5-[3-(diethylamino)propyl]-1H-indol-2-yl]methylene]-2,3-dihydro-2-oxo-1H-indol-5-yl]sulfonyl]- (9CI) (CA INDEX NAME)



RN 380242-47-7 CAPLUS
CN 1H-Indole-5-sulfonamide, 3-[[5-[3-(diethylamino)propyl]-1H-indol-2-yl]methylene]-2,3-dihydro-N-(2-methoxyethyl)-2-oxo- (9CI) (CA INDEX NAME)



RN 380242-48-8 CAPLUS
CN 1H-Indole-5-sulfonamide, 3-[[5-[3-(diethylamino)propyl]-1H-indol-2-yl]methylene]-2,3-dihydro-2-oxo-N-3-pyridinyl- (9CI) (CA INDEX NAME)



RN 380242-49-9 CAPLUS
CN 1H-Indole-5-sulfonamide, 3-[[5-[3-(diethylamino)propyl]-1H-indol-2-yl]methylene]-2,3-dihydro-N-(2-methoxyphenyl)-2-oxo- (9CI) (CA INDEX NAME)



RN 380242-50-2 CAPLUS
CN 1H-Indole-5-sulfonamide, N-(3-chlorophenyl)-3-[[5-[3-(diethylamino)propyl]-1H-indol-2-yl]methylene]-2,3-dihydro-2-oxo- (9CI) (CA INDEX NAME)



RN 380242-51-3 CAPLUS
CN 1H-Indole-5-sulfonamide, 3-[[5-[3-(diethylamino)propyl]-1H-indol-2-yl]methylene]-N-[(4-fluorophenyl)methyl]-2,3-dihydro-2-oxo- (9CI) (CA INDEX NAME)



RN 380242-52-4 CAPLUS
CN 1H-Indole-5-sulfonamide, 3-[[5-[3-(diethylamino)propyl]-1H-indol-2-yl]methylene]-2,3-dihydro-2-oxo- (9CI) (CA INDEX NAME)



RN 380242-53-5 CAPLUS
CN 1H-Indole-5-sulfonamide, 3-[[5-[3-(diethylamino)propyl]-1H-indol-2-yl]methylene]-2,3-dihydro-N-(1-methylethyl)-2-oxo- (9CI) (CA INDEX NAME)



RN 380242-54-6 CAPLUS
CN 1H-Indole-5-sulfonamide, 2,3-dihydro-3-(1H-indol-2-ylmethylene)-2-oxo-N-(phenylmethyl)- (9CI) (CA INDEX NAME)



RN 380242-55-7 CAPLUS
CN Pyrrolidine, 1-[[2,3-dihydro-3-(1H-indol-2-ylmethylene)-2-oxo-1H-indol-5-yl]sulfonyl]- (9CI) (CA INDEX NAME)



RN 380242-56-8 CAPLUS
CN 1H-Indole-5-sulfonamide, 2,3-dihydro-3-(1H-indol-2-ylmethylene)-N-(2-methoxyethyl)-2-oxo- (9CI) (CA INDEX NAME)



RN 380242-57-9 CAPLUS
CN 1H-Indole-5-sulfonamide, 2,3-dihydro-3-(1H-indol-2-ylmethylene)-N-(2-methoxyphenyl)-2-oxo- (9CI) (CA INDEX NAME)



RN 380242-58-0 CAPLUS
CN 1H-Indole-5-sulfonamide, N-(3-chlorophenyl)-2,3-dihydro-3-(1H-indol-2-ylmethylene)-2-oxo- (9CI) (CA INDEX NAME)



RN 380242-59-1 CAPLUS
CN 1H-Indole-5-sulfonamide, N-[(4-fluorophenyl)methyl]-2,3-dihydro-3-(1H-indol-2-ylmethylene)-2-oxo- (9CI) (CA INDEX NAME)



RN 380242-60-4 CAPLUS
CN 1H-Indole-5-sulfonamide, 2,3-dihydro-3-(1H-indol-2-ylmethylene)-N-(1-methylethyl)-2-oxo- (9CI) (CA INDEX NAME)





RN 380242-61-5 CAPLUS
CN 2H-Indol-2-one, 3-[[5-[2-(diethylamino)ethoxy]-1H-indol-2-yl]methylene]-1,3-dihydro-6-(3-methoxyphenyl)- (9CI) (CA INDEX NAME)



RN 380242-62-6 CAPLUS
CN 2H-Indol-2-one, 3-[[5-[2-(diethylamino)ethoxy]-1H-indol-2-yl]methylene]-1,3-dihydro-6-(4-methoxyphenyl)- (9CI) (CA INDEX NAME)



RN 380242-63-7 CAPLUS
CN 2H-Indol-2-one, 3-[[5-[2-(diethylamino)ethoxy]-1H-indol-2-yl]methylene]-1,3-dihydro-6-(2-methoxyphenyl)- (9CI) (CA INDEX NAME)



RN 380242-64-8 CAPLUS
CN 1H-Indole-4-carboxylic acid, 3-[[5-[2-(diethylamino)ethoxy]-1H-indol-2-yl]methylene]-2,3-dihydro-2-oxo- (9CI) (CA INDEX NAME)



RN 380242-65-9 CAPLUS
CN 2H-Indol-2-one, 6-bromo-3-[[5-[2-(diethylamino)ethoxy]-1H-indol-2-yl]methylene]-1,3-dihydro- (9CI) (CA INDEX NAME)



RN 380242-66-0 CAPLUS
CN 1H-Indole-4-carboxamide, N-(3-chloro-4-methoxyphenyl)-3-[[5-[2-(diethylamino)ethoxy]-1H-indol-2-yl]methylene]-2,3-dihydro-2-oxo- (9CI) (CA INDEX NAME)



RN 380242-67-1 CAPLUS
CN 1H-Indole-6-carboxylic acid, 2,3-dihydro-2-oxo-3-[[5-[3-(1-pyrrolidinyl)propyl]-1H-indol-2-yl]methylene]- (9CI) (CA INDEX NAME)



RN 380242-68-2 CAPLUS
CN Glycine, N-[[2,3-dihydro-2-oxo-3-[[5-[3-(1-pyrrolidinyl)propyl]-1H-indol-2-yl]methylene]-1H-indol-5-yl]carbonyl]- (9CI) (CA INDEX NAME)



RN 380242-69-3 CAPLUS
CN Glycine, N-[[2,3-dihydro-2-oxo-3-[[5-[3-(1-pyrrolidinyl)propyl]-1H-indol-2-yl]methylene]-1H-indol-6-yl]carbonyl]- (9CI) (CA INDEX NAME)



RN 380242-70-6 CAPLUS
CN L-Alanine, N-[[2,3-dihydro-2-oxo-3-[[5-[3-(1-pyrrolidinyl)propyl]-1H-indol-2-yl]methylene]-1H-indol-5-yl]carbonyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.



RN 380242-71-7 CAPLUS
CN L-Valine, N-[[2,3-dihydro-2-oxo-3-[[5-[3-(1-pyrrolidinyl)propyl]-1H-indol-2-yl]methylene]-1H-indol-5-yl]carbonyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.



RN 380242-72-8 CAPLUS
CN L-Alanine, N-[[2,3-dihydro-2-oxo-3-[[5-[3-(1-pyrrolidinyl)propyl]-1H-indol-2-yl]methylene]-1H-indol-6-yl]carbonyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.



RN 380242-73-9 CAPLUS
CN L-Valine, N-[[2,3-dihydro-2-oxo-3-[[5-[3-(1-pyrrolidinyl)propyl]-1H-indol-2-yl]methylene]-1H-indol-6-yl]carbonyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.



RN 380363-16-6 CAPLUS
CN 2H-Indol-2-one, 3-[[5-[2-(diethylamino)ethoxy]-1H-indol-2-yl]methylene]-1,3-dihydro-6-(pyridinyl)- (9CI) (CA INDEX NAME)





IT **380242-01-3P**
RL: CRT (Combinatorial reactant); RCT (Reactant); SPN (Synthetic preparation); CMBI (Combinatorial study); PREP (Preparation); RACT (Reactant or reagent)
(prepn. of (indolylmethylene)indolinones as protein kinase/phosphatase inhibitors for treatment of proliferative diseases)
RN 380242-01-3 CAPLUS
CN 1H-Indole-5-sulfonamide, 2,3-dihydro-3-[(4-methoxy-1H-indol-2-yl)methylene]-N-methyl-2-oxo- (9CI) (CA INDEX NAME)



IT **181223-16-5P 203988-69-6P 215543-45-6P**
258830-80-7P 258830-85-2P 258830-87-4P
258830-90-9P 258830-91-0P 380241-13-4P
380241-14-5P 380241-15-6P 380241-16-7P
380241-17-8P 380241-18-9P 380241-19-0P
380241-20-3P 380241-21-4P 380241-22-5P
380241-23-6P 380241-24-7P 380241-25-8P
380241-26-9P 380241-27-0P 380241-28-1P
380241-32-7P 380241-34-9P 380241-35-0P
380241-36-1P 380241-37-2P 380241-38-3P
380241-39-4P 380241-40-7P 380241-41-8P
380241-42-9P 380241-43-0P 380241-44-1P
380241-45-2P 380241-46-3P 380241-47-4P
380241-48-5P 380241-49-6P 380241-50-9P
380241-51-0P 380241-53-2P 380241-54-3P
380241-56-5P 380241-59-8P 380241-61-2P
380241-65-6P 380241-68-9P 380241-71-4P
380241-74-7P 380241-78-1P 380241-82-7P
380241-84-9P 380241-86-1P 380241-88-3P
380241-90-7P 380241-91-8P 380241-92-9P
380241-93-0P 380241-94-1P 380241-95-2P
380241-96-3P 380241-97-4P 380241-98-5P
380241-99-6P 380242-00-2P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of (indolylmethylene)indolinones as protein kinase/phosphatase inhibitors for treatment of proliferative diseases)

RN 181223-16-5 CAPLUS
CN 1H-Indole-5-sulfonamide, 2,3-dihydro-3-(1H-indol-3-ylmethylene)-2-oxo-(9CI) (CA INDEX NAME)



RN 203988-69-6 CAPLUS
CN 1H-Indole-5-sulfonamide, 2,3-dihydro-3-(1H-indol-3-ylmethylene)-N-methyl-2-oxo- (9CI) (CA INDEX NAME)



RN 215543-45-6 CAPLUS
CN 1H-Indole-5-sulfonamide, 2,3-dihydro-N-methyl-3-[(2-methyl-1H-indol-3-yl)methylene]-2-oxo- (9CI) (CA INDEX NAME)



RN 258830-80-7 CAPLUS
CN 1H-Indole-5-sulfonamide, 2,3-dihydro-3-(1H-indol-5-ylmethylene)-N-methyl-2-oxo- (9CI) (CA INDEX NAME)



RN 258830-85-2 CAPLUS
CN 1H-Indole-5-sulfonamide, 2,3-dihydro-3-(1H-indol-5-ylmethylene)-N,N-dimethyl-2-oxo- (9CI) (CA INDEX NAME)



RN 258830-87-4 CAPLUS
CN 1H-Indole-5-sulfonamide, 2,3-dihydro-3-(1H-indol-5-ylmethylene)-2-oxo- (9CI) (CA INDEX NAME)



RN 258830-90-9 CAPLUS
CN 1H-Indole-5-sulfonamide, 2,3-dihydro-3-(1H-indol-3-ylmethylene)-N,N-dimethyl-2-oxo- (9CI) (CA INDEX NAME)



RN 258830-91-0 CAPLUS
CN 1H-Indole-5-sulfonamide, 2,3-dihydro-3-[(2-methyl-1H-indol-3-yl)methylene]-2-oxo- (9CI) (CA INDEX NAME)



RN 380241-13-4 CAPLUS
CN 2H-Indol-2-one, 3-[[5-[3-(diethylamino)propyl]-1H-indol-2-yl]methylene]-1,3-dihydro- (9CI) (CA INDEX NAME)



RN 380241-14-5 CAPLUS
CN 2H-Indol-2-one, 5-bromo-3-[[5-[3-(diethylamino)propyl]-1H-indol-2-yl]methylene]-1,3-dihydro- (9CI) (CA INDEX NAME)



RN 380241-15-6 CAPLUS
CN 2H-Indol-2-one, 3-[[5-[3-(diethylamino)propyl]-1H-indol-2-yl]methylene]-1,3-dihydro-6-phenyl- (9CI) (CA INDEX NAME)



RN 380241-16-7 CAPLUS
CN 2H-Indol-2-one, 3-[[5-[3-(diethylamino)propyl]-1H-indol-2-yl]methylene]-1,3-dihydro-5-phenyl- (9CI) (CA INDEX NAME)



RN 380241-17-8 CAPLUS
CN 2H-Indol-2-one, 3-[[5-[2-(dimethylamino)ethoxy]-1H-indol-2-yl]methylene]-1,3-dihydro-5-phenyl- (9CI) (CA INDEX NAME)



RN 380241-18-9 CAPLUS
CN 2H-Indol-2-one, 1,3-dihydro-5-phenyl-3-[[5-[2-(1-pyrrolidinyl)ethoxy]-1H-indol-2-yl]methylene]- (9CI) (CA INDEX NAME)



RN 380241-19-0 CAPLUS
CN 2H-Indol-2-one, 1,3-dihydro-3-[[5-[2-(4-morpholinyl)ethoxy]-1H-indol-2-yl]methylene]- (9CI) (CA INDEX NAME)



RN 380241-20-3 CAPLUS
CN 2H-Indol-2-one, 5-bromo-1,3-dihydro-3-[[5-[2-(4-morpholinyl)ethoxy]-1H-indol-2-yl]methylene]- (9CI) (CA INDEX NAME)



RN 380241-21-4 CAPLUS
CN 2H-Indol-2-one, 1,3-dihydro-3-[[5-[2-(4-morpholinyl)ethoxy]-1H-indol-2-yl]methylene]-6-phenyl- (9CI) (CA INDEX NAME)



RN 380241-22-5 CAPLUS
CN 2H-Indol-2-one, 3-[[5-[2-(dimethylamino)ethoxy]-1H-indol-2-yl]methylene]-1,3-dihydro- (9CI) (CA INDEX NAME)



RN 380241-23-6 CAPLUS
CN 2H-Indol-2-one, 5-bromo-3-[[5-[2-(dimethylamino)ethoxy]-1H-indol-2-yl]methylene]-1,3-dihydro- (9CI) (CA INDEX NAME)



RN 380241-24-7 CAPLUS
CN 2H-Indol-2-one, 3-[[5-[2-(dimethylamino)ethoxy]-1H-indol-2-yl]methylene]-1,3-dihydro-6-phenyl- (9CI) (CA INDEX NAME)





RN 380241-25-8 CAPLUS
CN 2H-Indol-2-one, 1,3-dihydro-3-[[5-[2-(1-pyrrolidinyl)ethoxy]-1H-indol-2-yl]methylene]- (9CI) (CA INDEX NAME)



RN 380241-26-9 CAPLUS
CN 2H-Indol-2-one, 5-bromo-1,3-dihydro-3-[[5-[2-(1-pyrrolidinyl)ethoxy]-1H-indol-2-yl]methylene]- (9CI) (CA INDEX NAME)



RN 380241-27-0 CAPLUS
CN 2H-Indol-2-one, 1,3-dihydro-6-phenyl-3-[[5-[2-(1-pyrrolidinyl)ethoxy]-1H-indol-2-yl]methylene]- (9CI) (CA INDEX NAME)



RN 380241-28-1 CAPLUS
CN 2H-Indol-2-one, 3-[[5-[2-(diethylamino)ethoxy]-1H-indol-2-yl]methylene]-1,3-dihydro- (9CI) (CA INDEX NAME)



RN 380241-32-7 CAPLUS
CN 2H-Indol-2-one, 1,3-dihydro-3-[[5-[3-(1-pyrrolidinyl)propyl]-1H-indol-2-yl]methylene]- (9CI) (CA INDEX NAME)



RN 380241-34-9 CAPLUS
CN 1H-Indole-5-carboxylic acid, 2,3-dihydro-2-oxo-3-[[5-[2-(1-pyrrolidinyl)ethoxy]-1H-indol-2-yl]methylene]- (9CI) (CA INDEX NAME)



RN 380241-35-0 CAPLUS
CN 1H-Indole-6-carboxylic acid, 2,3-dihydro-2-oxo-3-[[5-[2-(1-pyrrolidinyl)ethoxy]-1H-indol-2-yl]methylene]- (9CI) (CA INDEX NAME)



RN 380241-36-1 CAPLUS
CN 2H-Indol-2-one, 1,3-dihydro-4-(2-hydroxyethyl)-3-[[5-[2-(1-pyrrolidinyl)ethoxy]-1H-indol-2-yl]methylene]- (9CI) (CA INDEX NAME)



RN 380241-37-2 CAPLUS
CN 2H-Indol-2-one, 1,3-dihydro-6-(3-pyridinyl)-3-[[5-[2-(1-pyrrolidinyl)ethoxy]-1H-indol-2-yl]methylene]- (9CI) (CA INDEX NAME)



RN 380241-38-3 CAPLUS
CN 2H-Indol-2-one, 1,3-dihydro-6-(4-methoxyphenyl)-3-[[5-[2-(1-

pyrrolidinyl)ethoxy]-1H-indol-2-yl]methylene]- (9CI) (CA INDEX NAME)



RN 380241-39-4 CAPLUS
CN 2H-Indol-2-one, 1,3-dihydro-6-(3-methoxyphenyl)-3-[[5-[2-(1-pyrrolidinyl)ethoxy]-1H-indol-2-yl]methylene]- (9CI) (CA INDEX NAME)



RN 380241-40-7 CAPLUS
CN 2H-Indol-2-one, 1,3-dihydro-6-(2-methoxyphenyl)-3-[[5-[2-(1-pyrrolidinyl)ethoxy]-1H-indol-2-yl]methylene]- (9CI) (CA INDEX NAME)



RN 380241-41-8 CAPLUS
CN 2H-Indol-2-one, 6-(4-fluorophenyl)-1,3-dihydro-3-[[5-[2-(1-pyrrolidinyl)ethoxy]-1H-indol-2-yl]methylene]- (9CI) (CA INDEX NAME)



RN 380241-42-9 CAPLUS
CN 1H-Indole-5-carboxylic acid, 2,3-dihydro-3-[[5-[2-(4-morpholinyl)ethoxy]-1H-indol-2-yl]methylene]-2-oxo- (9CI) (CA INDEX NAME)



RN 380241-43-0 CAPLUS
CN 1H-Indole-6-carboxylic acid, 2,3-dihydro-3-[[5-[2-(4-morpholinyl)ethoxy]-1H-indol-2-yl]methylene]-2-oxo- (9CI) (CA INDEX NAME)



RN 380241-44-1 CAPLUS
CN 2H-Indol-2-one, 1,3-dihydro-3-[[5-[2-(4-morpholinyl)ethoxy]-1H-indol-2-yl]methylene]-5-phenyl- (9CI) (CA INDEX NAME)



RN 380241-45-2 CAPLUS
CN 2H-Indol-2-one, 1,3-dihydro-4-(2-hydroxyethyl)-3-[[5-[2-(4-morpholinyl)ethoxy]-1H-indol-2-yl]methylene]- (9CI) (CA INDEX NAME)



RN 380241-46-3 CAPLUS
CN 2H-Indol-2-one, 1,3-dihydro-3-[[5-[2-(4-morpholinyl)ethoxy]-1H-indol-2-yl]methylene]-6-(3-pyridinyl)- (9CI) (CA INDEX NAME)



RN 380241-47-4 CAPLUS
CN 2H-Indol-2-one, 1,3-dihydro-6-(4-methoxyphenyl)-3-[[5-[2-(4-morpholinyl)ethoxy]-1H-indol-2-yl]methylene]- (9CI) (CA INDEX NAME)



RN 380241-48-5 CAPLUS
CN 2H-Indol-2-one, 1,3-dihydro-6-(3-methoxyphenyl)-3-[[5-[2-(4-morpholinyl)ethoxy]-1H-indol-2-yl]methylene]- (9CI) (CA INDEX NAME)



RN 380241-49-6 CAPLUS
CN 2H-Indol-2-one, 1,3-dihydro-6-(2-methoxyphenyl)-3-[[5-[2-(4-morpholinyl)ethoxy]-1H-indol-2-yl]methylene]- (9CI) (CA INDEX NAME)



RN 380241-50-9 CAPLUS
CN 2H-Indol-2-one, 6-(4-fluorophenyl)-1,3-dihydro-3-[[5-[2-(4-morpholinyl)ethoxy]-1H-indol-2-yl]methylene]- (9CI) (CA INDEX NAME)



RN 380241-51-0 CAPLUS
CN 1H-Indole-5-sulfonamide, 2,3-dihydro-2-oxo-3-[[5-[2-(1-pyrrolidinyl)ethoxy]-1H-indol-2-yl]methylene]- (9CI) (CA INDEX NAME)



RN 380241-53-2 CAPLUS
CN 1H-Indole-5-sulfonamide, 2,3-dihydro-3-[[5-[2-(4-morpholinyl)ethoxy]-1H-indol-2-yl]methylene]-2-oxo- (9CI) (CA INDEX NAME)



RN 380241-54-3 CAPLUS
CN 1H-Indole-5-sulfonamide, 2,3-dihydro-N-methyl-2-oxo-3-[[5-[2-(1-pyrrolidinyl)ethoxy]-1H-indol-2-yl]methylene]- (9CI) (CA INDEX NAME)



RN 380241-56-5 CAPLUS
CN 1H-Indole-5-sulfonamide, 2,3-dihydro-N,N-dimethyl-2-oxo-3-[[5-[2-(1-pyrrolidinyl)ethoxy]-1H-indol-2-yl]methylene]- (9CI) (CA INDEX NAME)



RN 380241-59-8 CAPLUS
CN 1H-Indole-5-sulfonamide, 2,3-dihydro-N-(1-methylethyl)-2-oxo-3-[[5-[2-(1-pyrrolidinyl)ethoxy]-1H-indol-2-yl]methylene]- (9CI) (CA INDEX NAME)



RN 380241-61-2 CAPLUS
CN 1H-Indole-5-sulfonamide, 2,3-dihydro-2-oxo-N-phenyl-3-[[5-[2-(1-pyrrolidinyl)ethoxy]-1H-indol-2-yl]methylene]- (9CI) (CA INDEX NAME)



RN 380241-65-6 CAPLUS
CN 1H-Indole-5-sulfonamide, 2,3-dihydro-2-oxo-N-3-pyridinyl-3-[[5-[2-(1-pyrrolidinyl)ethoxy]-1H-indol-2-yl]methylene]- (9CI) (CA INDEX NAME)



RN 380241-68-9 CAPLUS
CN 1H-Indole, 1-[[2,3-dihydro-2-oxo-3-[[5-[2-(1-pyrrolidinyl)ethoxy]-1H-indol-2-yl]methylene]-1H-indol-5-yl]sulfonyl]-2,3-dihydro- (9CI) (CA INDEX NAME)



RN 380241-71-4 CAPLUS
CN 1H-Indole-5-sulfonamide, N-(3-chlorophenyl)-2,3-dihydro-2-oxo-3-[[5-[2-(1-pyrrolidinyl)ethoxy]-1H-indol-2-yl]methylene]- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 1-B

PAGE 1-B

Cl

RN 380241-74-7 CAPLUS
CN 1H-Indole-5-sulfonamide, N-(3-chlorophenyl)-2,3-dihydro-N-methyl-2-oxo-3-[[5-[2-(1-pyrrolidinyl)ethoxy]-1H-indol-2-yl]methylene]- (9CI) (CA INDEX NAME)



RN 380241-78-1 CAPLUS
CN 1H-Indole-5-sulfonamide, N-(4-chloro-2-fluorophenyl)-2,3-dihydro-2-oxo-3-[[5-[2-(1-pyrrolidinyl)ethoxy]-1H-indol-2-yl]methylene]- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 1-B

Cl

RN 380241-82-7 CAPLUS
CN Quinoline, 1-[[2,3-dihydro-2-oxo-3-[[5-[2-(1-pyrrolidinyl)ethoxy]-1H-indol-2-yl]methylene]-1H-indol-5-yl]sulfonyl]-1,2,3,4-tetrahydro- (9CI) (CA INDEX NAME)



RN 380241-84-9 CAPLUS
CN Isoquinoline, 2-[[2,3-dihydro-2-oxo-3-[[5-[2-(1-pyrrolidinyl)ethoxy]-1H-indol-2-yl]methylene]-1H-indol-5-yl]sulfonyl]-1,2,3,4-tetrahydro- (9CI) (CA INDEX NAME)



RN 380241-86-1 CAPLUS
CN 1H-Indole, 5-bromo-1-[[2,3-dihydro-2-oxo-3-[[5-[2-(1-pyrrolidinyl)ethoxy]-1H-indol-2-yl]methylene]-1H-indol-5-yl]sulfonyl]-2,3-dihydro- (9CI) (CA INDEX NAME)



RN 380241-88-3 CAPLUS
CN 1H-Indole-5-sulfonamide, 2,3-dihydro-N-methyl-3-[[5-[2-(4-morpholinyl)ethoxy]-1H-indol-2-yl]methylene]-2-oxo- (9CI) (CA INDEX NAME)



RN 380241-90-7 CAPLUS
CN 1H-Indole-5-sulfonamide, 2,3-dihydro-N,N-dimethyl-3-[[5-[2-(4-morpholinyl)ethoxy]-1H-indol-2-yl]methylene]-2-oxo- (9CI) (CA INDEX NAME)



RN 380241-91-8 CAPLUS
CN 1H-Indole-5-sulfonamide, 2,3-dihydro-N-(1-methylethyl)-3-[[5-[2-(4-

morpholinyl)ethoxy]-1H-indol-2-yl]methylene]-2-oxo- (9CI) (CA INDEX NAME)



RN 380241-92-9 CAPLUS
CN 1H-Indole-5-sulfonamide, 2,3-dihydro-3-[[5-[2-(4-morpholinyl)ethoxy]-1H-indol-2-yl]methylene]-2-oxo-N-phenyl- (9CI) (CA INDEX NAME)



RN 380241-93-0 CAPLUS
CN 1H-Indole-5-sulfonamide, 2,3-dihydro-3-[[5-[2-(4-morpholinyl)ethoxy]-1H-indol-2-yl]methylene]-2-oxo-N-3-pyridinyl- (9CI) (CA INDEX NAME)



RN 380241-94-1 CAPLUS
CN 1H-Indole, 1-[[2,3-dihydro-3-[[5-[2-(4-morpholinyl)ethoxy]-1H-indol-2-yl]methylene]-2-oxo-1H-indol-5-yl]sulfonyl]-2,3-dihydro- (9CI) (CA INDEX NAME)



RN 380241-95-2 CAPLUS
CN 1H-Indole-5-sulfonamide, N-(3-chlorophenyl)-2,3-dihydro-3-[[5-[2-(4-morpholinyl)ethoxy]-1H-indol-2-yl]methylene]-2-oxo- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 1-B



RN 380241-96-3 CAPLUS
CN 1H-Indole-5-sulfonamide, N-(3-chlorophenyl)-2,3-dihydro-N-methyl-3-[[5-[2-(4-morpholinyl)ethoxy]-1H-indol-2-yl]methylene]-2-oxo- (9CI) (CA INDEX NAME)



RN 380241-97-4 CAPLUS
CN 1H-Indole-5-sulfonamide, N-(4-chloro-2-fluorophenyl)-2,3-dihydro-3-[[5-[2-(4-morpholinyl)ethoxy]-1H-indol-2-yl]methylene]-2-oxo- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 1-B



RN 380241-98-5 CAPLUS
CN Quinoline, 1-[[2,3-dihydro-3-[[5-[2-(4-morpholinyl)ethoxy]-1H-indol-2-

yl]methylene]-2-oxo-1H-indol-5-yl]sulfonyl]-1,2,3,4-tetrahydro- (9CI) (CA INDEX NAME)



RN 380241-99-6 CAPLUS
CN Isoquinoline, 2-[[2,3-dihydro-3-[[5-[2-(4-morpholinyl)ethoxy]-1H-indol-2-yl]methylene]-2-oxo-1H-indol-5-yl]sulfonyl]-1,2,3,4-tetrahydro- (9CI) (CA INDEX NAME)



RN 380242-00-2 CAPLUS
CN 1H-Indole, 5-bromo-1-[[2,3-dihydro-3-[[5-[2-(4-morpholinyl)ethoxy]-1H-indol-2-yl]methylene]-2-oxo-1H-indol-5-yl]sulfonyl]-2,3-dihydro- (9CI) (CA INDEX NAME)



L5 ANSWER 8 OF 66 CAPLUS COPYRIGHT 2002 ACS

ACCESSION NUMBER:	2001:830898 CAPLUS
DOCUMENT NUMBER:	135:357926
TITLE:	Synthesis of indolinone vinyl-derivatives used to modulate protein kinase activity
INVENTOR(S):	Tang, Peng Cho; Sun, Li; Mcmahon, Gerald; Harris, G. David
PATENT ASSIGNEE(S):	Sugen, Inc., USA
SOURCE:	U.S., 29 pp., Cont.-in-part of U.S. Ser. No. 212,494. CODEN: USXXAM
DOCUMENT TYPE:	Patent
LANGUAGE:	English
FAMILY ACC. NUM. COUNT:	8

09897755

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 6316635	B1	20011113	US 1999-293518	19990415
US 5880141	A	19990309	US 1995-485323	19950607
US 5792783	A	19980811	US 1996-655223	19960605
US 5883113	A	19990316	US 1996-659191	19960605
EP 934931	A2	19990811	EP 1999-103667	19960605
EP 934931	A3	19991020		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI				
JP 2000026412	A2	20000125	JP 1999-159567	19960605
US 6225335	B1	20010501	US 1998-212494	19981215
US 2001027207	A1	20011004	US 2001-765619	20010122
US 2002028840	A1	20020307	US 2001-899550	20010706

PRIORITY APPLN. INFO.:

US 1995-485323 A2 19950607
US 1995-485323 A2 19950607
US 1996-655223 A2 19960605
US 1996-659191 A1 19960605
US 1998-82056P P 19980416
US 1998-212494 A2 19981215
EP 1996-918093 A3 19960605
JP 1997-501363 A3 19960605
US 1999-293518 A1 19990415

OTHER SOURCE(S): MARPAT 135:357926

GI



I



II

AB Title compds. I [G, J = N such that, when G = N, J = C and when J = N, G = C, it being recognized that, when G or J = N, R5 or R5' does not exist; R1-3 = H; R4, R5, R5' H, alk(en/yn)yl, cycloalkyl, aryl, heteroaryl, heteroalicylic, halo, hydroxy, nitro, cyano, alkoxy, aryloxy, etc.; R6-9 =

H, alkyl, trihaloalkyl, cycloalkyl, alkenyl, alkynyl, aryl, heteroaryl, heteroalicyclic, hydroxy, alkoxy, aryloxy, thiohydroxy, thioalkoxy, thioaryloxy, etc.] with some exceptions, were prepd. For instance, 2-ethyl-4-formylimidazole was reacted with resin bound 2-chlorotriphenylmethyl chloride (CH2Cl2, iPr2NEt, 21 h, room temp.) and the isolated product condensed with 2-indolinone (DMF, piperidine, 80.degree.C, 20 h) to give the corresponding resin-bound 2-indolinone. The resin bound intermediate was cleaved (CH2Cl2, TFA, 2 h, room temp.) to give II as the TFA salt of a 10:1 E/Z mixt. I exhibit kinase inhibitory activity and are useful for treating, e.g., diabetes, autoimmune disorder, etc.

IT **186611-44-9P**, 3-[(Imidazol-4-yl)methylene]-2-indolinone **204006-26-8P**, 3-[(Imidazol-4-yl)methylene]-4,6-dimethyl-2-indolinone **204006-35-9P**, 3-[(Imidazol-4-yl)methylene]-5-chloro-2-indolinone **215434-21-2P**, 3-[(Imidazol-4-yl)methylene]-5-nitro-2-indolinone **215434-22-3P**, 3-[(Imidazol-4-yl)methylene]-5-fluoro-2-indolinone **215434-43-8P**, 3-[(Imidazol-4-yl)methylene]-5-amino-2-indolinone **215434-63-2P**, 3-[(Imidazol-4-yl)methylene]-5,6-dimethoxy-2-indolinone **245036-30-0P**, 3-[(Imidazol-4-yl)methylene]-4-methyl-2-indolinone **245036-31-1P**, 3-[(Imidazol-4-yl)methylene]-5-chloro-7-bromo-2-indolinone
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(drug; synthesis of indolinone vinyl-derivs. used to modulate protein kinase activity)

RN 186611-44-9 CAPLUS
CN 2H-Indol-2-one, 1,3-dihydro-3-(1H-imidazol-4-ylmethylene)- (9CI) (CA INDEX NAME)



RN 204006-26-8 CAPLUS
CN 2H-Indol-2-one, 1,3-dihydro-3-(1H-imidazol-4-ylmethylene)-4,6-dimethyl- (9CI) (CA INDEX NAME)



RN 204006-35-9 CAPLUS
CN 2H-Indol-2-one, 5-chloro-1,3-dihydro-3-(1H-imidazol-4-ylmethylene)- (9CI) (CA INDEX NAME)



RN 215434-21-2 CAPLUS
CN 2H-Indol-2-one, 1,3-dihydro-3-(1H-imidazol-4-ylmethylene)-5-nitro- (9CI) (CA INDEX NAME)



RN 215434-22-3 CAPLUS
CN 2H-Indol-2-one, 5-fluoro-1,3-dihydro-3-(1H-imidazol-4-ylmethylene)- (9CI) (CA INDEX NAME)



RN 215434-43-8 CAPLUS
CN 2H-Indol-2-one, 5-amino-1,3-dihydro-3-(1H-imidazol-4-ylmethylene)- (9CI) (CA INDEX NAME)



RN 215434-63-2 CAPLUS
CN 2H-Indol-2-one, 1,3-dihydro-3-(1H-imidazol-4-ylmethylene)-5,6-dimethoxy- (9CI) (CA INDEX NAME)



RN 245036-30-0 CAPLUS
CN 2H-Indol-2-one, 1,3-dihydro-3-(1H-imidazol-4-ylmethylene)-4-methyl- (9CI) (CA INDEX NAME)



RN 245036-31-1 CAPLUS
CN 2H-Indol-2-one, 7-bromo-5-chloro-1,3-dihydro-3-(1H-imidazol-4-ylmethylene)- (9CI) (CA INDEX NAME)



IT **372164-79-9P**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); RCT (Reactant); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent)
(intermediate; synthesis of indolinone vinyl-derivs. used to modulate protein kinase activity)
RN 372164-79-9 CAPLUS
CN 2H-Indol-2-one, 1,3-dihydro-3-(1H-imidazol-4-ylmethylene)-, (3Z)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



IT **186611-44-9DP**, polymer-bound **372164-72-2P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(intermediate; synthesis of indolinone vinyl-derivs. used to modulate protein kinase activity)
RN 186611-44-9 CAPLUS
CN 2H-Indol-2-one, 1,3-dihydro-3-(1H-imidazol-4-ylmethylene)- (9CI) (CA INDEX NAME)



RN 372164-72-2 CAPLUS
CN 2H-Indol-2-one, 1,3-dihydro-3-(1H-imidazol-4-ylmethylene)-, (3E)-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 372164-71-1
CMF C12 H9 N3 O

Double bond geometry as shown.



CM 2

CRN 76-05-1
CMF C2 H F3 O2



REFERENCE COUNT: 85 THERE ARE 85 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT